{
 "cells": [
  {
   "cell_type": "code",
   "id": "initial_id",
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2026-01-12T13:25:53.713885Z",
     "start_time": "2026-01-12T13:25:53.711373Z"
    }
   },
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import re\n",
    "from difflib import SequenceMatcher\n",
    "from pathlib import Path\n",
    "\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "from rapidfuzz import fuzz\n"
   ],
   "outputs": [],
   "execution_count": 74
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T13:34:46.236124Z",
     "start_time": "2026-01-12T13:34:46.233804Z"
    }
   },
   "cell_type": "code",
   "source": [
    "METHOD = 'agent'#[\"agent\", \"mrr\", \"sc\", \"default\", \"cot\", \"cot2\"]\n",
    "RUN_ID = 1 #[1, 2, 3]\n",
    "\n",
    "THRESH_MC = 0.9\n",
    "THRESH_OPEN_MC = 0.9\n",
    "THRESH_OPEN_bag = 0.15\n",
    "THRESH_OPEN_fuzzy = 0.95\n"
   ],
   "id": "4690a5d80f5d0689",
   "outputs": [],
   "execution_count": 84
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": [
    "#READ DATA\n",
    "questions = pd.read_json('data/curebench_valset_pharse1.jsonl',lines=True) \n",
    "path = Path(\"competition_results\",METHOD,str(RUN_ID),\"submission.csv\")\n",
    "answers = pd.read_csv(path)\n"
   ],
   "id": "cd7119e9472a4e5c"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:40:59.305199Z",
     "start_time": "2026-01-12T12:40:59.297266Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#SPLITTING DATA INTO MC, OPEN-ENDED MC, and OPEN QUESTIONS\n",
    "data = questions.merge(answers, on=\"id\", how=\"right\")\n",
    "colnames = data.columns\n",
    "\n",
    "data_mc = data[data[\"question_type\"] == \"multi_choice\"]\n",
    "data_open_mc = data[data[\"question_type\"] == \"open_ended_multi_choice\"]\n",
    "data_open = data[data[\"question_type\"] == \"open_ended\"]\n",
    "\n",
    "print(\"\\nü•∏------Uncleaned predictions for MC-questions:-------\\n\")\n",
    "print(data_mc[[\"prediction\",\"choice\"]].head())\n",
    "print(f\"***Observations: {len(data_mc)}***\")\n",
    "\n",
    "print(\"\\nü•∏------Uncleaned predictions for open-ended MC-questions:------\\n\")\n",
    "print(data_open_mc[[\"prediction\",\"choice\"]].head())\n",
    "print(f\"***Observations: {len(data_mc)}***\")\n",
    "\n",
    "print(\"\\nü•∏------Uncleaned predictions for open questions:------\\n\")\n",
    "print(data_open[[\"prediction\",\"choice\"]].head())\n",
    "print(f\"***Observations: {len(data_mc)}***\")\n",
    "\n",
    "\n"
   ],
   "id": "23d7930985b21309",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ü•∏------Uncleaned predictions for MC-questions:-------\n",
      "\n",
      "   prediction choice\n",
      "0   ANSWER: A      A\n",
      "4   ANSWER: B      B\n",
      "5   ANSWER: C      C\n",
      "6   ANSWER: A      A\n",
      "12  ANSWER: B      B\n",
      "***Observations: 183***\n",
      "\n",
      "ü•∏------Uncleaned predictions for open-ended MC-questions:------\n",
      "\n",
      "                                          prediction choice\n",
      "1  - Patients should seek immediate medical atten...      B\n",
      "2  - Replace the Stiolto Respimat inhaler with a ...      B\n",
      "3  - Patients with a history of severe allergic r...      B\n",
      "7  - Discontinue the use of PERTZYE immediately t...      B\n",
      "8  - Discontinue Inspra (eplerenone) immediately ...      B\n",
      "***Observations: 183***\n",
      "\n",
      "ü•∏------Uncleaned predictions for open questions:------\n",
      "\n",
      "                                           prediction     choice\n",
      "22                                                  A  NOTAVALUE\n",
      "37                                                  A  NOTAVALUE\n",
      "42                                                  A  NOTAVALUE\n",
      "44                                                  A  NOTAVALUE\n",
      "47  I'm sorry, but I cannot provide an answer with...  NOTAVALUE\n",
      "***Observations: 183***\n"
     ]
    }
   ],
   "execution_count": 60
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:41:02.227308Z",
     "start_time": "2026-01-12T12:41:02.180863Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#####ANALYZE MC DATA #######\n",
    "data_mc = data_mc.copy()\n",
    "\n",
    "for i,row in data_mc.iterrows():\n",
    "    prediction = row[\"prediction\"]\n",
    "    options = dict(row[\"options\"])\n",
    "    LCSratios = {}\n",
    "    for key in options.keys():\n",
    "        option = options[key]\n",
    "        LCSratios[key] = SequenceMatcher(None, prediction, option).ratio()\n",
    "    \n",
    "    best_pred = max(LCSratios, key=LCSratios.get)\n",
    "    data_mc.loc[i,\"pred_LCS\"] = best_pred\n",
    "    data_mc.loc[i,\"LCS_similarity\"]=LCSratios[best_pred]\n",
    "\n",
    "data_mc['final_choice'] = np.where(\n",
    "    data_mc['LCS_similarity'] > 0.9,\n",
    "    data_mc['pred_LCS'],\n",
    "    data_mc['choice']\n",
    "    \n",
    ")\n",
    "\n",
    "data_mc[\"is_correct\"] = data_mc['final_choice'] == data_mc[\"correct_answer\"]\n",
    "\n",
    "for i,row in data_mc.iterrows():\n",
    "    if row[\"final_choice\"] != 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}\")\n",
    "        print(f\"Is correct: {row['is_correct']}\")\n",
    "\n",
    "print(\"\\n\\n‚ö†üü®--------- INVALID ANSWERS-----------üü®\\n\\n\")\n",
    "for i,row in data_mc.iterrows():\n",
    "    if row[\"final_choice\"] == 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Question: {row['question']}\\n\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}:\")\n",
    "        print(f\"{ row['options'][row['correct_answer']] }\\n\")\n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\\n\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\\n\")\n",
    "        \n",
    "\n",
    "NaN_mc = len(data_mc[data_mc[\"final_choice\"] == 'NOTAVALUE'])\n",
    "valid_mc = len(data_mc) - NaN_mc\n",
    "ACC_mc = data_mc[\"is_correct\"].sum() / valid_mc\n",
    "\n",
    "print()\n",
    "print(f\"‚ÑπÔ∏èValid Answers: {valid_mc}\")\n",
    "print(f\"‚ÑπÔ∏èInvalid Answers: {NaN_mc}\")\n",
    "print(f\"üü¢ACC: {100*round(ACC_mc,4)}%\")"
   ],
   "id": "79fdfb649873c87f",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----Row 0:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 4:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 5:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 6:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 12:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 13:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 20:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 21:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 24:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 25:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 26:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 29:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 30:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 31:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 33:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 35:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 36:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 38:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 40:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 41:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 46:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 50:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 52:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 53:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 54:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 56:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 59:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 62:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 65:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 66:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 73:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 74:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 80:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 81:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 85:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 87:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 89:----\n",
      "Detailed Prediction: C: It results in no pharmacokinetic interactions.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 90:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 91:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 94:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 95:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 96:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 97:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 98:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 99:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 100:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 101:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 108:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 117:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 121:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 122:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 123:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 124:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 125:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 127:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 130:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 131:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 132:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 133:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 137:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 138:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 139:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 146:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 148:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 149:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 150:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 155:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 156:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 159:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 160:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 161:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 162:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 164:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 165:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 167:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 168:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 169:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 170:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 171:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 179:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 185:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 188:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 191:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 196:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 197:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 198:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 199:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 202:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 203:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 208:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 211:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 213:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 214:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 216:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 220:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 232:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 236:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 239:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 240:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 244:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 252:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 253:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 255:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 258:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 260:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 262:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 263:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 267:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 268:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 269:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 270:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 271:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 272:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 275:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 276:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 278:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 279:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 283:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 286:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 290:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 292:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 294:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 295:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 297:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 300:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 301:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 305:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 308:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 309:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 313:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 314:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 315:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 316:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 322:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 326:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 327:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 331:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 332:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 333:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 335:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 336:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 337:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 347:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 350:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 352:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 354:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 355:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 356:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 357:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 360:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 362:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 369:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 374:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 376:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 378:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 379:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 380:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 384:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 387:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 388:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 391:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 393:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 395:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 397:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 400:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 402:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 408:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 409:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 410:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 415:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 417:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 423:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 424:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 425:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 430:----\n",
      "Detailed Prediction: ANSWER: C\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 431:----\n",
      "Detailed Prediction: ANSWER: A\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 432:----\n",
      "Detailed Prediction: ANSWER: D\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 437:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 445:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 447:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 453:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 457:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 458:----\n",
      "Detailed Prediction: ANSWER: B\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "\n",
      "‚ö†üü®--------- INVALID ANSWERS-----------üü®\n",
      "\n",
      "\n",
      "\n",
      "‚ÑπÔ∏èValid Answers: 183\n",
      "‚ÑπÔ∏èInvalid Answers: 0\n",
      "üü¢ACC: 84.15%\n"
     ]
    }
   ],
   "execution_count": 61
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:41:18.989949Z",
     "start_time": "2026-01-12T12:41:18.696606Z"
    }
   },
   "cell_type": "code",
   "source": [
    "data_open_mc = data_open_mc.copy()\n",
    "\n",
    "for i,row in data_open_mc.iterrows():\n",
    "    prediction = row[\"prediction\"]\n",
    "    options = dict(row[\"options\"])\n",
    "    LCSratios = {}\n",
    "    for key in options.keys():\n",
    "        option = options[key]\n",
    "        LCSratios[key] = SequenceMatcher(None, prediction, option).ratio()\n",
    "    \n",
    "    best_pred = max(LCSratios, key=LCSratios.get)\n",
    "    data_open_mc.loc[i,\"pred_LCS\"] = best_pred\n",
    "    data_open_mc.loc[i,\"LCS_similarity\"] = LCSratios[best_pred]\n",
    "    \n",
    "data_open_mc['final_choice'] = np.where(\n",
    "    data_open_mc['LCS_similarity'] > 0.9,\n",
    "    data_open_mc['pred_LCS'],\n",
    "    data_open_mc['choice']\n",
    ")\n",
    "\n",
    "data_open_mc['is_correct'] = data_open_mc[\"final_choice\"] == data_open_mc[\"correct_answer\"]\n",
    "\n",
    "for i,row in data_open_mc.iterrows():\n",
    "    if row[\"final_choice\"] != 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}\")\n",
    "        print(f\"Is correct: {row['is_correct']}\")\n",
    "    \n",
    "print(\"\\n\\n‚ö†üü®--------- INVALID ANSWERS-----------üü®\\n\\n\")\n",
    "for i,row in data_open_mc.iterrows():\n",
    "    if row[\"final_choice\"] == 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Question: {row['question']}\\n\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}:\")\n",
    "        print(f\"{ row['options'][row['correct_answer']] }\\n\")\n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\\n\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\\n\")\n",
    "  \n",
    "  \n",
    "        \n",
    "NaN_open_mc = len(data_open_mc[data_open_mc[\"final_choice\"] == 'NOTAVALUE'])\n",
    "valid_open_mc = len(data_open_mc) - NaN_open_mc\n",
    "ACC_open_mc = data_open_mc[\"is_correct\"].sum() / valid_open_mc\n",
    "\n",
    "print()\n",
    "print(f\"‚ÑπÔ∏èValid Answers: {valid_open_mc}\")\n",
    "print(f\"‚ÑπÔ∏èInvalid Answers: {NaN_open_mc}\")\n",
    "print(f\"üü¢ACC: {100*round(ACC_open_mc,4)}%\")\n"
   ],
   "id": "b3c7d8aa641a454d",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----Row 1:----\n",
      "Detailed Prediction: - Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or hives after receiving fosaprepitant for injection.\n",
      "- It is important to inform healthcare providers about the allergic reaction to fosaprepitant, as they may need to administer emergency treatments like epinephrine.\n",
      "- Patients should avoid future doses of fosaprepitant and discuss alternative antiemetic options with their healthcare provider.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 2:----\n",
      "Detailed Prediction: - Replace the Stiolto Respimat inhaler with a new one, as it indicates that the medication is no longer available for use.\n",
      "- Ensure to follow the prescribed dosing regimen, which typically involves two inhalations once daily.\n",
      "- Dispose of the empty inhaler properly, following local guidelines for medication disposal.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 3:----\n",
      "Detailed Prediction: - Patients with a history of severe allergic reactions to gadolinium-based contrast agents should avoid Gadavist.\n",
      "- Individuals with acute or chronic renal insufficiency are at risk for nephrogenic systemic fibrosis and should not use Gadavist.\n",
      "- Pregnant women should consider the risks versus benefits before using Gadavist due to potential effects on the fetus.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 7:----\n",
      "Detailed Prediction: - Discontinue the use of PERTZYE immediately to prevent further allergic reactions.\n",
      "- Seek emergency medical attention if symptoms such as difficulty breathing, swelling of the face or throat, or hives occur.\n",
      "- Inform the healthcare provider about the allergic reaction to discuss alternative treatments or medications.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 8:----\n",
      "Detailed Prediction: - Discontinue Inspra (eplerenone) immediately to prevent further increases in potassium levels.\n",
      "- Assess the patient for symptoms of hyperkalemia, such as muscle weakness or cardiac irregularities.\n",
      "- Initiate potassium-lowering interventions, which may include the use of diuretics or potassium binders.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 9:----\n",
      "Detailed Prediction: - Assess the patient's history of allergic reactions, particularly to gadolinium-based contrast agents, before administering Gadavist.\n",
      "- Consider premedication with corticosteroids and antihistamines for patients with a known history of severe allergic reactions.\n",
      "- Monitor the patient closely for any signs of an allergic reaction during and after the administration of Gadavist.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 10:----\n",
      "Detailed Prediction: - Discontinuation of fluoxetine can lead to withdrawal symptoms such as dizziness and nausea.\n",
      "- Patients may experience mood disturbances, including increased anxiety or irritability, after stopping fluoxetine suddenly.\n",
      "- Fluoxetine discontinuation may also result in flu-like symptoms, including fatigue and muscle aches.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 11:----\n",
      "Detailed Prediction: - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the addition of a different antihypertensive medication if the current treatment is insufficient, as NURTEC ODT is primarily used for migraine treatment and may not address blood pressure control.\n",
      "- Assess for potential drug interactions or underlying conditions that may be contributing to the inadequate blood pressure control while on NURTEC ODT.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 14:----\n",
      "Detailed Prediction: - Monitor blood pressure regularly, as venlafaxine can cause dose-dependent increases in blood pressure.\n",
      "- Assess for signs of serotonin syndrome, especially if combined with other serotonergic medications.\n",
      "- Evaluate for potential withdrawal symptoms if discontinuing treatment, as venlafaxine has a short half-life and may require a tapering regimen.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 15:----\n",
      "Detailed Prediction: - Pemetrexed for Injection combined with Cisplatin is a standard regimen for the initial treatment of malignant pleural mesothelioma.\n",
      "- This combination therapy has been shown to improve overall survival compared to other treatments.\n",
      "- Pemetrexed is administered as an infusion, typically on the first day of each treatment cycle, alongside Cisplatin.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 16:----\n",
      "Detailed Prediction: - Patients with a history of substance use disorder, particularly those who have previously abused opioids or other controlled substances.\n",
      "- Individuals with chronic pain conditions who may seek higher doses or more frequent use of RoxyBond to manage their pain.\n",
      "- Young adults and adolescents, as they are often more susceptible to experimenting with prescription medications for recreational use.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 17:----\n",
      "Detailed Prediction: - If a patient misses a dose of JAYPIRCA and it has been more than 12 hours since the usual dosing time, they should skip the missed dose.\n",
      "- The patient should resume their regular dosing schedule with the next dose.\n",
      "- They should not take an extra dose to make up for the missed one.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 18:----\n",
      "Detailed Prediction: - Patients with a history of liver disease should avoid terbinafine due to the risk of hepatotoxicity.\n",
      "- Individuals with active or chronic liver impairment are contraindicated for terbinafine use.\n",
      "- Terbinafine is not recommended for patients with severe renal impairment, as it may lead to accumulation and increased risk of side effects.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 19:----\n",
      "Detailed Prediction: - Women over 35 who smoke should be aware that using Tri Femynor, which contains estrogen, significantly increases the risk of thromboembolic events.\n",
      "- It is crucial for these women to discuss alternative contraceptive methods with their healthcare provider, as the combination of smoking and estrogen can lead to serious cardiovascular complications.\n",
      "- Regular monitoring and assessment of smoking status and overall health are essential before starting Tri Femynor to ensure safety.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 23:----\n",
      "Detailed Prediction: - Albuterol sulfate was administered at doses up to 100 mg/kg/day in rats.\n",
      "- No evidence of impaired fertility was observed at this high dose.\n",
      "- The study indicated that reproductive performance remained unaffected at this level of exposure.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 27:----\n",
      "Detailed Prediction: - Venlafaxine has a protein binding percentage of approximately 27% in human plasma.\n",
      "- This binding primarily involves albumin and alpha-1 acid glycoprotein.\n",
      "- The relatively low protein binding may influence its pharmacokinetics and interactions with other medications.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 28:----\n",
      "Detailed Prediction: - The drug brand name 'sterile' is associated with the preparation of sterile solutions for injection.\n",
      "- It is commonly used in the step of ensuring aseptic technique during surgical procedures.\n",
      "- 'Sterile' is crucial in the step of maintaining a sterile field to prevent infections during medical interventions.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 32:----\n",
      "Detailed Prediction: - The target basal acid secretion level was less than 10 mEq/hour.\n",
      "- This target was specifically for patients with Zollinger-Ellison Syndrome who had not undergone prior gastric surgery.\n",
      "- Pantoprazole sodium for injection was used to achieve this target level in the treatment regimen.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 34:----\n",
      "Detailed Prediction: - Monitor the patient for increased effects of RoxyBond due to reduced metabolism after discontinuation of the CYP3A4 inhibitor.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression.\n",
      "- Educate the patient about potential changes in pain control and side effects following the discontinuation of the CYP3A4 inhibitor.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 39:----\n",
      "Detailed Prediction: - Use Zithromax (azithromycin) only for confirmed bacterial infections to avoid unnecessary exposure.\n",
      "- Complete the full course of Zithromax as prescribed, even if symptoms improve, to ensure all bacteria are eradicated.\n",
      "- Avoid using Zithromax for viral infections, as this can contribute to resistance without providing any therapeutic benefit.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 43:----\n",
      "Detailed Prediction: - NUZYRA contains the active ingredient omadacycline, which may have contraindications related to its excipients, such as sodium and lactose.\n",
      "- Patients with known hypersensitivity to any of the excipients in NUZYRA should avoid its use to prevent adverse reactions.\n",
      "- The presence of excipients like sodium may pose risks for patients on sodium-restricted diets, necessitating careful consideration before prescribing NUZYRA.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 45:----\n",
      "Detailed Prediction: - The suggested water temperature for a sitz bath is typically around 37-40 degrees Celsius (98.6-104 degrees Fahrenheit).\n",
      "- When using vaginal essential oil, ensure that the oil is diluted properly in the warm water to avoid irritation.\n",
      "- It is recommended to soak for about 15-20 minutes to achieve the desired therapeutic effect.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 48:----\n",
      "Detailed Prediction: - Consider confirming the urine test results with a more specific method, such as gas chromatography-mass spectrometry (GC-MS), to rule out false positives.\n",
      "- Review the patient's medication history to identify any other substances that may cause cross-reactivity in urine tests for THC.\n",
      "- Educate the patient about the potential for false positives and the importance of discussing any medication use, including Pantoprazole Sodium, with their healthcare provider.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 49:----\n",
      "Detailed Prediction: - BRILINTA (ticagrelor) has been shown to provide a more potent inhibition of platelet aggregation compared to clopidogrel after 6 weeks of treatment.\n",
      "- Studies indicate that patients on BRILINTA experience a greater reduction in platelet reactivity, leading to improved clinical outcomes.\n",
      "- Clopidogrel, while effective, typically results in a lesser degree of IPA compared to BRILINTA, particularly in high-risk cardiovascular patients.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 51:----\n",
      "Detailed Prediction: - In vitro studies have been conducted to assess the mutagenicity of Hydrocort using bacterial reverse mutation assays.\n",
      "- Animal studies have been performed to evaluate the potential mutagenic effects of Hydrocort in vivo, particularly focusing on chromosomal aberrations.\n",
      "- Clinical trials have monitored long-term exposure to Hydrocort for any genotoxic effects in patients receiving the drug for chronic conditions.\n",
      "Final Choice: D\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 55:----\n",
      "Detailed Prediction: - 'Meijer stomach relief regular strength' is indicated to treat upset stomach.\n",
      "- It contains the active ingredient bismuth subsalicylate, which helps alleviate nausea.\n",
      "- The product is also used for treating indigestion alongside diarrhea.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 57:----\n",
      "Detailed Prediction: - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to increased free concentrations of other highly protein-bound drugs when co-administered.\n",
      "- When venlafaxine is taken with drugs like warfarin or phenytoin, the displacement of these drugs from plasma proteins could enhance their effects or toxicity.\n",
      "- Clinicians should monitor patients for increased effects of anticoagulants or anticonvulsants when venlafaxine is introduced into their regimen.\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 58:----\n",
      "Detailed Prediction: - Discontinue AIRSUPRA immediately if hypersensitivity reactions, such as rash or difficulty breathing, occur.\n",
      "- Consider administering antihistamines or corticosteroids to manage mild to moderate reactions.\n",
      "- Monitor the patient closely for any signs of anaphylaxis and provide emergency treatment if necessary.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 60:----\n",
      "Detailed Prediction: - Ondansetron has been shown to have no mutagenic effects in various in vitro and in vivo studies.\n",
      "- The drug does not induce mutations in bacterial or mammalian cells, as evidenced by the Ames test and other genotoxicity assays.\n",
      "- Regulatory agencies, including the FDA, have classified ondansetron as having a low potential for mutagenicity based on available data.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 63:----\n",
      "Detailed Prediction: - Aprepitant is primarily eliminated through hepatic metabolism, so removal via dialysis is not effective.\n",
      "- In cases of overdose, supportive care is the mainstay of treatment, as there is no specific antidote for aprepitant.\n",
      "- Monitoring for adverse effects is crucial, as the half-life of aprepitant can lead to prolonged effects in overdose situations.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 64:----\n",
      "Detailed Prediction: - Tybost (cobicistat) is a booster for antiretroviral medications and does not have established safety for breastfeeding in HIV-1 infected mothers.\n",
      "- Breastfeeding can transmit HIV-1 to the infant, and the use of Tybost may not adequately suppress viral load to prevent transmission.\n",
      "- The risk of drug exposure to the infant through breast milk while on Tybost is a concern, as the effects of the drug on a breastfeeding infant are not well understood.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 68:----\n",
      "Detailed Prediction: - 1.25 mg Levalbuterol has been shown to provide a similar bronchodilator response to 2.5 mg racemic albuterol sulfate in patients with asthma or COPD.\n",
      "- The duration of action for both Levalbuterol and racemic Albuterol is comparable, maintaining bronchodilation over the 6-hour evaluation period.\n",
      "- Levalbuterol may have a more favorable side effect profile compared to racemic albuterol, potentially leading to better patient tolerance during the evaluation.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 69:----\n",
      "Detailed Prediction: - Avoid using WL-AAB-Z-W-1350 while wearing contact lenses to prevent potential irritation or discomfort.\n",
      "- If contact lenses must be worn, ensure they are removed before applying WL-AAB-Z-W-1350 to minimize the risk of adverse effects.\n",
      "- Consult with an eye care professional for specific recommendations regarding the use of WL-AAB-Z-W-1350 and contact lenses.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 70:----\n",
      "Detailed Prediction: - NURTEC ODT, which contains rimegepant, has been studied for its safety profile, and overdosage may lead to increased adverse effects.\n",
      "- Clinical trials have indicated that doses significantly higher than the recommended 75 mg may not provide additional therapeutic benefit and could exacerbate side effects.\n",
      "- In cases of suspected overdosage, supportive care is recommended, as there is no specific antidote for rimegepant.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 71:----\n",
      "Detailed Prediction: - TAKHZYRO (lanadelumab) is a monoclonal antibody used for the prevention of hereditary angioedema attacks, and overdosage may lead to increased risk of adverse effects.\n",
      "- In clinical studies, doses higher than the recommended 300 mg every two weeks have not been extensively evaluated, indicating potential unknown risks with overdosage.\n",
      "- Symptoms of overdosage may include increased incidence of injection site reactions or other immune-related effects due to the drug's mechanism of action.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 72:----\n",
      "Detailed Prediction: - Monitor INR levels closely when Pantoprazole Sodium is used with Warfarin, as Pantoprazole may increase Warfarin's anticoagulant effect.\n",
      "- Consider dose adjustments of Warfarin based on INR results to maintain therapeutic levels and prevent bleeding complications.\n",
      "- Educate patients about signs of increased bleeding risk, such as unusual bruising or prolonged bleeding from cuts, while on this combination therapy.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 75:----\n",
      "Detailed Prediction: - Vaginal essential oil may help to enhance the absorption of the subsequent gel application, potentially increasing its effectiveness in treating chronic inflammation.\n",
      "- The essential oil could provide a soothing effect, reducing discomfort and irritation associated with chronic inflammation before the gel is applied.\n",
      "- Using essential oil may also help to balance the vaginal microbiome, which can be beneficial in managing inflammation and promoting overall vaginal health.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 76:----\n",
      "Detailed Prediction: - Zynteglo is contraindicated in patients with active or uncontrolled infections, which is a specific concern not typically highlighted for many other gene therapies.\n",
      "- Unlike some immunosuppressive drugs, Zynteglo does not have contraindications related to live vaccines, allowing for broader vaccination options post-treatment.\n",
      "- The contraindication for Zynteglo includes hypersensitivity to any of its components, which is a common concern but may vary in specificity compared to other biologics or gene therapies.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 77:----\n",
      "Detailed Prediction: - The primary limitation is the lack of a specific antidote for Pemetrexed, making it challenging to reverse the effects of an overdose.\n",
      "- Supportive care is the mainstay of treatment, which may include hydration and monitoring for potential toxicities such as myelosuppression.\n",
      "- The risk of severe adverse effects, including renal impairment and gastrointestinal toxicity, complicates the management of overdose cases.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 78:----\n",
      "Detailed Prediction: - Consider using G-62 in combination with a beta-lactam antibiotic to enhance efficacy against resistant Gram-negative bacteria.\n",
      "- Monitor for potential drug interactions when G-62 is administered alongside aminoglycosides, as this may increase nephrotoxicity.\n",
      "- Evaluate the patient's renal function prior to initiating G-62 therapy to adjust dosing appropriately and minimize adverse effects.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 79:----\n",
      "Detailed Prediction: - The lack of response to Sumatriptan Injection may indicate that the patient's migraine is not of the type that responds to triptans, suggesting a need to explore alternative treatments or diagnoses.\n",
      "- If the patient does not experience relief from Sumatriptan, it may be necessary to evaluate for other underlying conditions, such as medication overuse headache or a different primary headache disorder.\n",
      "- The patient's response to Sumatriptan can help determine if the migraine is likely to be episodic or chronic, which may influence the overall treatment strategy and diagnosis.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 82:----\n",
      "Detailed Prediction: - Palonosetron has a half-life of approximately 40 hours, allowing for once-daily dosing.\n",
      "- It is primarily metabolized by the liver through the cytochrome P450 system, specifically CYP2D6 and CYP3A4.\n",
      "- Palonosetron is indicated for the prevention of nausea and vomiting associated with chemotherapy and surgery.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 86:----\n",
      "Detailed Prediction: - The recommended dosage adjustment for Paxlovid in patients with moderate renal impairment is to reduce the nirmatrelvir/ritonavir dosage to 300 mg/100 mg taken orally twice daily.\n",
      "- This adjustment is necessary to avoid potential accumulation of the drug due to decreased renal clearance.\n",
      "- Patients with eGFR ‚â•30 to <60 mL/min should not take the standard dosage of Paxlovid, which is 300 mg/100 mg taken orally twice daily for five days.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 88:----\n",
      "Detailed Prediction: - Guanfacine extended-release tablets are primarily used for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.\n",
      "- The medication works by stimulating alpha-2 adrenergic receptors in the brain, which helps to improve attention and reduce hyperactivity and impulsivity.\n",
      "- Common side effects of Guanfacine extended-release include sedation, fatigue, and dry mouth.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 92:----\n",
      "Detailed Prediction: - Carbamazepine induces its own metabolism, leading to increased clearance of carbamazepine epoxide, which may reduce its concentration in the body.\n",
      "- Carbamazepine also induces the metabolism of Lamotrigine, resulting in decreased concentrations of Lamotrigine when both drugs are administered together.\n",
      "- The interaction between Carbamazepine and Lamotrigine necessitates careful monitoring and potential dose adjustments of Lamotrigine to maintain therapeutic levels.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 93:----\n",
      "Detailed Prediction: - Fosaprepitant can cause fatigue, which is a common side effect reported in clinical studies.\n",
      "- Patients may experience nausea, although it is generally less severe compared to the nausea it aims to prevent.\n",
      "- Headache is another frequently reported side effect associated with the use of fosaprepitant for injection.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 103:----\n",
      "Detailed Prediction: - Patients prescribed venlafaxine tablets should be informed about potential side effects and benefits of the medication.\n",
      "- Healthcare providers, including doctors and pharmacists, should discuss the appropriate dosage and monitor for any adverse reactions.\n",
      "- Family members or caregivers may also be involved in the decision-making process to support the patient in understanding treatment options.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 105:----\n",
      "Detailed Prediction: - Ensure the patient is not allergic to any components of the Albuterol formulation, including preservatives or inactive ingredients.\n",
      "- Monitor the patient for any signs of an allergic reaction after the first dose of Albuterol.\n",
      "- Consider alternative bronchodilators if the patient has a history of severe allergic reactions to similar medications.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 107:----\n",
      "Detailed Prediction: - Dose increments of venlafaxine should typically be made every 4 to 7 days.\n",
      "- The increments should be gradual, often starting with 37.5 mg and increasing to a maximum of 375 mg per day based on patient response.\n",
      "- Monitoring for side effects is essential during these increments to ensure patient safety and tolerability.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 109:----\n",
      "Detailed Prediction: - The age group of adolescents (ages 12-17) showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts among younger patients compared to those receiving a placebo.\n",
      "- The efficacy of venlafaxine in reducing suicidality was particularly noted in the treatment of major depressive disorder in this age demographic.\n",
      "Final Choice: B\n",
      "Correct Answer: D\n",
      "Is correct: False\n",
      "\n",
      "----Row 110:----\n",
      "Detailed Prediction: - Women using hormonal birth control should be aware that fosaprepitant may reduce the effectiveness of their contraceptive method.\n",
      "- It is recommended to use an additional non-hormonal contraceptive method, such as condoms, during and for a period after the use of fosaprepitant.\n",
      "- Patients should consult their healthcare provider for personalized advice on contraceptive options while receiving fosaprepitant.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 111:----\n",
      "Detailed Prediction: - Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat depression and anxiety, which may lead to underreporting of misuse due to its therapeutic use.\n",
      "- The drug's long half-life and gradual onset of effects can complicate the identification of misuse patterns compared to more rapidly acting substances.\n",
      "- Variability in individual responses to Fluoxetine, including potential for euphoric effects in some users, can make it difficult to establish clear abuse trends.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 112:----\n",
      "Detailed Prediction: - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves symptoms such as cough, allowing for better sleep.\n",
      "- It often contains diphenhydramine, an antihistamine that helps reduce nighttime sneezing and runny nose.\n",
      "- The formulation may also include a pain reliever like acetaminophen to alleviate body aches associated with cold and flu symptoms.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 115:----\n",
      "Detailed Prediction: - The formulation contains phenylephrine, which acts as a decongestant to relieve nasal congestion.\n",
      "- It includes diphenhydramine, an antihistamine that helps reduce nasal discharge and sneezing.\n",
      "- The product may also have a soothing effect due to its combination of ingredients, providing relief from irritation in the nasal passages.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 116:----\n",
      "Detailed Prediction: - The smoker should use the 4 mg nicotine lozenge dosage, as it is recommended for those who smoke their first cigarette within 30 minutes of waking up.\n",
      "- This dosage is designed to help manage withdrawal symptoms and cravings more effectively for individuals with a higher level of nicotine dependence.\n",
      "- It is important to follow the recommended usage instructions for the lozenge to maximize its effectiveness in smoking cessation.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 118:----\n",
      "Detailed Prediction: - Albuterol sulfate was tested in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study indicated no evidence of tumorigenicity in this specific animal model.\n",
      "- This finding suggests a lack of carcinogenic potential for albuterol sulfate in rats at the tested dosage.\n",
      "Final Choice: B\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 119:----\n",
      "Detailed Prediction: - Take esomeprazole magnesium tablets once daily for 14 days.\n",
      "- Swallow the tablets whole, without crushing or chewing them.\n",
      "- Administer the medication at least one hour before a meal for optimal absorption.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 126:----\n",
      "Detailed Prediction: - Consider using Nivolumab, an immune checkpoint inhibitor, as it has shown efficacy in patients with recurrent metastatic non-squamous NSCLC after chemotherapy.\n",
      "- A combination of Atezolizumab with chemotherapy may also be appropriate, particularly if the patient has not previously received immunotherapy.\n",
      "- Evaluate the potential use of Docetaxel as a second-line chemotherapy option for patients who have progressed after Pemetrexed treatment.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 135:----\n",
      "Detailed Prediction: - Agrylin (anagrelide) is not recommended for use in lactating patients due to potential risks to the nursing infant.\n",
      "- It is advised to either discontinue breastfeeding or discontinue Agrylin treatment if necessary.\n",
      "- Consultation with a healthcare provider is essential to discuss alternative treatments and the safety of breastfeeding while on medication.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 136:----\n",
      "Detailed Prediction: - Discontinue the use of hydrocort and remove the occlusive dressings to allow for air exposure and prevent further irritation.\n",
      "- Initiate appropriate antimicrobial therapy based on the type of infection, which may include topical or systemic antibiotics.\n",
      "- Monitor the infection closely for signs of worsening or systemic involvement, and consider referral to a specialist if necessary.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 140:----\n",
      "Detailed Prediction: - Monitor for reduced efficacy of JAIMIESS due to increased metabolism when co-administered with enzyme inducers like rifampin or carbamazepine.\n",
      "- Consider dose adjustments of JAIMIESS to maintain therapeutic levels in patients taking enzyme inducers.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their condition while on enzyme inducers.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 141:----\n",
      "Detailed Prediction: - Monitor liver function tests regularly, as AIRSUPRA may require dose adjustments in patients with severe hepatic impairment.\n",
      "- Assess for signs of increased adverse effects or reduced efficacy due to altered metabolism in patients with significant liver dysfunction.\n",
      "- Consider alternative therapies if the patient's hepatic impairment is severe and impacts the pharmacokinetics of AIRSUPRA.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 142:----\n",
      "Detailed Prediction: - Administer supportive care to manage symptoms of overdose from Iclusig (ponatinib).\n",
      "- Monitor the patient for signs of severe toxicity, including thrombocytopenia and hypertension.\n",
      "- Consider the use of activated charcoal if the overdose is recent and the patient is alert.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 143:----\n",
      "Detailed Prediction: - Sumatriptan is classified as a Category C medication, indicating that risk cannot be ruled out during pregnancy.\n",
      "- Some studies suggest that the use of Sumatriptan may be associated with a slightly increased risk of congenital anomalies, but the evidence is not definitive.\n",
      "- It is generally recommended to use Sumatriptan during pregnancy only if the potential benefits outweigh the risks, particularly in cases of severe migraine.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 144:----\n",
      "Detailed Prediction: - After swimming or sweating, as water and perspiration can reduce the effectiveness of the sunscreen branded as '70%'.\n",
      "- If the sunscreen has been on the skin for more than two hours, it should be reapplied to maintain protection.\n",
      "- If the skin has been towel-dried, as this can remove the sunscreen and necessitate immediate reapplication.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 145:----\n",
      "Detailed Prediction: - Patients with a history of hypersensitivity to Levalbuterol or any of its components should avoid its use.\n",
      "- Individuals with severe cardiac disorders, such as arrhythmias, may experience exacerbated symptoms with Levalbuterol.\n",
      "- Caution is advised in patients with hyperthyroidism, as Levalbuterol can increase heart rate and exacerbate symptoms.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 147:----\n",
      "Detailed Prediction: - GOPRELTO contains the active ingredient remimazolam, which is a sedative that can affect the infant if present in breast milk.\n",
      "- The manufacturer recommends waiting at least 24 hours after GOPRELTO administration before breastfeeding to minimize the risk of sedation in the infant.\n",
      "- There is a potential risk of respiratory depression in the breastfed infant if breastfeeding occurs too soon after the administration of GOPRELTO.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 151:----\n",
      "Detailed Prediction: - The combination of venlafaxine tablets and MAOIs can lead to a dangerous increase in serotonin levels, resulting in serotonin syndrome.\n",
      "- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI), and when taken with MAOIs, it can cause hypertensive crises due to excessive norepinephrine.\n",
      "- The risk of severe side effects necessitates a washout period of at least 14 days between discontinuing MAOIs and starting venlafaxine.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 152:----\n",
      "Detailed Prediction: - Monitor the patient closely for any signs of cardiovascular complications, as GOPRELTO can potentially exacerbate underlying heart conditions.\n",
      "- Consider adjusting the dosage or frequency of GOPRELTO administration based on the patient's overall cardiovascular risk profile.\n",
      "- Consult with a cardiologist to evaluate the appropriateness of continuing GOPRELTO in the context of the patient's myocardial infarction history.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 153:----\n",
      "Detailed Prediction: - Completing the full course of Cleocin Phosphate is essential to ensure the complete eradication of the infection, preventing the development of antibiotic resistance.\n",
      "- Stopping treatment early, even if symptoms improve, can lead to a resurgence of the infection, as not all bacteria may have been eliminated.\n",
      "- Adhering to the prescribed regimen helps maintain effective drug levels in the body, which is crucial for the treatment's success.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 154:----\n",
      "Detailed Prediction: - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled environment, as it can have potent effects.\n",
      "- Always consult a healthcare professional before starting any regimen involving Belladona, especially in pediatric patients.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 157:----\n",
      "Detailed Prediction: - Consider discontinuing Agrylin (anagrelide) as it may be associated with pulmonary complications.\n",
      "- Evaluate the patient for potential drug-induced lung injury, including interstitial lung disease.\n",
      "- Initiate supportive care and further diagnostic imaging, such as a chest CT, to assess the extent of lung infiltrations.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 158:----\n",
      "Detailed Prediction: - Patients taking PERTZYE should consume a diet that is high in calories and protein to support digestion and nutrient absorption.\n",
      "- It is recommended to take PERTZYE with meals and snacks to ensure proper enzyme activity during digestion.\n",
      "- Patients should avoid high-fat meals, as they may lead to gastrointestinal discomfort and reduce the effectiveness of PERTZYE.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 163:----\n",
      "Detailed Prediction: - Zithromax (azithromycin) can lead to increased risk of QT prolongation in elderly patients, especially those with pre-existing heart conditions.\n",
      "- Renal function should be monitored, as elderly patients may have decreased renal clearance, affecting azithromycin metabolism.\n",
      "- Potential drug interactions with other medications commonly prescribed to elderly patients should be assessed to avoid adverse effects.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 166:----\n",
      "Detailed Prediction: - Consider using a backup contraceptive method, such as condoms, when taking enzyme inducers like rifampin or carbamazepine alongside Tri Femynor.\n",
      "- Monitor for potential decreased efficacy of Tri Femynor due to the enzyme-inducing effects of medications like phenytoin or St. John's Wort.\n",
      "- Consult with a healthcare provider to possibly adjust the dosage of Tri Femynor or explore alternative contraceptive options when using strong enzyme inducers.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 172:----\n",
      "Detailed Prediction: - Avoid using clindamycin due to the patient's hypersensitivity history.\n",
      "- Consider alternatives that do not belong to the lincosamide class, such as macrolides or tetracyclines.\n",
      "- Monitor for any cross-reactivity with other antibiotics if necessary.\n",
      "Final Choice: D\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 174:----\n",
      "Detailed Prediction: - Patients taking lamotrigine should immediately contact their healthcare provider if they experience any symptoms of depression or suicidal thoughts.\n",
      "- It is important for patients to not abruptly stop taking lamotrigine without consulting their doctor, as this can lead to withdrawal symptoms or seizure exacerbation.\n",
      "- Regular monitoring and communication with a healthcare professional are essential for managing any mental health changes while on lamotrigine.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 175:----\n",
      "Detailed Prediction: - Evaluate the patient's headache pattern and consider discontinuing Jaimiess if headaches are severe or recurrent.\n",
      "- Assess for other potential causes of headaches, such as medication interactions or underlying conditions, while the patient is on Jaimiess.\n",
      "- Recommend symptomatic treatment for headaches, such as over-the-counter analgesics, while monitoring the patient's response to Jaimiess.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 176:----\n",
      "Detailed Prediction: - Consider dose modification or interruption of MONJUVI based on the severity of the thrombocytopenia.\n",
      "- Monitor the patient's platelet count closely, especially if it drops to 50,000/mcL or less.\n",
      "- Evaluate for potential causes of thrombocytopenia, including drug interactions or underlying conditions.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 177:----\n",
      "Detailed Prediction: - The American Academy of Pediatrics provides evidence-based recommendations for the safe and effective use of D-109 in pediatric populations.\n",
      "- They evaluate clinical studies and data to establish guidelines that ensure appropriate dosing and administration of D-109 in children.\n",
      "- The organization also emphasizes the importance of monitoring for potential side effects and interactions when using D-109 in pediatric patients.\n",
      "Final Choice: E\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 178:----\n",
      "Detailed Prediction: - Zynteglo is not recommended for patients who are seropositive for HIV due to the potential for adverse effects and complications.\n",
      "- Patients with HIV should be evaluated for their viral load and immune status before considering any gene therapy, including Zynteglo.\n",
      "- The treatment may not be effective or safe in the context of an active HIV infection, necessitating alternative therapies.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 180:----\n",
      "Detailed Prediction: - Fosaprepitant for injection contains the active ingredient fosaprepitant dimeglumine.\n",
      "- Fosaprepitant is a prodrug that is converted to aprepitant in the body.\n",
      "- Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist used to prevent nausea and vomiting.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 181:----\n",
      "Detailed Prediction: - Administer Verkazia first before any other eye drops or ointments.\n",
      "- Wait at least 5 minutes before applying any subsequent eye drops after Verkazia.\n",
      "- If using an ointment, apply Verkazia and then wait at least 10 minutes before applying the ointment.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 182:----\n",
      "Detailed Prediction: - The starting regimen for pantoprazole sodium for injection is typically 80 mg administered intravenously as a bolus.\n",
      "- Following the initial bolus, a continuous infusion of pantoprazole sodium at a rate of 8 mg per hour is often used to maintain gastric acid control.\n",
      "- This regimen is specifically designed for patients with Zollinger-Ellison Syndrome to effectively manage excessive gastric acid secretion.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 183:----\n",
      "Detailed Prediction: - Using other short-acting sympathomimetic aerosol bronchodilators, such as levalbuterol, alongside Albuterol can increase the risk of cardiovascular side effects due to excessive stimulation of beta-adrenergic receptors.\n",
      "- Concomitant use may lead to diminished therapeutic effects, as both medications work through similar mechanisms, potentially causing a paradoxical bronchospasm.\n",
      "- The combination can complicate the management of asthma or COPD, making it difficult to assess the effectiveness of Albuterol as a rescue medication.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 187:----\n",
      "Detailed Prediction: - Reduce the JAYPIRCA dosage to 50 mg once daily when co-administered with strong CYP3A inhibitors.\n",
      "- Monitor for potential adverse effects and therapeutic efficacy due to the interaction with strong CYP3A inhibitors.\n",
      "- Consider alternative therapies if significant interactions are anticipated with the use of strong CYP3A inhibitors.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 189:----\n",
      "Detailed Prediction: - Paxlovid, which contains nirmatrelvir and ritonavir, may reduce the effectiveness of hormonal contraceptives containing ethinyl estradiol due to the interaction with ritonavir.\n",
      "- It is recommended to use an alternative or additional non-hormonal contraceptive method during and for at least 28 days after completing Paxlovid treatment.\n",
      "- Patients should be advised to consult their healthcare provider for personalized contraceptive advice while on Paxlovid.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 190:----\n",
      "Detailed Prediction: - Use a sufficient amount of hydrocort shampoo to cover the affected area of the scalp thoroughly.\n",
      "- Typically, a quarter-sized amount is recommended for each application, adjusting based on the size of the area being treated.\n",
      "- Apply the shampoo to dry hair, massaging it into the scalp and leaving it on for the recommended duration before rinsing.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 192:----\n",
      "Detailed Prediction: - Fluoxetine, when combined with Olanzapine, has been shown to be effective in reducing depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination therapy can help stabilize mood and reduce the frequency of depressive episodes compared to monotherapy.\n",
      "- Clinical studies indicate that the combination may improve overall functioning and quality of life for patients experiencing depressive episodes.\n",
      "Final Choice: E\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 193:----\n",
      "Detailed Prediction: - Diclofenac Sodium extended-release formulation may have different pharmacokinetics compared to Diclofenac Potassium tablets, affecting absorption and onset of action.\n",
      "- Topical Diclofenac gel or solution is applied locally and may not achieve systemic levels comparable to oral Diclofenac Potassium tablets, leading to differences in bioavailability.\n",
      "- The formulation of Diclofenac in a transdermal patch can also differ significantly in absorption rates and systemic effects compared to oral Diclofenac Potassium tablets.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 194:----\n",
      "Detailed Prediction: - Patients treated with pantoprazole sodium delayed-release tablets showed a significant percentage of endoscopically proven healing of esophageal lesions after 8 weeks.\n",
      "- The specific percentage reported for healing in these patients was 80%.\n",
      "- This outcome highlights the effectiveness of pantoprazole in managing esophageal lesions compared to placebo.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 195:----\n",
      "Detailed Prediction: - Administer growth factors such as filgrastim or pegfilgrastim to stimulate white blood cell production.\n",
      "- Provide erythropoiesis-stimulating agents like epoetin alfa to manage anemia associated with myelosuppression.\n",
      "- Ensure adequate hydration and consider transfusions for severe thrombocytopenia or anemia to support overall blood counts.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 200:----\n",
      "Detailed Prediction: - The initial treatment with pantoprazole sodium for injection lasted for 3 days.\n",
      "- After the initial treatment, patients were switched to oral pantoprazole sodium delayed-release tablets for continued management.\n",
      "- This regimen aimed to provide rapid symptom relief followed by maintenance therapy with the oral formulation.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 201:----\n",
      "Detailed Prediction: - Fosaprepitant can cause infusion site reactions, including pain and swelling at the injection site.\n",
      "- There is a risk of thrombophlebitis, which is inflammation of the vein where the drug is infused.\n",
      "- Serious allergic reactions, such as anaphylaxis, may also occur at or near the infusion site.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 204:----\n",
      "Detailed Prediction: - Assess the patient's baseline cardiac function, as Agrylin (anagrelide) can cause dose-dependent cardiotoxicity.\n",
      "- Monitor for signs of heart failure or arrhythmias, particularly in patients with pre-existing heart conditions.\n",
      "- Consider alternative therapies if the patient has significant underlying cardiopulmonary disease, due to the potential for exacerbation of these conditions.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 205:----\n",
      "Detailed Prediction: - BRILINTA (ticagrelor) should be used with caution in patients with end-stage renal disease (ESRD) on dialysis due to the lack of specific dosing recommendations for this population.\n",
      "- The prescribing information suggests that the use of BRILINTA in patients with severe renal impairment should be considered only if the potential benefits outweigh the risks.\n",
      "- Close monitoring for bleeding and other adverse effects is recommended when administering BRILINTA to patients undergoing dialysis.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 206:----\n",
      "Detailed Prediction: - Antifungal medications are commonly indicated for conditions such as tinea pedis (athlete's foot), which is caused by dermatophyte fungi.\n",
      "- They are also used to treat candidiasis, particularly in cases of cutaneous candidiasis where Candida species infect the skin.\n",
      "- Another condition that antifungals can address is tinea corporis (ringworm), which is another dermatophyte infection affecting the body.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 207:----\n",
      "Detailed Prediction: - Patients with a history of hypersensitivity to Levalbuterol should avoid using this medication to prevent potential allergic reactions.\n",
      "- Alternative bronchodilators, such as Albuterol, may be considered, but should be used with caution and under medical supervision.\n",
      "- It is essential to monitor for any signs of an allergic reaction if a different medication is prescribed.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 209:----\n",
      "Detailed Prediction: - ARIKAYCE, which contains the active ingredient amikacin liposome inhalation suspension, has not been specifically studied for its effects on fertility in clinical trials.\n",
      "- The available data primarily focus on its efficacy and safety in treating lung infections caused by Mycobacterium avium complex, rather than reproductive outcomes.\n",
      "- As a result, there is limited information regarding the impact of ARIKAYCE on fertility in both males and females.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 210:----\n",
      "Detailed Prediction: - Patients with a known hypersensitivity to Guanfacine or any of its components should not be prescribed this medication.\n",
      "- Guanfacine extended-release is contraindicated in patients with severe cardiovascular disorders, such as bradycardia or hypotension.\n",
      "- It should not be used in patients with a history of syncope, as it may exacerbate this condition.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 212:----\n",
      "Detailed Prediction: - Patients with hepatic impairment should undergo careful evaluation before starting Zynteglo treatment due to potential altered drug metabolism.\n",
      "- It is recommended to monitor liver function tests closely during the treatment with Zynteglo to assess any adverse effects.\n",
      "- Dose adjustments may be necessary for patients with moderate to severe hepatic impairment when considering Zynteglo therapy.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 215:----\n",
      "Detailed Prediction: - Motion Sickness is commonly used to prevent and treat dizziness associated with travel-related nausea, such as in cars, boats, or airplanes.\n",
      "- The drug is often administered in the form of transdermal patches or oral tablets to provide relief from symptoms during motion.\n",
      "- It works by blocking signals to the brain that cause the sensation of dizziness and nausea, particularly in individuals prone to motion sickness.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 218:----\n",
      "Detailed Prediction: - The maximum number of nicotine lozenges that can be used in a single day is 24.\n",
      "- This dosage is typically recommended for individuals who are using the lozenges as part of a smoking cessation program.\n",
      "- It is important to follow the guidelines provided by healthcare professionals to avoid potential side effects from excessive nicotine intake.\n",
      "Final Choice: D\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 221:----\n",
      "Detailed Prediction: - Take the missed dose of RoxyBond as soon as remembered, unless it is almost time for the next scheduled dose.\n",
      "- If it is close to the time for the next dose, skip the missed dose and resume the regular dosing schedule.\n",
      "- Do not take two doses of RoxyBond at the same time to make up for the missed dose.\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 222:----\n",
      "Detailed Prediction: - Assess the patient's renal function, as Paxlovid dosage may need adjustment in patients with renal impairment.\n",
      "- Review the patient's current medications for potential drug interactions, particularly with CYP3A inhibitors and inducers.\n",
      "- Confirm the patient's COVID-19 diagnosis and symptom onset to ensure they meet the criteria for Paxlovid treatment.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 223:----\n",
      "Detailed Prediction: - JAYPIRCA is known to inhibit CYP3A4, which can lead to increased plasma concentrations of drugs metabolized by this enzyme.\n",
      "- Co-administration of JAYPIRCA with CYP3A substrates may require dose adjustments to avoid potential toxicity.\n",
      "- Patients taking medications that are CYP3A substrates should be monitored closely when starting or stopping JAYPIRCA therapy.\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 224:----\n",
      "Detailed Prediction: - Reduce the dosage of Dopamine due to the potential for increased sensitivity and risk of hypertensive crisis in patients who have recently used MAO inhibitors.\n",
      "- Monitor the patient closely for any signs of excessive adrenergic stimulation or hypertensive episodes when initiating Dopamine therapy.\n",
      "- Consider starting at a lower infusion rate and titrate cautiously based on the patient's response and blood pressure readings.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 226:----\n",
      "Detailed Prediction: - G-62 is a cephalosporin antibiotic, which may have cross-reactivity with penicillins in patients with a history of penicillin allergy.\n",
      "- It is advisable to assess the severity of the previous allergic reaction to penicillins before considering G-62.\n",
      "- If the allergic reaction was severe (e.g., anaphylaxis), G-62 should be avoided and an alternative antibiotic should be prescribed.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 227:----\n",
      "Detailed Prediction: - Nicotine is primarily indicated for smoking cessation to help individuals quit smoking by reducing withdrawal symptoms and cravings.\n",
      "- It is available in various forms, including nicotine patches, gum, and lozenges, to provide a controlled dose of nicotine.\n",
      "- The drug is often used as part of a comprehensive smoking cessation program that may include behavioral therapy and support.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 228:----\n",
      "Detailed Prediction: - The use of a laxative specifically formulated for women is expected to provide relief from occasional constipation by promoting bowel movements.\n",
      "- These laxatives may contain ingredients such as polyethylene glycol or senna, which help soften stool and stimulate intestinal activity.\n",
      "- Users can anticipate a decrease in abdominal discomfort and an improvement in bowel regularity following the administration of the laxative.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 229:----\n",
      "Detailed Prediction: - At a dosage of less than 5 mcg/kg/minute, Dopamine primarily activates D1 receptors, leading to renal vasodilation.\n",
      "- This low dose of Dopamine has minimal effect on beta-adrenergic receptors, which are more influenced at higher doses.\n",
      "- The primary action at this dosage is to enhance renal blood flow without significant increases in heart rate or contractility.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 230:----\n",
      "Detailed Prediction: - The drug that blocked the tumorigenic effect of albuterol sulfate in Sprague-Dawley rats is a specific beta-blocker.\n",
      "- This beta-blocker was administered in a regimen that counteracted the effects of albuterol sulfate.\n",
      "- The study demonstrated a significant reduction in tumor formation when the beta-blocker was used alongside albuterol sulfate compared to controls.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 231:----\n",
      "Detailed Prediction: - Junel 21 Day, a combination oral contraceptive pill, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective.\n",
      "- Barrier methods, such as condoms, have a typical failure rate of about 13% with typical use, which is higher than that of Junel 21 Day.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 234:----\n",
      "Detailed Prediction: - Dialysis can help remove certain drugs from the bloodstream, but AIRSUPRA, which contains the active ingredient sublingual sufentanil, is primarily metabolized by the liver.\n",
      "- The effectiveness of dialysis in managing AIRSUPRA overdosage is limited due to its high protein binding and lipophilicity, which reduces its clearance through dialysis.\n",
      "- Supportive care and monitoring are typically the mainstays of treatment for AIRSUPRA overdosage rather than dialysis.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 235:----\n",
      "Detailed Prediction: - Activated charcoal may be administered to reduce absorption of the active ingredients in the Nighttime Sleep Aid if the patient presents within a suitable time frame post-ingestion.\n",
      "- Supportive care, including monitoring vital signs and providing respiratory support, is crucial in managing symptoms of overdose from the Nighttime Sleep Aid.\n",
      "- Flumazenil, a benzodiazepine antagonist, may be considered in cases of severe sedation, but its use is controversial and should be approached with caution.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 237:----\n",
      "Detailed Prediction: - Albuterol sulfate did not show any adverse effects on fertility or reproductive performance in rats at oral doses up to 50 mg/kg.\n",
      "- The study indicated that there were no significant changes in mating performance or reproductive outcomes in the treated groups compared to controls.\n",
      "- No teratogenic effects were observed in offspring from rats administered albuterol sulfate at the specified doses.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 238:----\n",
      "Detailed Prediction: - Evaluate for potential infections, as persistent fever may indicate an underlying infection in patients receiving REMICADE (infliximab).\n",
      "- Consider discontinuing REMICADE if the fever persists and is associated with other systemic symptoms, to prevent further complications.\n",
      "- Monitor the patient's clinical status closely and initiate appropriate diagnostic tests to identify the cause of the fever.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 241:----\n",
      "Detailed Prediction: - The treatment arm that included pembrolizumab plus pemetrexed and carboplatin had the highest overall response rate (ORR).\n",
      "- This combination was compared to the placebo plus pemetrexed and carboplatin in the study.\n",
      "- The assessment was conducted using BICR RECIST v1.1 criteria.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 242:----\n",
      "Detailed Prediction: - Animal studies have shown that pantoprazole sodium can lead to decreased bone mineral density in offspring.\n",
      "- Exposure to pantoprazole during pregnancy resulted in altered bone development parameters in animal models.\n",
      "- The drug's mechanism as a proton pump inhibitor may interfere with calcium absorption, impacting skeletal growth in developing offspring.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 243:----\n",
      "Detailed Prediction: - Patients with a history of severe allergic reactions to gadolinium-based contrast agents should avoid Gadavist.\n",
      "- Individuals with acute or chronic renal insufficiency are at increased risk for nephrogenic systemic fibrosis when using Gadavist.\n",
      "- Pregnant women should consider the risks versus benefits of Gadavist, as its safety during pregnancy has not been established.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 245:----\n",
      "Detailed Prediction: - The drug branded as 70% is effective when applied daily as part of a comprehensive skincare regimen that includes sun protection.\n",
      "- It significantly reduces the risk of skin cancer and early skin aging when used in conjunction with other protective measures, such as wearing protective clothing and seeking shade.\n",
      "- Clinical studies have shown that consistent use of the drug leads to a 70% decrease in the incidence of skin cancer compared to a placebo group.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 246:----\n",
      "Detailed Prediction: - Fluoxetine treatment in juvenile rats resulted in altered reproductive hormone levels, specifically decreased testosterone and increased prolactin.\n",
      "- The study observed a reduction in sperm count and motility in male rats treated with fluoxetine.\n",
      "- Female rats exhibited disrupted estrous cycles and reduced fertility rates following fluoxetine administration.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 247:----\n",
      "Detailed Prediction: - Contains diphenhydramine, an antihistamine that promotes drowsiness and helps alleviate nighttime symptoms of cold and flu.\n",
      "- Includes a pain reliever like acetaminophen, which can reduce discomfort and allow for more restful sleep.\n",
      "- Formulated to relieve nasal congestion and cough, minimizing disturbances during the night for better sleep quality.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 248:----\n",
      "Detailed Prediction: - Renal impairment can lead to decreased clearance of AIRSUPRA, resulting in higher plasma concentrations of the drug.\n",
      "- Patients with moderate to severe renal impairment may require dose adjustments to avoid potential toxicity.\n",
      "- Monitoring for adverse effects is essential in patients with renal impairment receiving AIRSUPRA due to altered pharmacokinetics.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 249:----\n",
      "Detailed Prediction: - The group receiving the placebo showed the smallest mean change in plasma glucose 1 hour after the first dose.\n",
      "- In contrast, the active treatment group with the drug demonstrated a more significant change in plasma glucose levels.\n",
      "- The results indicate that the placebo had minimal impact on plasma glucose compared to the active intervention.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 251:----\n",
      "Detailed Prediction: - Junel 21 Day contains ethinyl estradiol and norethindrone, which may affect milk production in breastfeeding mothers.\n",
      "- It is recommended to wait until at least 6 weeks postpartum before starting combination oral contraceptives like Junel 21 Day to minimize potential risks to breastfeeding.\n",
      "- Breastfeeding mothers should discuss with their healthcare provider the timing and potential impact of Junel 21 Day on both milk supply and infant health.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 254:----\n",
      "Detailed Prediction: - Consuming food or beverages can interfere with the absorption of nicotine from the lozenge, reducing its effectiveness.\n",
      "- Acidic drinks, such as coffee or soda, can alter the pH in the mouth, potentially affecting how well the nicotine is absorbed.\n",
      "- To maximize the therapeutic effect of the nicotine lozenge, it is advised to keep the mouth free of other substances during its use.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 257:----\n",
      "Detailed Prediction: - ARIKAYCE is formulated as a liposomal formulation of amikacin, which allows for localized delivery to the lungs, reducing systemic absorption.\n",
      "- The dosing regimen for ARIKAYCE involves once-daily administration, which minimizes the risk of accumulation compared to traditional intravenous amikacin dosing.\n",
      "- In patients with renal impairment, the pharmacokinetics of inhaled amikacin from ARIKAYCE differ significantly from systemic administration, leading to lower systemic exposure and reduced risk of toxicity.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 259:----\n",
      "Detailed Prediction: - The symptom of \"sore throat\" is not mentioned as being relieved by 'nighttime severe cold and flu'.\n",
      "- \"Cough\" is specifically noted as being alleviated by the medication.\n",
      "- \"Fever\" is also listed among the symptoms that the product aims to relieve.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 261:----\n",
      "Detailed Prediction: - Dopamine HCl can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood is contaminated, increasing the risk of infection.\n",
      "- Administering dopamine with blood can alter the effectiveness of the drug, potentially affecting hemodynamic stability in patients.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 264:----\n",
      "Detailed Prediction: - Consider discontinuing BRILINTA (ticagrelor) if the dyspnea is severe and persistent, as this medication can cause respiratory side effects.\n",
      "- Evaluate the patient's overall clinical status and consider alternative antiplatelet therapy, such as clopidogrel, if BRILINTA is not tolerated.\n",
      "- Monitor the patient closely for any signs of worsening respiratory distress or other complications related to the dyspnea.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 265:----\n",
      "Detailed Prediction: - Assess the patient's current medications to avoid potential interactions, particularly with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs.\n",
      "- Evaluate the patient's history of hypertension, as venlafaxine can increase blood pressure, especially at higher doses.\n",
      "- Consider the patient's mental health history, particularly any history of bipolar disorder, to prevent the risk of manic episodes.\n",
      "Final Choice: C\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 266:----\n",
      "Detailed Prediction: - The formulation includes acetaminophen, which is effective for reducing fever and alleviating pain associated with cold and flu symptoms.\n",
      "- It targets body aches and sore throat discomfort, providing symptomatic relief during nighttime.\n",
      "- The product is designed to help manage pain while also addressing other cold and flu symptoms, ensuring a more restful sleep.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 273:----\n",
      "Detailed Prediction: - Discontinue NURTEC ODT if Raynaud‚Äôs phenomenon develops, as it may exacerbate vasospasm.\n",
      "- Consider alternative treatments for migraine management that do not have vasoconstrictive properties.\n",
      "- Monitor the patient for any worsening symptoms and provide supportive care for Raynaud‚Äôs phenomenon.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 274:----\n",
      "Detailed Prediction: - Administer atropine as it is the first-line treatment for severe bradycardia.\n",
      "- Consider discontinuing the BREVIBLOC injection if bradycardia persists despite atropine administration.\n",
      "- Monitor the patient's heart rate and rhythm closely after any intervention to assess response.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 277:----\n",
      "Detailed Prediction: - GOPRELTO contains the active ingredient remimazolam, which can interact with disulfiram, potentially leading to increased sedation or respiratory depression.\n",
      "- Disulfiram is used to treat alcohol dependence and can cause adverse reactions when combined with certain medications, including those that affect the central nervous system like remimazolam.\n",
      "- The combination may lead to unpredictable pharmacological effects, making it crucial to avoid using GOPRELTO in patients currently on disulfiram therapy.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 280:----\n",
      "Detailed Prediction: - Monitor for increased suicidal thoughts or behaviors, particularly during the initial treatment phase or when doses are adjusted.\n",
      "- Assess for changes in mood, anxiety levels, and any emergence of agitation or irritability.\n",
      "- Regularly evaluate for side effects such as increased blood pressure, as venlafaxine can cause dose-dependent hypertension.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 281:----\n",
      "Detailed Prediction: - OCELLA is a combination oral contraceptive that contains ethinyl estradiol and drospirenone, which are not recommended for use during pregnancy due to potential risks to the fetus.\n",
      "- If a woman becomes pregnant while taking OCELLA, she should discontinue the medication immediately and consult her healthcare provider for further guidance.\n",
      "- The use of OCELLA during pregnancy is classified as Category X, indicating that the risks of using the drug in pregnant women clearly outweigh any potential benefits.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 282:----\n",
      "Detailed Prediction: - The pregnancy registry for Albuterol Sulfate HFA aims to collect data on the effects of the drug on pregnant women and their infants.\n",
      "- It helps to assess the safety and potential risks of using Albuterol Sulfate HFA during pregnancy compared to a control group not using the medication.\n",
      "- The registry provides valuable information to healthcare providers and patients regarding the outcomes of pregnancies exposed to Albuterol Sulfate HFA.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 284:----\n",
      "Detailed Prediction: - Nighttime severe cold and flu can relieve nasal congestion, allowing for easier breathing during sleep.\n",
      "- It may reduce coughing, which can disrupt sleep and lead to better rest.\n",
      "- The formulation often includes ingredients that alleviate body aches, contributing to overall comfort and improved sleep quality.\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 285:----\n",
      "Detailed Prediction: - Ondansetron may enhance the analgesic effects of Tramadol, potentially leading to improved pain relief.\n",
      "- The combination could increase the risk of serotonin syndrome, especially if Tramadol is used at higher doses.\n",
      "- Patients should be monitored for increased sedation or gastrointestinal side effects due to the interaction between Ondansetron and Tramadol.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 287:----\n",
      "Detailed Prediction: - The highest dose of fluoxetine administered to adult rats was 40 mg/kg.\n",
      "- This dose is approximately 2.5 times the maximum recommended human dose (MRHD) on a mg/m¬≤ basis.\n",
      "Final Choice: E\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 288:----\n",
      "Detailed Prediction: - Assess the patient's renal function using the estimated glomerular filtration rate (eGFR) to determine the risk of nephrogenic systemic fibrosis (NSF) associated with Gadavist.\n",
      "- Consider alternative imaging modalities that do not require gadolinium-based contrast agents if the eGFR is below 30 mL/min.\n",
      "- Ensure that hydration status is optimized and discuss the potential use of alternative contrast agents or protocols if renal impairment is significant.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 289:----\n",
      "Detailed Prediction: - The antifungal brand-name drug should be used daily for a duration of 2 to 4 weeks.\n",
      "- It is important to apply the medication to the affected area and surrounding skin as directed.\n",
      "- Consistent daily use is crucial for effective treatment and to prevent recurrence of athlete's foot.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 291:----\n",
      "Detailed Prediction: - Concurrent use of monoamine oxidase inhibitors (MAOIs) such as phenelzine or tranylcypromine increases the risk of serotonin syndrome when combined with fluoxetine.\n",
      "- Use of other serotonergic drugs like triptans (e.g., sumatriptan) or certain antidepressants (e.g., venlafaxine) alongside fluoxetine can lead to serotonin syndrome.\n",
      "- A history of serotonin syndrome with previous use of fluoxetine or other SSRIs is a contraindication for its use due to the heightened risk.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 293:----\n",
      "Detailed Prediction: - The product should not be stored at temperatures above 25¬∞C (77¬∞F), as excessive heat can degrade its effectiveness.\n",
      "- It should not be exposed to direct sunlight or moisture, which can compromise the integrity of the active ingredients.\n",
      "- The product should not be kept in a bathroom, where humidity levels can fluctuate and affect the medication.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "----Row 298:----\n",
      "Detailed Prediction: - The median seizure frequency reduction with a 400 mg/day dose of lamotrigine was significantly greater than that observed with placebo.\n",
      "- In the trial, patients receiving lamotrigine experienced a median reduction of approximately 50% in seizure frequency.\n",
      "- The results indicated that lamotrigine at this dosage provided a meaningful therapeutic benefit over the placebo group.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 299:----\n",
      "Detailed Prediction: - Users may experience a tingling sensation in the mouth as the nicotine lozenge dissolves.\n",
      "- Some individuals report a mild burning sensation on the tongue or mucous membranes due to the nicotine content.\n",
      "- A user might also feel a rush of nicotine, leading to a sense of alertness or increased focus shortly after using the lozenge.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 302:----\n",
      "Detailed Prediction: - Patients using OZOBAX DS, which contains the active ingredient buprenorphine, during pregnancy should be monitored for neonatal withdrawal symptoms.\n",
      "- Infants born to mothers who have been treated with buprenorphine may experience withdrawal symptoms due to in utero exposure.\n",
      "- Close observation of neonates for signs of withdrawal, such as irritability, feeding difficulties, and tremors, is essential in this population.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 303:----\n",
      "Detailed Prediction: - Breastfeeding is generally considered safe for mothers treated with FOSAPREPITANT, as it is not expected to significantly affect breast milk.\n",
      "- The drug is a neurokinin-1 receptor antagonist used for the prevention of nausea and vomiting associated with chemotherapy, and limited data suggest minimal transfer into breast milk.\n",
      "- However, it is always advisable for breastfeeding mothers to consult their healthcare provider for personalized recommendations based on their specific situation.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 304:----\n",
      "Detailed Prediction: - Liver function tests (LFTs) should be monitored at baseline and every 3 months during the first year of treatment with Signifor LAR.\n",
      "- If LFTs are elevated, more frequent monitoring may be necessary, and treatment should be reassessed.\n",
      "- Patients should be monitored for symptoms of liver dysfunction, such as jaundice or abdominal pain, throughout the treatment period.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 306:----\n",
      "Detailed Prediction: - Physicians should monitor for potential misuse or abuse of Fluoxetine, as it is an SSRI that can be misused by individuals with a history of substance use disorders.\n",
      "- It's important to assess the patient's overall treatment plan, including any concurrent medications or therapies, to avoid interactions that could lead to increased risk of abuse.\n",
      "- Regular follow-up appointments should be scheduled to evaluate the patient's response to Fluoxetine and to ensure adherence to the treatment regimen without relapse into substance abuse.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 307:----\n",
      "Detailed Prediction: - Monitor lipid levels regularly to assess the impact of Tri Femynor on dyslipidemia.\n",
      "- Consider lifestyle modifications alongside the use of Tri Femynor to improve lipid profiles.\n",
      "- Evaluate the potential need for additional lipid-lowering medications if dyslipidemia remains uncontrolled while on Tri Femynor.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 311:----\n",
      "Detailed Prediction: - Discontinue the use of Ondansetron immediately to prevent further hypersensitivity reactions.\n",
      "- Administer appropriate emergency treatment for anaphylaxis, which may include epinephrine and supportive care.\n",
      "- Document the hypersensitivity reaction in the patient's medical record and consider alternative antiemetic therapies.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 312:----\n",
      "Detailed Prediction: - Patients with mild to moderate renal impairment should avoid using ibuprofen concurrently with Pemetrexed, as ibuprofen can increase the risk of Pemetrexed toxicity due to reduced renal clearance.\n",
      "- It is recommended that renal function be monitored closely in patients taking Pemetrexed, especially if they are also using nonsteroidal anti-inflammatory drugs like ibuprofen.\n",
      "- Dose adjustments for Pemetrexed may be necessary in patients with renal impairment to prevent adverse effects, particularly if they are also taking ibuprofen.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 317:----\n",
      "Detailed Prediction: - The primary indication for the use of 'laxative for women' is to relieve constipation, particularly in women who may experience hormonal changes affecting bowel regularity.\n",
      "- It is often recommended for women during pregnancy or postpartum to manage constipation safely.\n",
      "- The formulation may include ingredients specifically designed to be gentle on the digestive system while effectively promoting bowel movements.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 318:----\n",
      "Detailed Prediction: - Consider discontinuing Ogivri if the patient shows a ‚â•16% absolute decrease in LVEF, as this may indicate potential cardiotoxicity.\n",
      "- Monitor the patient's cardiac function closely, including regular echocardiograms, to assess any further changes in LVEF.\n",
      "- Evaluate the patient's overall clinical status and consider alternative treatment options if the decrease in LVEF is significant and persistent.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 319:----\n",
      "Detailed Prediction: - The recommended storage temperature range for the drug 'sterile' is between 36¬∞F and 46¬∞F.\n",
      "- It is important to keep the drug away from extreme temperatures to maintain its efficacy.\n",
      "- Storing the drug outside of this range may compromise its sterility and effectiveness.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 320:----\n",
      "Detailed Prediction: - Regular use of dg health nasal may lead to noticeable effects within a few days to a week.\n",
      "- Full therapeutic benefits are typically observed after consistent use over several weeks.\n",
      "- Individual responses can vary, but ongoing use is essential for optimal results.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 323:----\n",
      "Detailed Prediction: - Albuterol primarily acts as a selective beta-2 adrenergic agonist, leading to bronchodilation with minimal cardiovascular effects compared to Isoproterenol.\n",
      "- Isoproterenol is a non-selective beta-adrenergic agonist that can increase heart rate and myocardial contractility, resulting in more pronounced cardiovascular effects.\n",
      "- At comparable doses, Albuterol is less likely to cause tachycardia and other cardiovascular side effects than Isoproterenol.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 324:----\n",
      "Detailed Prediction: - The daytime formulation typically contains non-drowsy ingredients, allowing individuals to manage cold and flu symptoms without sedation.\n",
      "- It often includes a combination of pain relievers like acetaminophen and decongestants to alleviate symptoms while maintaining alertness.\n",
      "- The formulation is designed to provide relief from symptoms such as nasal congestion and headache, enabling continued daily activities.\n",
      "Final Choice: D\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 325:----\n",
      "Detailed Prediction: - Nicotine specifically targets withdrawal symptoms, particularly cravings for cigarettes.\n",
      "- It helps alleviate irritability and anxiety that often accompany the cessation of smoking.\n",
      "- Nicotine replacement therapies aim to reduce the physical dependence on nicotine, making it easier for individuals to quit.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 328:----\n",
      "Detailed Prediction: - Monitor patients closely for potential cardiovascular effects, as Albuterol can exacerbate side effects when used with monoamine oxidase inhibitors.\n",
      "- Consider adjusting the dosage of Albuterol, as the interaction with tricyclic antidepressants may increase the risk of hypertension and tachycardia.\n",
      "- Educate patients about the signs of increased heart rate or blood pressure, which may occur due to the combined effects of Albuterol and their current medications.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 329:----\n",
      "Detailed Prediction: - Hepatic impairment can lead to decreased metabolism of Jaimiess, resulting in increased plasma concentrations of the drug.\n",
      "- Patients with moderate to severe hepatic impairment may require dose adjustments of Jaimiess to avoid potential toxicity.\n",
      "- The pharmacokinetics of Jaimiess are significantly altered in individuals with liver dysfunction, necessitating careful monitoring.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 330:----\n",
      "Detailed Prediction: - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of the laxative for women, taken once daily.\n",
      "- It is important to ensure that the laxative is suitable for pediatric use and to follow the specific product guidelines.\n",
      "- Always consult a healthcare professional before administering any laxative to children to confirm the appropriate dosage and safety.\n",
      "Final Choice: D\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 334:----\n",
      "Detailed Prediction: - Clindamycin phosphate is present in Clindamycin topical lotion at a concentration of 1%.\n",
      "- This formulation is specifically designed for topical application to treat acne.\n",
      "- Clindamycin phosphate is a prodrug that is converted to clindamycin, which is the active antibiotic component.\n",
      "Final Choice: E\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 339:----\n",
      "Detailed Prediction: - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25¬∞C (77¬∞F).\n",
      "- It is important to keep the medication away from excessive heat and moisture to maintain its efficacy.\n",
      "- Proper storage conditions help prevent degradation of the active ingredient in 'up and up ibuprofen'.\n",
      "Final Choice: A\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 341:----\n",
      "Detailed Prediction: - RETHYMIC is contraindicated in patients with a history of hypersensitivity to any of its components, similar to how certain drugs like penicillin are contraindicated in individuals with a known allergy to penicillin.\n",
      "- Unlike some immunosuppressants that may have contraindications related to active infections, RETHYMIC's contraindications specifically include active infections due to its immunosuppressive effects.\n",
      "- RETHYMIC should not be used in patients with severe hepatic impairment, which is a common contraindication seen in drugs like methotrexate that also require careful liver function monitoring.\n",
      "Final Choice: C\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 342:----\n",
      "Detailed Prediction: - JAYPIRCA is contraindicated in patients with a history of hypersensitivity to its active ingredient, which is the drug itself.\n",
      "- It should not be used in patients with severe hepatic impairment, as this can lead to increased drug exposure and toxicity.\n",
      "- Co-administration with strong CYP3A inhibitors is contraindicated due to the potential for significantly increased plasma concentrations of JAYPIRCA.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 343:----\n",
      "Detailed Prediction: - Rinse the mouth with water after using AIRSUPRA to help remove any residual medication that could promote fungal growth.\n",
      "- Consider using an antifungal mouthwash if there is a history of recurrent oropharyngeal candidiasis.\n",
      "- Maintain good oral hygiene practices, including regular brushing and flossing, to minimize the risk of infections.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 344:----\n",
      "Detailed Prediction: - The patient may have significant drug interactions with Paxlovid, particularly if they are taking medications like certain statins or anticonvulsants that are contraindicated with the components of Paxlovid.\n",
      "- The patient could have a history of severe allergic reactions to components of Paxlovid, such as nirmatrelvir or ritonavir, which would warrant avoiding its use.\n",
      "- The patient may have renal impairment, as Paxlovid dosing is adjusted based on renal function, and in severe cases, it may not be recommended.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 345:----\n",
      "Detailed Prediction: - The Ames test was used to evaluate the genotoxicity of Fluoxetine and Norfluoxetine, showing no mutagenic effects.\n",
      "- In vitro assays, including the micronucleus test, indicated that neither Fluoxetine nor Norfluoxetine caused chromosomal damage.\n",
      "- The results from the Comet assay confirmed that Fluoxetine and its metabolite did not induce DNA strand breaks.\n",
      "Final Choice: D\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 346:----\n",
      "Detailed Prediction: - The mortality rate in patients treated with NUZYRA for CABP was observed to be lower than that in patients treated with moxifloxacin.\n",
      "- In clinical trials, NUZYRA demonstrated a statistically significant reduction in mortality compared to moxifloxacin.\n",
      "- The specific mortality rates reported for NUZYRA were 2.5% versus 4.0% for moxifloxacin in the studied population.\n",
      "Final Choice: E\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 349:----\n",
      "Detailed Prediction: - Use CLEOCIN PHOSPHATE only for confirmed bacterial infections to minimize unnecessary exposure.\n",
      "- Complete the full course of CLEOCIN PHOSPHATE as prescribed, even if symptoms improve, to ensure all bacteria are eradicated.\n",
      "- Avoid using CLEOCIN PHOSPHATE in combination with other antibiotics unless specifically directed by a healthcare provider to prevent resistance development.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 351:----\n",
      "Detailed Prediction: - Apply the beard growth oil twice daily to the areas of beard loss or where facial hair is desired.\n",
      "- Ensure the oil is massaged gently into the skin to promote absorption and stimulate hair follicles.\n",
      "- Consistent application over several weeks is recommended for optimal results in hair regrowth.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 358:----\n",
      "Detailed Prediction: - Seek immediate medical attention, as a sudden, severe headache could indicate a serious condition such as a stroke or blood clot, especially while on Tri Femynor.\n",
      "- Inform the healthcare provider about the use of Tri Femynor, as hormonal contraceptives can increase the risk of thromboembolic events.\n",
      "- Do not ignore other accompanying symptoms such as vision changes, weakness, or difficulty speaking, as these may indicate a more serious issue related to the headache.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 359:----\n",
      "Detailed Prediction: - Patients should immediately report any signs or symptoms of Raynaud‚Äôs phenomenon, such as color changes in fingers or toes, to their healthcare provider while taking NURTEC ODT.\n",
      "- It is important to assess the need for a potential adjustment in treatment or additional management strategies if symptoms occur during NURTEC ODT therapy.\n",
      "- Patients may need to consider lifestyle modifications, such as avoiding cold exposure, to help manage symptoms associated with Raynaud‚Äôs phenomenon while on NURTEC ODT.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 363:----\n",
      "Detailed Prediction: - Monitor patients closely for signs of misuse, abuse, or addiction, especially if they have a history of substance use disorders.\n",
      "- Consider starting with a lower dose of Lyrica CR and titrate slowly to minimize the risk of dependence.\n",
      "- Educate patients about the potential for abuse and the importance of adhering to the prescribed regimen without exceeding the recommended dosage.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 364:----\n",
      "Detailed Prediction: - Consider using the combination of Drug X and Drug Y for severe cases, as they have shown improved efficacy compared to TOXEX.\n",
      "- In clinical trials, the regimen involving Drug Z demonstrated a significant reduction in disease severity, making it a preferred alternative.\n",
      "- For patients with contraindications to TOXEX, the use of Placebo A has been suggested to monitor disease progression without active intervention.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 365:----\n",
      "Detailed Prediction: - Women taking Jaimiess should consider stopping the medication at least 4 weeks prior to major surgery to reduce the risk of thromboembolic events.\n",
      "- It is important to discuss with the healthcare provider about the timing of resuming Jaimiess after surgery, typically around 2 weeks post-operative if there are no complications.\n",
      "- Patients should be monitored for any signs of thrombosis during the perioperative period, especially if they have additional risk factors.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 367:----\n",
      "Detailed Prediction: - The beta blocker that produced significant bronchospasm in mildly asthmatic patients is propranolol.\n",
      "- Propranolol is a non-selective beta blocker, which can affect both beta-1 and beta-2 adrenergic receptors.\n",
      "- Clinical studies have shown that non-selective beta blockers like propranolol can exacerbate asthma symptoms.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 368:----\n",
      "Detailed Prediction: - Co-administration of Lyrica (pregabalin) with ethanol can lead to increased sedation and impairment in cognitive and motor functioning.\n",
      "- The combination may enhance the side effects of Lyrica, such as dizziness and drowsiness, leading to a higher risk of accidents.\n",
      "- Patients should be cautioned against consuming alcohol while taking Lyrica due to the potential for additive central nervous system depression.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 370:----\n",
      "Detailed Prediction: - Agrylin (anagrelide) is primarily metabolized in the liver, and severe hepatic impairment can lead to increased plasma concentrations of the drug.\n",
      "- Elevated levels of Agrylin may increase the risk of adverse effects, such as thrombocytopenia and cardiovascular complications.\n",
      "- The pharmacokinetics of Agrylin are significantly altered in patients with severe hepatic impairment, necessitating caution or avoidance of its use.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 372:----\n",
      "Detailed Prediction: - Reduce the JAYPIRCA dose to 50 mg once daily when used with a strong CYP3A inhibitor.\n",
      "- Monitor for increased adverse reactions due to elevated JAYPIRCA levels from the interaction with the CYP3A inhibitor.\n",
      "- Consider alternative treatments that do not involve strong CYP3A inhibitors if possible.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 373:----\n",
      "Detailed Prediction: - The primary endpoint was the time to intervention for mood episodes, specifically focusing on the prevention of depressive episodes in patients treated with lamotrigine.\n",
      "- Lamotrigine was compared to placebo to assess its efficacy in maintaining mood stability over a specified duration.\n",
      "- The study measured the occurrence of manic or depressive episodes as a key outcome to determine the effectiveness of lamotrigine in long-term management.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 377:----\n",
      "Detailed Prediction: - Gadavist is a gadolinium-based contrast agent, which may pose risks to fetal development due to potential toxicity associated with gadolinium exposure.\n",
      "- Pregnant women may experience altered pharmacokinetics, leading to increased retention of Gadavist in the body, which could heighten the risk of adverse effects.\n",
      "- The use of Gadavist during pregnancy is generally avoided unless absolutely necessary, as there are concerns regarding its safety profile and the lack of sufficient studies on its effects in pregnant populations.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 382:----\n",
      "Detailed Prediction: - The dg health nasal spray may influence growth rates in children aged 4 to 11 years by potentially affecting hormonal levels related to growth.\n",
      "- If the nasal spray contains active ingredients that impact metabolism or appetite, it could lead to changes in growth patterns in this age group.\n",
      "- Long-term use of the nasal spray should be monitored for any adverse effects on growth, particularly if it alters nutritional intake or hormonal balance.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 383:----\n",
      "Detailed Prediction: - Sumatriptan succinate is the salt form of sumatriptan, and it is commonly used in injectable formulations.\n",
      "- The molecular weight of sumatriptan succinate is approximately 413.5 g/mol, while the molecular weight of sumatriptan is about 295.4 g/mol.\n",
      "- Therefore, 8.4 mg of sumatriptan succinate is equivalent to approximately 6.1 mg of sumatriptan.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 385:----\n",
      "Detailed Prediction: - The recommended dosage of vaginal essential oil is typically 2-3 drops applied to the vaginal area.\n",
      "- Essential oils such as tea tree oil or lavender oil are commonly used for their antimicrobial properties.\n",
      "- It is advised to use this regimen during menstruation to help prevent repeated cross-infection.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 389:----\n",
      "Detailed Prediction: - Use the nicotine lozenge 1 to 2 times per hour during Weeks 7 to 9.\n",
      "- Do not exceed 5 lozenges in a 6-hour period during this phase.\n",
      "- Gradually reduce the number of lozenges used as you approach the end of the 12-week schedule.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 394:----\n",
      "Detailed Prediction: - The drug brand name that is explicitly stated as not being a controlled substance is Claritin.\n",
      "- Claritin is an antihistamine used to relieve allergy symptoms without the potential for abuse associated with controlled substances.\n",
      "- Unlike other allergy medications, Claritin does not have restrictions under the Controlled Substances Act.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 396:----\n",
      "Detailed Prediction: - Patients taking lamotrigine in combination with valproate have a higher risk of serious rashes.\n",
      "- Individuals with a history of skin rashes or hypersensitivity reactions to other medications may also be at increased risk when using lamotrigine.\n",
      "- Pediatric patients, particularly those under 16 years of age, are more susceptible to serious rashes associated with lamotrigine therapy.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 398:----\n",
      "Detailed Prediction: - Discontinue the use of Tybost in pregnant individuals receiving darunavir or atazanavir therapy.\n",
      "- Monitor the pregnancy closely due to potential risks associated with the use of Tybost during pregnancy.\n",
      "- Consult with a healthcare provider for alternative treatment options that are safer during pregnancy.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 399:----\n",
      "Detailed Prediction: - The maximum dose of ondansetron administered to rats in carcinogenicity studies is significantly higher than the maximum recommended human oral dose.\n",
      "- In these studies, rats received doses up to 100 mg/kg/day, while the maximum recommended human oral dose is typically 16 mg/day.\n",
      "- This indicates a substantial difference in dosing, with the animal studies using doses that are approximately 6250 times higher than the human equivalent.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 401:----\n",
      "Detailed Prediction: - Ondansetron has been shown to have no mutagenic effects in various in vitro and in vivo studies.\n",
      "- The drug is classified as a 5-HT3 receptor antagonist and is primarily used to prevent nausea and vomiting associated with chemotherapy and surgery.\n",
      "- Regulatory agencies, including the FDA, have not identified ondansetron as a mutagenic agent based on available data.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 403:----\n",
      "Detailed Prediction: - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to avoid the risk of serotonin syndrome.\n",
      "- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that can interact dangerously with MAOIs.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 404:----\n",
      "Detailed Prediction: - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine use compared to active treatment groups.\n",
      "- Clinical trials did not report an increase in the risk of developing tardive dyskinesia in patients treated with venlafaxine.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 406:----\n",
      "Detailed Prediction: - WL-AAB-Z-W-982 has a contraindication profile that includes severe renal impairment, similar to drugs like lisinopril, which is contraindicated in patients with a history of angioedema.\n",
      "- Unlike metformin, which is contraindicated in patients with significant renal dysfunction, WL-AAB-Z-W-982 may have additional contraindications related to hepatic impairment.\n",
      "- The contraindications for WL-AAB-Z-W-982 also extend to patients with a known hypersensitivity to its components, paralleling the profile of drugs like penicillin.\n",
      "Final Choice: D\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 411:----\n",
      "Detailed Prediction: - Co-administration of OCELLA with ketoconazole, a strong CYP3A4 inhibitor, can lead to increased plasma concentrations of the ethinyl estradiol component in OCELLA.\n",
      "- This interaction may enhance the risk of estrogen-related side effects, such as thromboembolic events or other hormonal side effects.\n",
      "- It is recommended to monitor for these effects and consider alternative contraceptive methods or dosage adjustments when using OCELLA with ketoconazole.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 412:----\n",
      "Detailed Prediction: - Assess the patient's history of substance use disorders and consider alternative treatments if there is a significant risk of misuse.\n",
      "- Monitor the patient closely for signs of misuse or abuse, especially during the initial treatment phase with Venlafaxine Hydrochloride.\n",
      "- Educate the patient about the potential risks associated with Venlafaxine Hydrochloride, including the possibility of dependence and withdrawal symptoms.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 413:----\n",
      "Detailed Prediction: - Monitor for reduced effectiveness of CLEOCIN PHOSPHATE due to the induction of CYP3A4 by rifampicin.\n",
      "- Consider alternative treatments or adjust the dosage of CLEOCIN PHOSPHATE if necessary.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their condition.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 414:----\n",
      "Detailed Prediction: - Zynteglo has undergone genotoxicity testing, which included assessments for chromosomal damage and mutagenicity in vitro and in vivo.\n",
      "- In preclinical studies, Zynteglo demonstrated no significant genotoxic effects, indicating a favorable safety profile regarding DNA integrity.\n",
      "- Clinical data from trials showed no evidence of genotoxicity in patients treated with Zynteglo, supporting its use in gene therapy for beta-thalassemia.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 416:----\n",
      "Detailed Prediction: - The updated label claim for 'sterile' indicates that the product is free from viable microorganisms, ensuring safety for use in medical procedures.\n",
      "- The label specifies that the sterility is maintained throughout the product's shelf life, emphasizing the importance of proper storage conditions.\n",
      "- The claim may also include specific testing methods used to confirm sterility, such as the use of ethylene oxide or gamma radiation sterilization processes.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 418:----\n",
      "Detailed Prediction: - Venlafaxine was found to produce discriminative stimulus effects similar to those of amphetamines in primate studies.\n",
      "- The drug exhibited a lower potential for abuse compared to traditional stimulants, indicating a moderate abuse liability.\n",
      "- In comparison to placebo, venlafaxine showed significant effects that were distinguishable from non-active treatments.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 419:----\n",
      "Detailed Prediction: - Consult with a healthcare provider to discuss the potential risks and benefits of continuing OZOBAX DS during pregnancy or breastfeeding.\n",
      "- Consider alternative treatments that are safer for use during pregnancy or lactation if advised by a healthcare professional.\n",
      "- Ensure to inform the healthcare provider about the pregnancy or breastfeeding status before starting or continuing OZOBAX DS.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 421:----\n",
      "Detailed Prediction: - Remove the spray nozzle from the dg health nasal spray bottle.\n",
      "- Rinse the nozzle under warm running water to remove any residue.\n",
      "- Allow the nozzle to air dry completely before reattaching it to the bottle.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 422:----\n",
      "Detailed Prediction: - For patients with moderately impaired hepatic function (Child-Pugh B), the dose of Signifor LAR should be reduced to 40 mg every 28 days.\n",
      "- Close monitoring for efficacy and safety is essential due to altered pharmacokinetics in this population.\n",
      "- Consideration should be given to the potential for increased side effects and the need for further dose adjustments based on individual patient response.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 426:----\n",
      "Detailed Prediction: - Pemetrexed for Injection is typically used in combination with cisplatin as a first-line treatment for unresectable malignant pleural mesothelioma.\n",
      "- The recommended regimen involves administering Pemetrexed at a dose of 500 mg/m¬≤ intravenously on day 1, alongside cisplatin at a dose of 75 mg/m¬≤ on the same day.\n",
      "- Maintenance therapy with Pemetrexed may be considered after the initial treatment cycle, depending on the patient's response and tolerance.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 427:----\n",
      "Detailed Prediction: - Sumatriptan can lead to increased risk of serotonin syndrome when used with MAO-A inhibitors due to impaired metabolism of the drug.\n",
      "- The combination may cause excessive vasoconstriction, leading to potential cardiovascular complications.\n",
      "- Patients on MAO-A inhibitors should avoid Sumatriptan to prevent adverse effects related to serotonin levels and vascular responses.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 428:----\n",
      "Detailed Prediction: - Beard growth oil is specifically intended to be applied to the facial hair area, particularly the beard and mustache.\n",
      "- It is designed to nourish and promote the growth of facial hair follicles.\n",
      "- The oil may also be used on the skin beneath the beard to maintain hydration and health.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 429:----\n",
      "Detailed Prediction: - The drug indicated for the treatment of hypertension is lisinopril, an ACE inhibitor.\n",
      "- Metformin is specifically used for managing type 2 diabetes mellitus.\n",
      "- Atorvastatin is prescribed for lowering cholesterol levels and preventing cardiovascular disease.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 433:----\n",
      "Detailed Prediction: - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was approximately 50%.\n",
      "- In the clinical trial, patients receiving lamotrigine showed a significant improvement compared to the placebo group.\n",
      "- The results indicated that lamotrigine was effective in reducing the frequency of PGTC seizures in the studied population.\n",
      "Final Choice: B\n",
      "Correct Answer: C\n",
      "Is correct: False\n",
      "\n",
      "----Row 434:----\n",
      "Detailed Prediction: - The highest dietary dose of albuterol sulfate tested in Golden hamsters was 1,000 mg/kg/day.\n",
      "- At this dosage, there was no evidence of tumorigenicity observed in the study.\n",
      "- The study specifically focused on the long-term effects of albuterol sulfate in the diet of the hamsters.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 435:----\n",
      "Detailed Prediction: - The hair regrowth treatment should be applied twice daily to the scalp in the hair loss area.\n",
      "- Consistent application is crucial for optimal results, as missing doses can reduce effectiveness.\n",
      "- It is important to apply the treatment directly to the affected areas for proper absorption.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 436:----\n",
      "Detailed Prediction: - The brand name product that is indicated for preventing the recurrence of flaking and itching associated with dandruff is Head & Shoulders, which contains active ingredients like pyrithione zinc.\n",
      "- Another option is Nizoral, which contains ketoconazole as its active ingredient, effective in treating dandruff.\n",
      "- Selsun Blue is also indicated for dandruff prevention, utilizing selenium sulfide as its active component.\n",
      "Final Choice: B\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 440:----\n",
      "Detailed Prediction: - Administer appropriate antiarrhythmic medications to stabilize the patient's heart rhythm.\n",
      "- Monitor the patient closely for any signs of further complications or recurrence of arrhythmias.\n",
      "- Consider discontinuing Sumatriptan and evaluating alternative treatments for migraine management.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 441:----\n",
      "Detailed Prediction: - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungal medications, while viral infections like influenza are not.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, are ineffective against conditions like tuberculosis, which is treated with antibiotics.\n",
      "Final Choice: D\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 442:----\n",
      "Detailed Prediction: - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg.\n",
      "- The maximum recommended human dose (MRHD) for fluoxetine is 80 mg/day, which translates to approximately 1.1 mg/m¬≤ based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg is significantly higher than the MRHD on a mg/m¬≤ basis, indicating a much greater exposure in the animal study.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 446:----\n",
      "Detailed Prediction: - The primary concern is the increased risk of sedation and respiratory depression when OZOBAX DS is combined with other CNS depressants such as benzodiazepines or opioids.\n",
      "- Patients may experience enhanced drowsiness, impaired motor function, and potential overdose effects due to the additive effects of these medications.\n",
      "- Monitoring for signs of excessive sedation and respiratory compromise is crucial when OZOBAX DS is used alongside other CNS depressants.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 448:----\n",
      "Detailed Prediction: - The brand name of the drug used for general body cleansing processes is \"Miralax.\"\n",
      "- Miralax is commonly used to treat constipation by drawing water into the intestines.\n",
      "- It is an osmotic laxative that helps to promote bowel movements effectively.\n",
      "Final Choice: E\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 450:----\n",
      "Detailed Prediction: - The drug branded as 70% is primarily used as a topical antiseptic for skin disinfection.\n",
      "- It is commonly utilized in healthcare settings for cleaning skin before injections or surgical procedures.\n",
      "- The formulation typically contains 70% isopropyl alcohol, which is effective in killing bacteria and viruses on the skin.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 452:----\n",
      "Detailed Prediction: - NUZYRA (sarecycline) may have reduced absorption when taken with iron-containing preparations, leading to decreased effectiveness of the antibiotic.\n",
      "- Patients should be advised to separate the administration of NUZYRA and iron supplements by at least 2-3 hours to minimize interaction.\n",
      "- Monitoring for therapeutic efficacy of NUZYRA is essential if patients are concurrently using iron-containing preparations.\n",
      "Final Choice: B\n",
      "Correct Answer: B\n",
      "Is correct: True\n",
      "\n",
      "----Row 454:----\n",
      "Detailed Prediction: - HIMARK should be stored at a temperature between 2¬∞C to 8¬∞C to maintain its efficacy.\n",
      "- It must be protected from light to prevent degradation of the active ingredients.\n",
      "- The product should be kept in its original packaging until use to ensure stability and prevent contamination.\n",
      "Final Choice: C\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 455:----\n",
      "Detailed Prediction: - Discontinue the use of Sumatriptan to prevent further medication overuse headaches.\n",
      "- Implement a gradual tapering strategy for Sumatriptan to minimize withdrawal symptoms.\n",
      "- Consider alternative treatments for migraine management, such as preventive medications or non-pharmacological therapies.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 456:----\n",
      "Detailed Prediction: - Reduce the dose of Inspra (eplerenone) to 25 mg once daily for patients on moderate CYP3A inhibitors.\n",
      "- Monitor for signs of hyperkalemia and adjust potassium levels as necessary while on the reduced dose.\n",
      "- Consider alternative antihypertensive therapies if the interaction poses significant risks to the patient.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "\n",
      "‚ö†üü®--------- INVALID ANSWERS-----------üü®\n",
      "\n",
      "\n",
      "\n",
      "----Row 106:----\n",
      "Question: Which gadolinium-based contrast agent retains the least amount of gadolinium in the body?\n",
      "\n",
      "Correct Answer: C:\n",
      "Gadavist\n",
      "\n",
      "Detailed Prediction: - Gadobutrol is known for its low retention of gadolinium in the body due to its high relaxivity and low dose.\n",
      "- Compared to other agents, gadobutrol has a higher stability which contributes to reduced gadolinium deposition in tissues.\n",
      "- Studies indicate that gadobutrol has a favorable safety profile with minimal long-term gadolinium accumulation.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 217:----\n",
      "Question: For the indication 'INDICATION', which drug brand name is relevant?\n",
      "\n",
      "Correct Answer: A:\n",
      "Arnica gel\n",
      "\n",
      "Detailed Prediction: - The drug brand name relevant for the indication is Lipitor, which is used for lowering cholesterol levels.\n",
      "- Another relevant drug brand name is Lantus, indicated for long-acting insulin therapy in diabetes management.\n",
      "- Additionally, Advair is a brand name relevant for the indication of asthma and chronic obstructive pulmonary disease (COPD) treatment.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 310:----\n",
      "Question: Which brand name drug is specifically indicated for the treatment of acne?\n",
      "\n",
      "Correct Answer: A:\n",
      "MD-Acne Body Acne Treatment\n",
      "\n",
      "Detailed Prediction: - The brand name drug Accutane is specifically indicated for the treatment of severe acne.\n",
      "- Another option is Differin, which is a topical retinoid used for acne treatment.\n",
      "- Additionally, the brand name drug Epiduo combines adapalene and benzoyl peroxide for acne management.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 375:----\n",
      "Question: What was the maximum oral dose of ondansetron administered to rats in carcinogenicity studies?\n",
      "\n",
      "Correct Answer: A:\n",
      "10 mg/kg per day\n",
      "\n",
      "Detailed Prediction: - The maximum oral dose of ondansetron administered to rats in carcinogenicity studies was 80 mg/kg/day.\n",
      "- This dose was given for a duration of 2 years to assess potential carcinogenic effects.\n",
      "- The studies aimed to evaluate the long-term safety profile of ondansetron in a rodent model.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 438:----\n",
      "Question: What was the maximum oral dose of ondansetron administered to rats in the carcinogenicity studies, expressed in mg/kg per day?\n",
      "\n",
      "Correct Answer: A:\n",
      "10 mg/kg per day\n",
      "\n",
      "Detailed Prediction: - The maximum oral dose of ondansetron administered to rats in the carcinogenicity studies was 16 mg/kg per day.\n",
      "- This dose was part of a long-term study to evaluate the potential carcinogenic effects of ondansetron.\n",
      "- The study aimed to assess the safety profile of ondansetron at high doses over an extended period.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "‚ÑπÔ∏èValid Answers: 225\n",
      "‚ÑπÔ∏èInvalid Answers: 5\n",
      "üü¢ACC: 75.56%\n"
     ]
    }
   ],
   "execution_count": 62
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:46:44.538108Z",
     "start_time": "2026-01-12T12:46:44.535150Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#################\n",
    "# TOTAL ACCURACY\n",
    "#################\n",
    "\n",
    "ACC_total = ((ACC_mc*valid_mc + \n",
    "             ACC_open_mc*valid_open_mc) / \n",
    "             (valid_open_mc + valid_mc))\n",
    "\n",
    "print(f\"Total valid answers: {valid_open_mc + valid_mc}\")\n",
    "print(f\"Total invalid answers: {NaN_open_mc + NaN_mc}\")\n",
    "print(f\"%valid: {round(100*(valid_open_mc + valid_mc)/(valid_open_mc+valid_mc+NaN_open_mc+NaN_mc),2)}%\")\n",
    "print(f\"\\nüü¢ Total Accuracy: {round(100*ACC_total,2)}%\")\n"
   ],
   "id": "28575ecd33a502b1",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total valid answers: 408\n",
      "Total invalid answers: 5\n",
      "%valid: 98.79%\n",
      "\n",
      "üü¢ Total Accuracy: 79.41%\n"
     ]
    }
   ],
   "execution_count": 72
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:15:55.787360Z",
     "start_time": "2026-01-12T12:15:55.580594Z"
    }
   },
   "cell_type": "code",
   "source": [
    "# Open questipons\n",
    "patterns = [r\"\\bANSWER:\\s*([ABCDE])\\b\",\n",
    "           r\"THE ANSWER IS:\\s*([ABCDE])\\b\",\n",
    "           r\"\\bOUTPUT:\\s*([ABCDE])\\b\"]\n",
    "\n",
    "def extract_choice_from_prediction(pred: str) -> str:\n",
    "    if pred is None:\n",
    "        return \"\"\n",
    "    s = str(pred).strip().upper()\n",
    "    if not s:\n",
    "        return \"\"\n",
    "\n",
    "    # try regex patterns (in order)\n",
    "    for pat in patterns:\n",
    "        m = re.search(pat, s)\n",
    "        if m:\n",
    "            return m.group(1)\n",
    "\n",
    "    # fallback: first line is exactly one letter\n",
    "    first_line = s.splitlines()[0].strip()\n",
    "    if re.fullmatch(r\"[ABCDE]\", first_line):\n",
    "        return first_line\n",
    "\n",
    "    return \"NOTAVALUE\"\n",
    "\n",
    "data_open = data_open.copy()\n",
    "data_open[\"choice\"] = data_open[\"prediction\"].apply(extract_choice_from_prediction)\n",
    "\n",
    "for i,row in data_open.iterrows():\n",
    "    prediction = row[\"prediction\"]\n",
    "    options = dict(row[\"options\"])\n",
    "    LCSratios = {}\n",
    "    for key in options.keys():\n",
    "        option = options[key]\n",
    "        LCSratios[key] = SequenceMatcher(None, prediction, option).ratio()\n",
    "    \n",
    "    best_pred = max(LCSratios, key=LCSratios.get)\n",
    "    data_open.loc[i,\"pred_LCS\"] = best_pred\n",
    "    data_open.loc[i,\"LCS_similarity\"] = LCSratios[best_pred]\n",
    "    \n",
    "data_open['final_choice'] = np.where(\n",
    "    data_open['LCS_similarity'] > 0.15,\n",
    "    data_open['pred_LCS'],\n",
    "    data_open['choice']\n",
    ")\n",
    "\n",
    "data_open['is_correct'] = data_open[\"final_choice\"] == data_open[\"correct_answer\"]\n",
    "\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] != 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}\")\n",
    "        print(f\"Is correct: {row['is_correct']}\")\n",
    "    \n",
    "print(\"\\n\\n‚ö†üü®--------- INVALID ANSWERS-----------üü®\\n\\n\")\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] == 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Question: {row['question']}\\n\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}:\")\n",
    "        print(f\"{ row['options'][row['correct_answer']] }\\n\")\n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\\n\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\\n\")\n",
    "\n",
    "\n",
    "\n",
    "NaN_open = len(data_open[data_open[\"final_choice\"] == 'NOTAVALUE'])\n",
    "valid_open = len(data_open) - NaN_open\n",
    "ACC_open = data_open[\"is_correct\"].sum() / valid_open\n",
    "\n",
    "print()\n",
    "print(f\"‚ÑπÔ∏èValid Answers: {valid_open}\")\n",
    "print(f\"‚ÑπÔ∏èInvalid Answers: {NaN_open}\")\n",
    "print(f\"üü¢ACC: {100*round(ACC_open,4)}%\")\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ],
   "id": "8e523ec1cb34e490",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----Row 61:----\n",
      "Detailed Prediction: Error\n",
      "Final Choice: B\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "----Row 451:----\n",
      "Detailed Prediction: Error\n",
      "Final Choice: C\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "\n",
      "‚ö†üü®--------- INVALID ANSWERS-----------üü®\n",
      "\n",
      "\n",
      "\n",
      "----Row 22:----\n",
      "Question: Which of the following is a withdrawal symptom that Nicotine helps alleviate?\n",
      "\n",
      "Correct Answer: A:\n",
      "Nicotine craving.\n",
      "\n",
      "Detailed Prediction: Withdrawal symptoms from nicotine are common when a person stops smoking or using nicotine products. Nicotine helps alleviate several of these withdrawal symptoms, which can include:\n",
      "\n",
      "1. **Cravings for nicotine**: One of the most prominent symptoms, cravings can lead to relapse if not managed appropriately.\n",
      "   \n",
      "2. **Irritability and anxiety**: These emotional symptoms are frequently reported during withdrawal, and nicotine can help stabilize mood.\n",
      "\n",
      "3. **Increased appetite**: Many individuals experience an increase in appetite and subsequent weight gain upon stopping nicotine, which nicotine can suppress.\n",
      "\n",
      "4. **Difficulty concentrating**: Cognitive function may be impaired during withdrawal, with nicotine improving attention and focus.\n",
      "\n",
      "5. **Sleep disturbances**: Insomnia or altered sleep patterns are common, and nicotine can initially provide calming effects that help with sleep regulation.\n",
      "\n",
      "Research shows that various interventions, including pharmacological treatments and non-pharmacological strategies like acupuncture, can significantly alleviate these withdrawal symptoms. For example, a study indicated that electroacupuncture resulted in a greater reduction of nicotine withdrawal symptoms compared to other methods.\n",
      "\n",
      "In summary, nicotine plays a critical role in alleviating withdrawal symptoms such as cravings, irritability, increased appetite, cognitive difficulties, and sleep disturbances.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 37:----\n",
      "Question: What is the primary indication for the use of esomeprazole magnesium?\n",
      "\n",
      "Correct Answer: B:\n",
      "Treatment of frequent heartburn occurring 2 or more days a week.\n",
      "\n",
      "Detailed Prediction: Esomeprazole magnesium, a proton pump inhibitor (PPI), is primarily indicated for the treatment of several conditions related to excessive stomach acid production. The main indications for its use include:\n",
      "\n",
      "1. **Gastroesophageal Reflux Disease (GERD)**: Esomeprazole is effective in managing symptoms of GERD, a condition where stomach acid frequently flows back into the esophagus, causing heartburn and potential damage to the esophageal lining.\n",
      "\n",
      "2. **Peptic Ulcer Disease**: It is also used to treat peptic ulcers, either alone or in combination with antibiotics, to eradicate Helicobacter pylori infections, which are often responsible for these ulcers.\n",
      "\n",
      "3. **Erosive Esophagitis**: This condition, characterized by inflammation and damage to the esophagus due to acid reflux, is treated effectively with esomeprazole.\n",
      "\n",
      "4. **Zollinger-Ellison Syndrome**: Esomeprazole is indicated for this rare condition, where the stomach produces excessive amounts of acid due to tumors in the pancreas or duodenum.\n",
      "\n",
      "5. **Prevention of Gastric Ulcers**: It is used in patients who are at risk for ulcers following NSAID (non-steroidal anti-inflammatory drugs) use, particularly in long-term therapies.\n",
      "\n",
      "6. **Management of dyspepsia**: Esomeprazole can help alleviate symptoms of dyspepsia (indigestion), particularly when associated with high acid secretion.\n",
      "\n",
      "These indications illustrate the role of esomeprazole in managing acid-related gastrointestinal disorders effectively, enhancing patient quality of life by reducing symptoms associated with excess gastric acidity and promoting healing of the esophagus and stomach lining.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 42:----\n",
      "Question: What should patients do if they experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue Levalbuterol Inhalation Solution and consult their physician.\n",
      "\n",
      "Detailed Prediction: If patients experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution, they should take the following steps:\n",
      "\n",
      "1. **Stop Using the Inhaler**: Immediately discontinue the use of the Levalbuterol inhaler if paradoxical bronchospasm occurs. This adverse reaction can be life-threatening, and it is critical to stop taking the medication that is causing the problem.\n",
      "\n",
      "2. **Seek Medical Attention**: Contact a healthcare provider right away or seek emergency medical attention if breathing difficulties worsen. Paradoxical bronchospasm can manifest as increased wheezing, shortness of breath, or chest tightness, which may necessitate prompt intervention.\n",
      "\n",
      "3. **Monitor Symptoms**: Patients should closely monitor their respiratory status and report any changes in their breathing or other symptoms to their healthcare professional. Keeping a record of symptoms may help in the management and follow-up care.\n",
      "\n",
      "4. **Alternative Treatments**: Discuss with a healthcare provider about alternative bronchodilator medications or treatment options, as the use of Levalbuterol should be avoided in such cases in the future.\n",
      "\n",
      "5. **Emergency Plan**: Have an emergency plan established with a healthcare provider, including knowing when and how to use other rescue inhalers or medications if needed.\n",
      "\n",
      "Awareness of the potential for paradoxical bronchospasm is essential for safe medication use, as highlighted in a report indicating it can occur with both Levalbuterol and Albuterol, and being cognizant of this can help prevent life-threatening situations (Raghunathan et al., 2006).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 44:----\n",
      "Question: Which of the following is the molecular formula of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "C17H27NO2HCl\n",
      "\n",
      "Detailed Prediction: The molecular formula of venlafaxine hydrochloride is **C‚ÇÅ‚ÇáH‚ÇÇ‚ÇàClN‚ÇÅO‚ÇÇ**. Venlafaxine hydrochloride is an antidepressant medication used primarily to treat major depressive disorder and anxiety disorders. It functions as a serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 47:----\n",
      "Question: Which of the following statements is true regarding the storage of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature.\n",
      "\n",
      "Detailed Prediction: The storage of sterile drugs is crucial for maintaining their efficacy, safety, and sterility. Here are some important considerations regarding their storage:\n",
      "\n",
      "1. **Temperature Control**: Sterile drugs often require specific temperature conditions to ensure their stability. Many sterile medications need to be stored at controlled room temperatures, while others may require refrigeration or freezing to maintain their integrity.\n",
      "\n",
      "2. **Humidity and Light Protection**: Exposure to humidity and light can alter the chemical structure of sterile drugs, leading to degradation. Therefore, they should be stored in a dry place and in containers that protect them from light exposure.\n",
      "\n",
      "3. **Packaging and Containers**: The type of packaging can play a significant role in maintaining sterility. Aseptic packaging techniques and the use of barriers such as blister packs and sterile containers help to prevent contamination.\n",
      "\n",
      "4. **Expiration Dates and Shelf Life**: Every sterile drug has an expiration date, and it is essential to adhere to these dates to ensure safety. The storage conditions may also affect the shelf life of sterile medications.\n",
      "\n",
      "5. **Avoiding Contamination**: It is important to ensure that the storage area is clean and that proper hygiene practices are followed when handling sterile drugs, to prevent any form of contamination.\n",
      "\n",
      "In summary, to safely store sterile drugs, it is crucial to maintain appropriate temperature and humidity levels, protect them from light, use proper packaging, adhere to expiration dates, and follow strict hygiene protocols. For detailed guidelines, refer to specialized sources on drug storage and stability. \n",
      "\n",
      "For further reading, you can explore [this article](https://www.em-consulte.com/article/513841/drug-storage-and-stability) on drug storage and stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 67:----\n",
      "Question: What is the recommended action if a patient on Coreg CR develops renal function deterioration?\n",
      "\n",
      "Correct Answer: C:\n",
      "Monitor renal function and reduce or discontinue Coreg CR if necessary.\n",
      "\n",
      "Detailed Prediction: If a patient on Coreg CR (carvedilol phosphate) develops renal function deterioration, the following actions are recommended:\n",
      "\n",
      "1. **Monitor Renal Function**: It is crucial to assess renal function regularly, especially during the initiation and up-titration of Coreg CR. This monitoring helps in detecting any changes early and in making timely interventions.\n",
      "\n",
      "2. **Discontinuation or Dose Adjustment**: If there is evidence of worsening renal function, the prescribing physician should consider discontinuing the medication or reducing the dosage. This step is particularly important in high-risk patients who may be more susceptible to renal impairment.\n",
      "\n",
      "3. **Patient Evaluation**: Evaluate for potential underlying causes of renal dysfunction that may be exacerbated by Coreg CR. Consider any additional comorbidities or medications that may contribute to renal deterioration.\n",
      "\n",
      "4. **Alternative Therapies**: Depending on the patient's overall clinical situation, alternative antihypertensive or heart failure management strategies may need to be deployed if Coreg CR adversely affects renal function.\n",
      "\n",
      "5. **Consultation with a Specialist**: If the renal function does not improve upon adjusting or discontinuing Coreg CR, a consultation with a nephrologist may be appropriate for further evaluation and management.\n",
      "\n",
      "In summary, careful monitoring and appropriate adjustments in the management of patients receiving Coreg CR are essential if there is a sign of renal function deterioration. For more detailed information, the [DailyMed entry for Coreg CR](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9008ede8-3e53-4061-ae4c-c51cbbb56ef2) contains pertinent guidelines regarding the management of renal function changes associated with this medication.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 83:----\n",
      "Question: Which document should patients read and understand when prescribed venlafaxine tablets?\n",
      "\n",
      "Correct Answer: A:\n",
      "The Medication Guide about 'Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions.'\n",
      "\n",
      "Detailed Prediction: Patients prescribed venlafaxine tablets should read and understand the **Patient Information Leaflet (PIL)** provided with their medication. This document includes essential information about the medication such as its uses, dosage instructions, potential side effects, and precautions. \n",
      "\n",
      "Some key elements that are typically covered in the PIL include:\n",
      "\n",
      "1. **Description of the Drug**: What venlafaxine is, including its classification as a serotonin-norepinephrine reuptake inhibitor (SNRI), and its common uses for treating conditions like depression and anxiety.\n",
      "\n",
      "2. **Dosage and Administration**: Instructions on how to take the medication correctly, including the timing and whether to take it with food.\n",
      "\n",
      "3. **Side Effects**: Common and serious side effects that may occur, such as nausea, dizziness, or increased blood pressure. Important notes about any severe reactions that require immediate medical attention are also included.\n",
      "\n",
      "4. **Warnings and Precautions**: Information about contraindications, what to discuss with healthcare providers (e.g., other medications being taken or existing health issues), and the risk of withdrawal symptoms if the medication is stopped suddenly.\n",
      "\n",
      "5. **Interaction with Other Drugs**: Potential interactions with other medications, which could affect how venlafaxine works or increase the risk of side effects.\n",
      "\n",
      "6. **Storage Instructions**: Guidelines on how to properly store the tablets to maintain their efficacy.\n",
      "\n",
      "Patients may also find the following resources useful:\n",
      "- [Venlafaxine 75 mg tablets - Patient Information Leaflet](https://www.medicines.org.uk/emc/product/764/pil)\n",
      "- [Important Patient Information PDF](https://www.urmc.rochester.edu/medialibraries/urmcmedia/medicine/general-medicine/patientcare/documents/venlafaxine_brochure.pdf)\n",
      "\n",
      "Understanding this information is crucial for the safe and effective use of venlafaxine and for making informed decisions about their treatment.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 84:----\n",
      "Question: What precaution should be taken when initiating Coreg CR therapy in patients with diabetes?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor blood glucose levels closely.\n",
      "\n",
      "Detailed Prediction: When initiating Coreg CR (carvedilol controlled release) therapy in patients with diabetes, several precautions should be considered:\n",
      "\n",
      "1. **Monitor Blood Glucose Levels**: Carvedilol, a beta-blocker, can mask some of the adrenergic symptoms of hypoglycemia, such as palpitations and tremors. Therefore, it's crucial for healthcare providers to closely monitor blood glucose levels and educate patients on recognizing other signs of low blood sugar.\n",
      "\n",
      "2. **Adjust Dosage Carefully**: Given that patients with diabetes may have varying sensitivities to blood glucose fluctuations, any dose adjustments should be made cautiously. Start with a low dose and titrate slowly based on the patient's tolerance and blood sugar control.\n",
      "\n",
      "3. **Evaluate for Comorbidities**: Patients with diabetes often have additional comorbid conditions, such as hypertension or heart failure. The presence of these conditions requires careful assessment to ensure the benefits of initiating Coreg CR outweigh potential risks.\n",
      "\n",
      "4. **Patient Education**: Informing patients about the potential side effects of beta-blockers, including fatigue and dizziness, is essential. They should understand the need for regular follow-ups to monitor their cardiovascular status as well as diabetes management while on this medication.\n",
      "\n",
      "5. **Assess for Renal Function**: Diabetes can lead to renal impairment, affecting drug metabolism and clearance. Renal function should be evaluated prior to starting Coreg CR, and the patient should be monitored for any increases in creatinine or changes in renal function during therapy.\n",
      "\n",
      "By taking these precautions, healthcare providers can help ensure safe and effective use of Coreg CR in patients with diabetes.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 102:----\n",
      "Question: In animal studies, what developmental toxicity was observed in rats exposed to lamotrigine during pregnancy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Decreased fetal folate concentrations.\n",
      "\n",
      "Detailed Prediction: In animal studies, particularly those involving pregnant rats, developmental toxicity associated with lamotrigine (LTG) has been observed, highlighting several significant effects on offspring. \n",
      "\n",
      "1. **Study Overview**: Research conducted on Sprague Dawley rats assessed the impact of prenatal exposure to LTG, administered from gestational day 3 until postnatal day 11. The doses used were 11.5, 23, and 46 mg/kg. The study primarily observed postnatal development and behavioral changes in the offspring.\n",
      "\n",
      "2. **Findings**: \n",
      "   - **Maternal Toxicity**: At the highest dosage of 46 mg/kg, signs of severe toxicity were observed in the mother rats, leading to mortality between gestational days 15 and 17.\n",
      "   - **Developmental Effects on Offspring**: Offspring exposed to both 11.5 mg/kg and 23 mg/kg doses showed significant deviations compared to control groups. Notably, there were alterations in milestones such as the eruption of incisors and the timing of vaginal opening, indicating potential disruptions in normal development.\n",
      "   - **Behavioral Changes**: Female offspring exposed to 23 mg/kg exhibited hyperactivity, alongside a decrease in GABA-A receptor expression, which suggests alterations in neural development and functioning.\n",
      "\n",
      "3. **Implications**: These findings indicate that prenatal exposure to lamotrigine can lead to essential developmental issues in rats, including both physical and behavioral alterations that may differ based on sex. Such variations underscore the need for further investigation into the mechanisms behind these effects and their relevance to fetal development in humans.\n",
      "\n",
      "In summary, prenatal exposure to lamotrigine in rats resulted in notable developmental toxicity, including maternal toxicity, altered developmental milestones, and behavioral changes in the offspring, pointing towards potential risks associated with its use during pregnancy.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 104:----\n",
      "Question: What should a user do if they are under 18 years of age and want to use nicotine lozenges?\n",
      "\n",
      "Correct Answer: B:\n",
      "Consult a doctor before use\n",
      "\n",
      "Detailed Prediction: If a user under 18 years of age is considering the use of nicotine lozenges, there are several important steps and considerations to keep in mind:\n",
      "\n",
      "1. **Consult a Healthcare Professional**: The first and most crucial step is to speak with a healthcare provider. A doctor or a trained pharmacist can provide guidance on whether nicotine lozenges are suitable for the individual, considering their age and health status.\n",
      "\n",
      "2. **Consider Alternatives for Smoking Cessation**: Research shows that adolescent-specific smoking cessation programs can be beneficial. A study from T√ºrkiye highlighted the effectiveness of adolescents attending smoking cessation clinics, with various methods including nicotine patches showing positive outcomes (PMID: 41509942). It‚Äôs essential to explore comprehensive smoking cessation plans tailored for young individuals.\n",
      "\n",
      "3. **Understand the Risks and Regulations**: In many regions, the sale and use of nicotine products (including lozenges) are typically restricted for minors. Familiarizing oneself with local laws and regulations is important, as well as understanding the health risks associated with nicotine use, particularly before reaching adulthood. Adolescents are generally more susceptible to addiction and the potential health consequences of nicotine.\n",
      "\n",
      "4. **Explore Ongoing Clinical Trials**: There may be clinical trials assessing the efficacy and safety of nicotine replacement therapies in adolescents, such as the Aggressive Smoking Cessation Trial (NCT05257629). Engaging in a clinical trial might provide access to resources and support designed for young smokers looking to quit.\n",
      "\n",
      "5. **Educate on Smoking Cessation Techniques**: In addition to lozenges, various methods exists for quitting smoking that are safe for adolescents, including behavioral therapies, counseling, and support groups. \n",
      "\n",
      "In summary, the use of nicotine lozenges by individuals under 18 requires careful consideration and guidance from healthcare professionals, alongside understanding the associated risks and exploring alternative cessation methods tailored for young users.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 113:----\n",
      "Question: Which brand produces the Beloved Coconut & Warm Vanilla Hand Sanitizer?\n",
      "\n",
      "Correct Answer: A:\n",
      "Love Beauty and Planet\n",
      "\n",
      "Detailed Prediction: The Beloved Coconut & Warm Vanilla Hand Sanitizer is produced by Love Beauty and Planet. This brand focuses on creating beauty products that are environmentally friendly and incorporate natural ingredients, aligning well with their ethos of sustainability and care for nature. The hand sanitizer combines the tropical scent of coconut with the comforting warmth of vanilla, providing a pleasant user experience while helping to reduce bacteria on the skin.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 114:----\n",
      "Question: For children aged 6 to under 12 years, what is the appropriate dosage of the laxative for women?\n",
      "\n",
      "Correct Answer: A:\n",
      "1 tablet in a single daily dose\n",
      "\n",
      "Detailed Prediction: The appropriate dosage of laxatives for children aged 6 to under 12 years can vary depending on the specific type of laxative used. Here's a general guideline based on various sources:\n",
      "\n",
      "1. **Over-the-counter Laxatives**: \n",
      "   - Most over-the-counter laxatives are not recommended for children under the age of 6 without consulting a healthcare provider.\n",
      "   - For children aged 6 to 11 years, it's typically advised to administer half the adult dosage indicated on the package unless otherwise directed by a healthcare professional.\n",
      "\n",
      "2. **Senna-Based Laxatives** (like Senokot):\n",
      "   - For children aged 6-11 years, the recommendation is usually to use 1 tablet once or twice daily.\n",
      "\n",
      "3. **Dulcolax Suppositories**:\n",
      "   - These are typically not recommended for children under 12 years without medical advice, but if used, a 10 mg suppository may be inserted as needed (usually one suppository for quicker effect).\n",
      "\n",
      "4. **Liquid Laxatives**: \n",
      "   - The dosage may be around 15 to 30 mL for children over 6 years, but this can depend on the formulation and should be guided by a physician.\n",
      "\n",
      "**Important Note**: Consultation with a healthcare provider is crucial before administering any laxative to children for proper dosing and to rule out any underlying health issues causing constipation. It's essential to follow specific product guidance and medical advice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 120:----\n",
      "Question: Why is it recommended not to eat or drink 15 minutes before using or while the NICOTINE lozenge is in the mouth?\n",
      "\n",
      "Correct Answer: B:\n",
      "To ensure proper absorption of nicotine\n",
      "\n",
      "Detailed Prediction: It is recommended not to eat or drink for 15 minutes before using or while the nicotine lozenge is in the mouth due to several reasons related to absorption and effectiveness of the medication:\n",
      "\n",
      "1. **Absorption Mechanism**: Nicotine lozenges are designed to dissolve slowly in the mouth, allowing nicotine to be absorbed through the mucosal membranes. Eating or drinking can interfere with this absorption process. The presence of food or liquids can wash away the lozenge's active ingredients, leading to a reduction in the amount of nicotine that enters the bloodstream.\n",
      "\n",
      "2. **pH Levels**: The pH levels in the mouth can change due to food or beverage consumption. These changes can affect how effectively nicotine is absorbed. For example, acidic foods or drinks may enhance nicotine absorption, but the overall interaction may lead to inconsistent dosing, which is not ideal for someone trying to quit smoking.\n",
      "\n",
      "3. **Maintaining Effectiveness**: For optimal effectiveness in reducing cravings and withdrawal symptoms, it is crucial for the lozenge to provide a steady release of nicotine. Disruption by eating or drinking can lead to fluctuating nicotine levels in the blood, which can undermine the lozenge's intended purpose.\n",
      "\n",
      "4. **Taste and Experience**: Additionally, substances like coffee or acidic drinks can impair the taste of the lozenge, potentially leading to a decreased likelihood of continued use. This sensory experience can influence adherence to using the lozenge as part of a smoking cessation strategy.\n",
      "\n",
      "In summary, avoiding eating and drinking before and during the use of a nicotine lozenge maximizes nicotine absorption, maintains steady blood levels, and helps ensure that the lozenge is effective in curbing smoking urges.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 128:----\n",
      "Question: In which animal model did albuterol sulfate show no evidence of tumorigenicity at dietary doses of up to 50 mg/kg?\n",
      "\n",
      "Correct Answer: C:\n",
      "Golden hamsters\n",
      "\n",
      "Detailed Prediction: Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg in a 22-month study involving **Golden Hamsters**. This study indicated that the doses tested were significantly higher than the maximum recommended daily inhalation doses for both adults and children when adjusted for body surface area. \n",
      "\n",
      "For more detailed information, you can refer to the source [here](https://medlibrary.org/lib/rx/meds/albuterol-sulfate-38/page/3/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 129:----\n",
      "Question: What is the recommended action if a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Prohibit intercourse to avoid hemoperitoneum\n",
      "\n",
      "Detailed Prediction: If a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy, the recommended action is to carefully evaluate the situation for any potential complications, primarily the risk of ovarian hyperstimulation syndrome (OHSS). Here are several key steps to consider:\n",
      "\n",
      "1. **Monitoring and Assessment**: Close monitoring of the patient's symptoms and ovarian size via ultrasound is crucial. Significant enlargement may indicate overstimulation, which can lead to complications.\n",
      "\n",
      "2. **Symptomatic Management**: If the enlargement is accompanied by symptoms such as abdominal pain, shortness of breath, or weight gain, symptomatic treatment may be warranted.\n",
      "\n",
      "3. **Adjustment of Medication**: Depending on the severity of the enlargement, it may be necessary to adjust or even suspend Follistim AQ therapy. This could involve dose reduction or pausing treatment until the patient's condition stabilizes.\n",
      "\n",
      "4. **Consultation**: If there are concerns regarding complications such as OHSS, involve a reproductive endocrinologist for expert management. \n",
      "\n",
      "5. **Patient Education**: Inform the patient about the signs and symptoms of OHSS, emphasizing the importance of reporting any worsening symptoms immediately.\n",
      "\n",
      "6. **Follow-up Care**: Ensure regular follow-up appointments to monitor the patient's ovarian response and overall health. This may involve repeating ultrasound examinations and possibly hormone level testing.\n",
      "\n",
      "Individuals on fertility treatments like Follistim AQ should be monitored closely for responses, and any signs of ovarian enlargement should be managed proactively to prevent complications. \n",
      "\n",
      "For more detailed guidelines, you can refer to the official product information from sources such as [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48489027-e52b-4b10-ae74-4ba03839150c).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 134:----\n",
      "Question: What is a potential risk when Labetalol HCL is used in combination with tricyclic antidepressants?\n",
      "\n",
      "Correct Answer: B:\n",
      "Increased risk of tremor\n",
      "\n",
      "Detailed Prediction: A potential risk when Labetalol HCL is used in combination with tricyclic antidepressants (TCAs) is the inhibition of mIBG (metaiodobenzylguanidine) uptake in cardiac tissues, which could impact cardiac imaging studies. \n",
      "\n",
      "Labetalol, a beta-blocker with alpha-blocking activity, has a strong inhibition effect on mIBG uptake, which is rated as having high evidence. In contrast, tricyclic antidepressants have a medium level of evidence for their impact on mIBG uptake. The combination of these medications may therefore lead to an insufficient uptake of mIBG during imaging, potentially complicating the assessment of cardiac function or disease. This interaction underscores the need for clinicians to reconsider the timing of these medications before conducting mIBG cardiac imaging and may warrant temporary withdrawal to ensure accurate diagnostic results. \n",
      "\n",
      "In summary, the use of Labetalol in conjunction with tricyclic antidepressants can pose significant risks for cardiac imaging accuracy due to their combined effects on mIBG uptake.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 173:----\n",
      "Question: Which of the following symptoms is NOT associated with a lamotrigine overdose?\n",
      "\n",
      "Correct Answer: C:\n",
      "Hypertension\n",
      "\n",
      "Detailed Prediction: Lamotrigine overdose is associated with several symptoms, including seizures, cardiac arrest, and potentially fatal arrhythmias. In clinical findings, patients have presented with significant neurological and cardiovascular instability following an overdose. While activated charcoal and sodium bicarbonate are common treatments, alternative therapies are limited.\n",
      "\n",
      "To conclude, one symptom NOT associated with a lamotrigine overdose is *hypertension*. The primary symptoms remain centered around neurological effects (like seizures) and cardiovascular complications (such as arrhythmias), rather than increases in blood pressure.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 184:----\n",
      "Question: What precaution should be taken for patients with multiple cardiovascular risk factors before administering Sumatriptan injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Perform a cardiovascular evaluation\n",
      "\n",
      "Detailed Prediction: Before administering Sumatriptan injection to patients with multiple cardiovascular risk factors, several precautions should be taken:\n",
      "\n",
      "1. **Cardiovascular Evaluation**: It is crucial to perform a thorough cardiac evaluation for patients with cardiovascular risk factors, such as diabetes, hypertension, smoking history, obesity, or a strong family history of coronary artery disease (CAD). This evaluation helps assess the potential risk of myocardial ischemia or infarction, which can be exacerbated by Sumatriptan.\n",
      "\n",
      "2. **Setting of Administration**: If the patient has significant cardiovascular risk factors, the initial dose of Sumatriptan should ideally be administered in a medically supervised setting, such as a physician‚Äôs office. This precaution allows for immediate medical assistance if any adverse cardiovascular events occur.\n",
      "\n",
      "3. **Monitoring**: Continuous monitoring of cardiovascular status is advisable in patients with a history of cardiovascular disease or risk factors when they receive Sumatriptan. Monitoring helps in the early detection of any complications.\n",
      "\n",
      "4. **Patient Counseling**: Patients should be informed about the signs and symptoms of cardiovascular events, and they should be advised to seek medical attention if they experience chest pain, shortness of breath, or any unusual symptoms following administration.\n",
      "\n",
      "Taking these precautions can help mitigate the risks associated with Sumatriptan in patients with multiple cardiovascular risk factors. For more detailed information about the drug and its precautions, healthcare providers can refer to the official prescribing information available from sources such as [Drugs.com](https://www.drugs.com/pro/sumatriptan-injection.html) and [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a4c0c2f-497d-4c5c-84c4-9ab42780cbde).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 186:----\n",
      "Question: What precaution should be taken when prescribing fluoxetine to a patient with diabetes?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor for hypoglycemia during therapy and hyperglycemia after discontinuation\n",
      "\n",
      "Detailed Prediction: When prescribing fluoxetine to a patient with diabetes, there are several important precautions to consider:\n",
      "\n",
      "1. **Monitoring Blood Sugar Levels**: Fluoxetine can affect glycemic control, which may lead to changes in blood sugar levels. Careful monitoring of blood sugar is essential, especially when beginning treatment or adjusting the dose. \n",
      "\n",
      "2. **Potential Risk of Hypoglycemia**: There is a risk that fluoxetine may increase the effectiveness of insulin or other antidiabetic medications, potentially leading to hypoglycemia (low blood sugar). Symptoms of hypoglycemia include headache, dizziness, drowsiness, confusion, and tremor. Patients should be educated on recognizing these symptoms and advised on how to manage them.\n",
      "\n",
      "3. **Adjustment of Diabetes Medications**: The dosage of insulin or oral hypoglycemic agents may need to be altered when a patient starts fluoxetine. Collaboration with the endocrinologist or the healthcare provider managing the diabetes is advisable to determine appropriate medication adjustments.\n",
      "\n",
      "4. **Patient Education**: Patients should be informed about the potential effects of fluoxetine on their diabetes management, including the signs of hypoglycemia and the importance of adherence to blood glucose monitoring.\n",
      "\n",
      "5. **Close Follow-up**: Regular follow-up appointments should be scheduled to assess the patient's mental health as well as their diabetes control, adjusting treatment as necessary.\n",
      "\n",
      "In summary, careful monitoring, potential medication adjustments, and patient education are critical when prescribing fluoxetine to individuals with diabetes to ensure both their mental health and glycemic control are optimized.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 219:----\n",
      "Question: If a hypersensitivity reaction occurs during TAKHZYRO treatment, what is the primary concern for the healthcare provider?\n",
      "\n",
      "Correct Answer: C:\n",
      "Discontinuing TAKHZYRO and initiating appropriate treatment.\n",
      "\n",
      "Detailed Prediction: If a hypersensitivity reaction occurs during TAKHZYRO (lanadelumab) treatment, the primary concern for the healthcare provider is the potential for serious allergic reactions, which may include anaphylaxis. Healthcare providers must be vigilant in monitoring patients for signs of hypersensitivity after administration, including symptoms like rash, urticaria, difficulty breathing, or gastrointestinal symptoms. Immediate intervention may be required if severe symptoms manifest, including the use of epinephrine in cases of anaphylaxis. It is crucial to have a plan in place for managing such reactions, including the provision of emergency care.\n",
      "\n",
      "In the context of managing patients receiving TAKHZYRO, which is used to prevent attacks of hereditary angioedema, understanding the risk of hypersensitivity is critical as it ensures patient safety and effective management of their condition. Regular assessment and education of the patient about the symptoms of hypersensitivity are essential components of care during treatment with this medication.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 225:----\n",
      "Question: What is the physical appearance of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "White to off-white crystalline powder\n",
      "\n",
      "Detailed Prediction: Venlafaxine hydrochloride is a medication commonly used as an antidepressant and in the treatment of anxiety disorders. \n",
      "\n",
      "In its physical form, venlafaxine hydrochloride is typically presented in the form of tablets or capsules. The appearance of these pharmaceutical forms can vary based on the manufacturer and specific formulation:\n",
      "\n",
      "1. **Tablets**: The extended-release tablets may resemble conventional tablets and typically have a smooth surface with a specific coating for gradual release of the medication. The appearance can be described as circular and may contain specific identifiers such as numbers or letters stamped on them for identification.\n",
      "\n",
      "2. **Capsules**: For the capsule form, venlafaxine hydrochloride might be presented in a hard or soft gelatin shell, generally in colors such as light green or blue, and may be oval or elongated in shape. Each capsule usually contains the active ingredient as well as various inactive ingredients necessary for stability and absorption.\n",
      "\n",
      "3. **Color and Texture**: The color can range from off-white to tan when in solid form (e.g., as a powder before compression into tablets or encapsulation). When describing the physical properties, some studies report the color and texture may vary slightly among different preparations, but they remain within a specific pharmaceutical standard.\n",
      "\n",
      "For specific appearances, more details can be checked through pharmaceutical labels or product descriptions provided by the manufacturers and regulatory bodies (e.g., FDA labels).\n",
      "\n",
      "Overall, the precise physical appearance of venlafaxine hydrochloride can depend on the dosage form and manufacturer but generally conforms to these descriptions. For a more detailed visual reference, you may consult the manufacturer's product label.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 233:----\n",
      "Question: Which of the following is NOT a contraindication for Ciprofloxacin use?\n",
      "\n",
      "Correct Answer: D:\n",
      "A history of hypersensitivity to cephalosporins\n",
      "\n",
      "Detailed Prediction: Ciprofloxacin is an antibiotic that is part of the fluoroquinolone class, and it has several contraindications for its use. The common contraindications include:\n",
      "\n",
      "1. **History of tendon disorders**: Ciprofloxacin has been associated with an increased risk of tendon rupture, especially in patients with a history of tendon disorders, particularly the Achilles tendon.\n",
      "2. **Myasthenia gravis**: The use of ciprofloxacin may exacerbate muscle weakness in patients with myasthenia gravis.\n",
      "3. **Pregnancy**: Ciprofloxacin is generally contraindicated in pregnancy due to the potential risk to the developing fetus.\n",
      "\n",
      "However, there are certain conditions where ciprofloxacin use may not be contraindicated, which might include:\n",
      "\n",
      "- **Mild to moderate renal impairment**, if the dosage is adjusted accordingly.\n",
      "- **Certain types of infections**, where ciprofloxacin is found to be effective despite other risk factors.\n",
      "\n",
      "Thus, it is essential for healthcare providers to carefully assess the risks and benefits before prescribing ciprofloxacin in patients with varying health conditions. Therefore, the answer to the question regarding which is NOT a contraindication for ciprofloxacin would involve identifying a condition that does not fall under the typical contraindications mentioned above.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 250:----\n",
      "Question: What is the recommendation for dosing Lantus Solostar in geriatric patients?\n",
      "\n",
      "Correct Answer: C:\n",
      "Start with conservative dosing to avoid hypoglycemia.\n",
      "\n",
      "Detailed Prediction: In geriatric patients, dosing recommendations for Lantus (insulin glargine) should be approached with caution due to the physiological changes associated with aging, potential comorbidities, and the possibility of polypharmacy effects. \n",
      "\n",
      "1. **Starting Dose**: It is generally recommended to start at a lower dose than in younger patients. A typical initiation dose might range from 0.2 to 0.4 units/kg/day, depending on the individual patient's requirements and current blood glucose levels.\n",
      "\n",
      "2. **Adjustment Based on Glycemic Control**: The dose should then be titrated based on self-monitored blood glucose readings, with adjustments typically made in increments of 2 to 4 units as necessary. \n",
      "\n",
      "3. **Risk of Hypoglycemia**: Geriatric patients are at a higher risk for hypoglycemia due to factors like decreased renal function, altered pharmacokinetics of insulin, and cognitive impairment. Therefore, it is crucial to monitor for signs of hypoglycemia and adjust the dosage accordingly.\n",
      "\n",
      "4. **Consideration for Comorbidities**: Many elderly patients may have comorbid conditions such as renal impairment or cardiovascular diseases that could influence insulin metabolism and action. \n",
      "\n",
      "5. **Regular Monitoring**: Frequent monitoring of glucose levels is recommended to prevent both hyperglycemia and hypoglycemia, especially during dose adjustments.\n",
      "\n",
      "In summary, while using Lantus in geriatric patients, careful consideration of the starting dose, monitoring for hypoglycemia, and adjustment based on individual patient needs are essential for effective and safe management of diabetes in this population.\n",
      "\n",
      "For more detailed clinical guidelines and specific studies, please refer to recent literature from resources such as PubMed.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 256:----\n",
      "Question: What is the recommendation for dose adjustment of Signifor LAR in patients with renal impairment?\n",
      "\n",
      "Correct Answer: A:\n",
      "No dose adjustment is required.\n",
      "\n",
      "Detailed Prediction: The dosing recommendations for Signifor LAR (pasireotide) in patients with renal impairment specifically are not well detailed in available literature. However, it is generally accepted that drugs primarily excreted by the kidneys may require dose adjustments in patients with renal impairment.\n",
      "\n",
      "Based on the information gathered:\n",
      "- **General Dosing**: The standard initial dose of Signifor LAR for the treatment of conditions like acromegaly is typically 40 mg administered by intramuscular injection once every 4 weeks. Adjustments may be considered if the patient experiences side effects or inadequate response.\n",
      "- **Lack of Specific Guidance**: There is limited data directly addressing dosage adjustments for Signifor LAR in patients with renal impairment, which suggests that more individualized assessment may be necessary. \n",
      "\n",
      "For deeper insights, referring to the package insert and consulting a healthcare provider or pharmacist is recommended. Additionally, continuous monitoring is important in any patient with renal impairment receiving this medication. \n",
      "\n",
      "For more detailed information, you can refer to sources such as the [Drugs.com package insert](https://www.drugs.com/pro/signifor-lar-injection.html).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 296:----\n",
      "Question: In which scenario should Lamotrigine not be prescribed?\n",
      "\n",
      "Correct Answer: A:\n",
      "A patient with hypersensitivity to Lamotrigine\n",
      "\n",
      "Detailed Prediction: Lamotrigine is a medication primarily used to treat epilepsy and bipolar disorder. However, there are specific scenarios where its use is contraindicated or should be approached with caution:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Individuals who have a known hypersensitivity to lamotrigine or any of its components should not be prescribed this medication. Rash or other allergic reactions can occur, and in some cases, they may lead to severe conditions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).\n",
      "\n",
      "2. **History of Serious Skin Reactions**: Patients who have experienced severe skin reactions from lamotrigine in the past should avoid its use. This includes cases of SJS, TEN, or other serious cutaneous adverse drug reactions.\n",
      "\n",
      "3. **Concurrent Use with Valproate**: Lamotrigine metabolism can be significantly affected by the concomitant use of valproate (valproic acid), leading to increased levels of lamotrigine and a higher risk of serious side effects, particularly skin rashes. Caution is needed when these medications are used together, and dosage adjustments may be necessary.\n",
      "\n",
      "4. **Pregnancy and Lactation**: While lamotrigine can be used in pregnancy under careful monitoring, potential risks to the fetus exist, particularly regarding neural tube defects if used at high doses. Pregnant individuals or those planning to become pregnant should consult healthcare providers to evaluate risks versus benefits.\n",
      "\n",
      "5. **Renal or Hepatic Impairment**: Patients with significant renal or hepatic impairment may require dosage adjustments, and potential risks associated with lamotrigine should be considered carefully.\n",
      "\n",
      "6. **Non-dystrophic Myotonia**: While there have been studies showing efficacy, patients with specific neuromuscular disorders where muscle relaxation is significantly impaired should be evaluated carefully due to potential unusual responses (as per the findings observed in real-world cases).\n",
      "\n",
      "In summary, lamotrigine should not be prescribed in cases of hypersensitivity to the drug or its components, in patients with a history of severe skin reactions caused by lamotrigine, when used in conjunction with valproate without careful monitoring, during pregnancy (without a thorough risk assessment), in significant renal or hepatic impairment, and with caution in patients with certain neuromuscular disorders. Always consulting with a healthcare provider for individualized assessment is essential.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 321:----\n",
      "Question: What action should patients take if they develop signs of heart failure while on REMICADE?\n",
      "\n",
      "Correct Answer: B:\n",
      "Seek medical attention and consult their prescriber.\n",
      "\n",
      "Detailed Prediction: If a patient develops signs of heart failure while on REMICADE (infliximab), they should take the following actions:\n",
      "\n",
      "1. **Immediate Consultation**: Patients are advised to seek immediate medical attention. Heart failure can manifest as symptoms like shortness of breath, swelling in the legs or abdomen, fatigue, and rapid or irregular heartbeat. Recognizing these signs and acting promptly is vital.\n",
      "\n",
      "2. **Discontinuation of REMICADE**: Upon presentation with symptoms suggestive of heart failure, healthcare providers may recommend discontinuing REMICADE, as it has been associated with cardiovascular issues in some patients.\n",
      "\n",
      "3. **Comprehensive Evaluation**: The healthcare provider will likely conduct a thorough evaluation, including physical exams and diagnostic tests such as echocardiograms and EKGs, to assess cardiovascular function and rule out other possible causes of heart failure.\n",
      "\n",
      "4. **Management of Heart Failure**: If diagnosed, treatment may include medication to help manage heart failure symptoms such as diuretics to reduce fluid overload, ACE inhibitors, or beta-blockers to improve heart function.\n",
      "\n",
      "5. **Monitoring and Follow-Up**: Close monitoring by a cardiologist or primary care provider is crucial to manage heart health effectively. Follow-up visits and adjustments to medication and treatment plans may be necessary based on the patient's response.\n",
      "\n",
      "It is essential for patients to communicate openly with their healthcare team regarding any symptoms experienced while on immunotherapy treatments like REMICADE, as timely intervention can significantly improve outcomes.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 338:----\n",
      "Question: If a user requires higher sunburn protection than Arizona Sun Sunscreen SPF15, what should they consider?\n",
      "\n",
      "Correct Answer: A:\n",
      "Using a sunscreen with a higher SPF\n",
      "\n",
      "Detailed Prediction: When considering higher sunburn protection than Arizona Sun Sunscreen SPF 15, users should keep the following factors in mind:\n",
      "\n",
      "1. **Higher SPF Values**: Choose sunscreens with higher SPF ratings. The SPF (Sun Protection Factor) indicates the level of protection from UVB rays. For instance, products with SPF 30 to SPF 50 provide significantly better protection. It's important to note that SPF values above 50 offer diminishing returns in terms of protection.\n",
      "\n",
      "2. **Broad-Spectrum Protection**: Ensure that the sunscreen provides broad-spectrum protection against both UVA and UVB rays. UVB rays cause sunburn and contribute to skin cancer, while UVA rays penetrate the skin more deeply and can cause aging and also contribute to skin cancer.\n",
      "\n",
      "3. **Water Resistance**: Consider water-resistant formulations if engaging in activities that involve swimming or sweating. Look for products labeled as \"water-resistant\" for 40 or 80 minutes, as these can retain their SPF for that duration even when exposed to water.\n",
      "\n",
      "4. **Active Ingredients**: The effectiveness of sunscreens can vary based on their active ingredients. Common ingredients include:\n",
      "   - **Chemical Filters**: Such as avobenzone, octisalate, and octocrylene, which absorb UV radiation.\n",
      "   - **Physical (Mineral) Filters**: Such as zinc oxide or titanium dioxide, which reflect UV rays and are often recommended for sensitive skin.\n",
      "\n",
      "5. **Formulation and Application**: Choose a formulation that suits the user's skin type and preference (gel, cream, lotion, spray, etc.). It's essential to apply sunscreen generously and evenly to all exposed skin, using about an ounce (a shot glass full) for full body coverage.\n",
      "\n",
      "6. **Reapplication**: Reapply sunscreen every two hours, or more frequently if swimming or sweating. This is critical for maintaining effective protection.\n",
      "\n",
      "7. **Additional Protective Measures**: Along with using high SPF sunscreen, users should consider other protective measures such as wearing protective clothing, sunglasses, and seeking shade during peak sun hours (10 a.m. to 4 p.m.).\n",
      "\n",
      "8. **New Innovations**: Recent developments in sunscreen technology, like the use of bilayer hydrogels with exceptional UV absorption and enhanced skin adhesion, offer promising advancements for sun protection. These formulations can significantly exceed traditional SPF levels, providing better protection and therapeutic benefits to the skin (as noted in recent studies).\n",
      "\n",
      "In summary, when seeking higher sunburn protection, users should opt for a higher SPF, ensure broad-spectrum coverage, choose suitable formulations, and incorporate additional protective practices to effectively safeguard their skin from UV damage.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 340:----\n",
      "Question: What should be done if a patient taking Tri Femynor experiences a significant increase in blood pressure?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue Tri Femynor immediately.\n",
      "\n",
      "Detailed Prediction: If a patient taking Tri Femynor (a combination oral contraceptive containing ethinyl estradiol and norgestimate) experiences a significant increase in blood pressure, the following steps should be taken:\n",
      "\n",
      "1. **Monitor Blood Pressure**: The first step is to consistently monitor the patient's blood pressure to confirm the significant increase. Blood pressure measurements should be taken at different times to ensure accuracy.\n",
      "\n",
      "2. **Assess Symptoms**: Evaluate the patient for any additional symptoms that may accompany the increased blood pressure, such as headaches, visual changes, or shortness of breath, which may indicate a more serious condition.\n",
      "\n",
      "3. **Review Medical History**: Consider the patient's medical history, including any pre-existing hypertension, risk factors (such as smoking, obesity, or a family history of hypertension), and other medications that the patient may be taking that could contribute to increased blood pressure.\n",
      "\n",
      "4. **Consult Healthcare Provider**: The patient should consult their healthcare provider to discuss the increase in blood pressure in the context of their overall health and any potential risk factors. The provider may consider switching the patient to a different contraceptive method that has a lower risk of affecting blood pressure.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage the patient to adopt lifestyle changes that can help manage blood pressure, such as dietary adjustments (reducing sodium intake), regular physical activity, weight management, and stress reduction techniques.\n",
      "\n",
      "6. **Consider Discontinuation or Alternatives**: If high blood pressure persists and is concerning, it may be necessary to discontinue Tri Femynor and explore alternative contraceptive options that do not affect blood pressure as significantly.\n",
      "\n",
      "7. **Follow-up**: Ensure that the patient has regular follow-up appointments to monitor their blood pressure and assess the effectiveness of any changes made to their treatment plan.\n",
      "\n",
      "In summary, addressing a significant increase in blood pressure while taking Tri Femynor involves monitoring, assessing, and potentially adjusting the treatment plan in consultation with a healthcare provider.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 348:----\n",
      "Question: What is the approximate incidence rate of serious rashes, including Stevens-Johnson syndrome, in pediatric patients aged 2 to 17 years taking lamotrigine?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.3% to 0.8%\n",
      "\n",
      "Detailed Prediction: The incidence rate of serious rashes, including Stevens-Johnson syndrome (SJS), in pediatric patients aged 2 to 17 years taking lamotrigine is relatively low. A retrospective cohort study involving adolescents aged 13 to 20 years treated with lamotrigine reported that out of 102 patients, 23 developed a skin rash, leading to an incidence of approximately 22.5%. However, only one patient developed a serious rash classified as Stevens-Johnson syndrome. This indicates that while skin rashes are not uncommon, serious adverse reactions such as SJS are rare, highlighting an incidence rate of about 1% for severe rashes in this specific demographic.\n",
      "\n",
      "Additional studies support that the overall risk of developing serious skin reactions with lamotrigine, particularly when introduced at higher doses or more rapidly, has potential to increase, but careful dosing and monitoring can mitigate risks. Therefore, healthcare providers often recommend gradually titrating the dosage of lamotrigine to lower the likelihood of rash development. \n",
      "\n",
      "In summary, while rashes are a common side effect of lamotrigine treatment in pediatric patients, serious complications such as Stevens-Johnson syndrome occur infrequently, emphasizing the importance of careful clinical monitoring.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 353:----\n",
      "Question: What monitoring is recommended for patients on chronic warfarin therapy who are administered FOSAPREPITANT?\n",
      "\n",
      "Correct Answer: B:\n",
      "Monitor INR in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant.\n",
      "\n",
      "Detailed Prediction: The interaction between warfarin and fosaprepitant necessitates careful monitoring due to the potential for altered anticoagulation effects. Here are some considerations and recommendations for monitoring patients on chronic warfarin therapy who are administered fosaprepitant:\n",
      "\n",
      "1. **INR Monitoring**: Regular INR (International Normalized Ratio) tests are crucial. Patients should have their INR checked more frequently (at least once a week) after initiating fosaprepitant, as it may affect warfarin metabolism due to its influence on CYP3A4.\n",
      "\n",
      "2. **Clinical Assessment**: Monitor for signs of bleeding or thrombosis closely. Increased vigilance is warranted during the initial days of therapy with fosaprepitant as it may interact with the pharmacokinetics of warfarin.\n",
      "\n",
      "3. **Dosage Adjustment**: Be prepared to adjust the dose of warfarin based on INR results. If significant changes in INR occur, modifications to the warfarin regimen should be done cautiously.\n",
      "\n",
      "4. **Patient Education**: Educate patients about the signs of bleeding, such as unusual bruising, blood in urine or stool, and prolonged bleeding from cuts. They should also be informed about the importance of adherence to follow-up INR checks.\n",
      "\n",
      "5. **Duration of Monitoring**: The adjustments and increased monitoring should continue until the INR stabilizes at the desired therapeutic range post-initiation of fosaprepitant therapy.\n",
      "\n",
      "6. **Professional Collaboration**: Consider involving a pharmacist or anticoagulation management service for optimal management strategies during this concurrent therapy.\n",
      "\n",
      "Due to the lack of specific clinical trials currently linking these therapies directly, healthcare providers should base their decisions on pharmacological principles and existing guidelines on warfarin management and the effects of CYP3A4 inhibitors. Always assess the individual patient's risk factors and clinical scenario when determining monitoring strategies.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 361:----\n",
      "Question: What should a user do if irritation or sensitivity develops while using BP Wash?\n",
      "\n",
      "Correct Answer: B:\n",
      "Stop using BP Wash and consult a doctor.\n",
      "\n",
      "Detailed Prediction: If irritation or sensitivity develops while using BP (benzoyl peroxide) Wash, here are some recommended steps to manage the situation:\n",
      "\n",
      "1. **Discontinue Use**: Immediately stop using the BP Wash to prevent further irritation. Continuing to use the product can worsen the sensitivity and delay healing.\n",
      "\n",
      "2. **Rinse Thoroughly**: Gently rinse your skin with lukewarm water to remove any residual product. This helps to soothe the skin and reduce the irritation.\n",
      "\n",
      "3. **Use a Gentle Cleanser**: Switch to a mild, non-irritating cleanser for your regular skin care routine. Look for products that are fragrance-free and formulated for sensitive skin.\n",
      "\n",
      "4. **Apply Soothing Agents**: Consider applying soothing agents such as aloe vera gel or hydrocortisone cream (if approved by a healthcare professional) to alleviate irritation. These products can help calm the skin and reduce redness.\n",
      "\n",
      "5. **Moisturize**: Use a gentle, non-comedogenic moisturizer to help restore the skin barrier. Keeping your skin hydrated can reduce dryness and irritation.\n",
      "\n",
      "6. **Avoid Active Ingredients**: While your skin is healing, avoid using other active ingredients that may irritate the skin, such as salicylic acid, retinoids, or other exfoliants.\n",
      "\n",
      "7. **Gradual Reintroduction**: Once the irritation has resolved, if you wish to continue using benzoyl peroxide, consider reintroducing it slowly. You can start with a lower concentration and use it less frequently (e.g., every other day) to see how your skin reacts.\n",
      "\n",
      "8. **Consult a Healthcare Professional**: If irritation persists or worsens, consult a dermatologist or healthcare provider for tailored advice and possible alternative treatments.\n",
      "\n",
      "For more detailed information on managing skin irritation while using benzoyl peroxide, you can refer to [this article](https://viraltrench.com/reduce-irritation-using-benzoyl-peroxide-wash/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 366:----\n",
      "Question: What is the incidence of infusion-site erythema in patients receiving FOSAPREPITANT for HEC compared to oral aprepitant?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.5% in FOSAPREPITANT group and 0.1% in oral aprepitant group\n",
      "\n",
      "Detailed Prediction: The incidence of infusion-site erythema in patients receiving FOSAPREPITANT has been reported to be significant. In a study that evaluated symptoms from 61 injections of Fosaprepitant, erythema was observed in 10 patients, representing approximately 16% of the injections. Pain at the injection site was noted in 23% of cases, further indicating that injection-site reactions can be prevalent. \n",
      "\n",
      "Currently, specific comparative data for the incidence of infusion-site erythema between FOSAPREPITANT and oral aprepitant is limited, but the infusion-related reactions to FOSAPREPITANT appear to be notable. Oral aprepitant typically does not involve injection-site reactions as it is administered orally; thus, it offers a different route of administration that may mitigate such local reactions, but direct comparative incidence rates remain to be elucidated in research. \n",
      "\n",
      "For further details, you can refer to the relevant study discussing these findings [here](https://www.jcancer.org/v05p0390.htm).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 371:----\n",
      "Question: In the trial comparing Ondansetron to metoclopramide for single high-dose fraction radiotherapy, which drug was more effective in achieving complete control of emesis?\n",
      "\n",
      "Correct Answer: A:\n",
      "Ondansetron\n",
      "\n",
      "Detailed Prediction: In the context of treating radiation-induced emesis (RIE) during single high-dose fraction radiotherapy, Ondansetron has been shown to be effective. According to a study published in *Seminars in Oncology*, the incidence and severity of RIE can significantly vary based on factors such as radiation dose and field size.\n",
      "\n",
      "Although the specific trial directly comparing Ondansetron and metoclopramide for this purpose was not found in the clinical trials database, existing literature indicates that Ondansetron, a 5-HT3 receptor antagonist, may provide better control of emesis compared to traditional antiemetics like metoclopramide, especially in cases of high radiation doses over 500 cGy. The effectiveness of Ondansetron relates to its mechanism of action in blocking the serotonin receptors involved in the emetic response.\n",
      "\n",
      "The reported data indicate that radiation-induced emesis occurs in a high percentage of patients receiving high-dose hemibody irradiation, which suggests that administering antiemetics prior to treatment can be beneficial. In summary, while a direct comparative study between the two drugs for RIE was not located, Ondansetron is generally recognized as more effective for controlling emesis in patients undergoing high-dose radiotherapy.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 381:----\n",
      "Question: Based on animal studies, what is the role of leucovorin in the context of Pemetrexed for injection overdose?\n",
      "\n",
      "Correct Answer: B:\n",
      "It mitigates the toxicities of Pemetrexed\n",
      "\n",
      "Detailed Prediction: Leucovorin, also known as folinic acid, is a medication primarily used to mitigate the toxic effects of certain drugs, particularly methotrexate, and can play a supportive role in chemotherapy regimens. In the context of pemetrexed (a chemotherapy agent used to treat certain types of cancer), animal studies suggest that leucovorin may indeed help to reduce the toxicities associated with pemetrexed overdose.\n",
      "\n",
      "The mechanism thought to underlie the protective role of leucovorin involves its function as a reduced form of folate, which can help to replenish folate levels in the body. Pemetrexed exerts its effects by inhibiting several enzymes involved in folate metabolism, leading to a potential depletion of folates and resultant toxicity. By administering leucovorin, the goal is to provide the body with a source of folate that can help counteract this depletion and mitigate side effects.\n",
      "\n",
      "According to resources, the specific finding is that in animal studies, administration of leucovorin can alleviate the toxic effects seen during pemetrexed overdose, although the precise dosing and efficacy may vary based on animal models and individual responses. It is important to note, however, that while the animal models provide useful insights, clinical protocols for overdose management in humans must always integrate comprehensive clinical judgment and adhere to established medical guidelines. \n",
      "\n",
      "In conclusion, leucovorin appears to play a beneficial role in scenarios of Pemtrexed overdose based on animal studies, primarily by counteracting the drug's toxicity through folate replenishment. Further research and clinical studies are, however, essential to fully understand this interaction and guidelines for application in human cases.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 386:----\n",
      "Question: Which of the following statements is true regarding the storage conditions of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature between 15 - 30¬∞C.\n",
      "\n",
      "Detailed Prediction: The storage conditions for sterile drugs are critical to maintaining their efficacy and preventing contamination. Based on the reviewed literature, here are key points about sterile drug storage:\n",
      "\n",
      "1. **Temperature Regulation**: Most sterile drugs need to be stored in controlled environments, with specific temperatures being crucial. For example, certain formulations may require refrigeration at 4¬∞C to maintain stability, while others may be affected negatively by freezing temperatures (-20¬∞C to -80¬∞C) (PubMed PMID: 41414880, 41266122).\n",
      "\n",
      "2. **Microbial Contamination Prevention**: Sterile medications must be stored in a manner that prevents microbial contamination. This often involves using aseptic techniques during preparation and storage in sterile, airtight containers (PubMed PMID: 41176402).\n",
      "\n",
      "3. **Stability Considerations**: The stability of sterile drugs can differ based on the medium they are compounded in. For instance, preservative-free formulations may exhibit different stability profiles compared to those that contain preservatives (PubMed PMID: 41266122).\n",
      "\n",
      "4. **Humidity Control**: In addition to temperature, humidity control may also impact the stability of certain sterile medications. High humidity can encourage contamination or degradation.\n",
      "\n",
      "5. **Shelf Life Monitoring**: It is essential to actively monitor the shelf life of sterile products. Proper labeling with expiration dates and adherence to storage guidelines helps ensure efficacy throughout their intended use.\n",
      "\n",
      "In summary, the proper storage conditions for sterile drugs typically include maintaining specific temperature controls (most commonly refrigeration but avoiding freezing for many), using sterile containers, ensuring microbiological safety during storage, and monitoring for stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 390:----\n",
      "Question: What action should be taken if a patient develops a serious infection while on REMICADE therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue REMICADE immediately\n",
      "\n",
      "Detailed Prediction: If a patient develops a serious infection while undergoing therapy with REMICADE (infliximab), immediate and appropriate actions should be taken. REMICADE is a tumor necrosis factor (TNF) inhibitor used primarily to treat autoimmune diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, and others. However, patients on such therapies are at an increased risk for infections due to their immunosuppressive effects.\n",
      "\n",
      "### Steps to Take When a Serious Infection Develops:\n",
      "\n",
      "1. **Discontinue REMICADE**: The first step is to discontinue REMICADE immediately. Continuing treatment can worsen the infection or complicate the patient's condition.\n",
      "\n",
      "2. **Clinical Assessment**: A thorough clinical evaluation should be conducted to assess the severity and type of infection. This often includes:\n",
      "   - Physical examination\n",
      "   - Laboratory tests (e.g., blood cultures, complete blood count, inflammatory markers)\n",
      "   - Imaging studies, if necessary (e.g., X-rays, CT scans) to localize the infection.\n",
      "\n",
      "3. **Initiate Appropriate Antibiotic Therapy**: Based on the clinical assessment and laboratory results, appropriate empirical antibacterial therapy should start as soon as possible. The choice of antibiotics may depend on the suspected source and type of infection.\n",
      "\n",
      "4. **Monitor the Patient**: Close monitoring of vital signs and the patient's clinical status is essential to ensure that the infection does not worsen and that there are no signs of sepsis or other complications.\n",
      "\n",
      "5. **Consult Specialists**: If necessary, consultations with infectious disease specialists may be warranted, especially if the infection is atypical or resistant to initial treatment.\n",
      "\n",
      "6. **Adjunctive Care**: Supportive care, including hydration and management of symptoms, should be provided as needed. This may involve pain management and any specific interventions required based on the site and severity of the infection.\n",
      "\n",
      "7. **Evaluate for Re-initiating Therapy**: Once the infection is resolved and the patient has stabilized, healthcare providers should consider the risks versus benefits of re-initiating REMICADE therapy. This evaluation may include assessing the reasons for therapy (the condition being treated) versus the potential for recurrent infections.\n",
      "\n",
      "8. **Patient Education**: Educating the patient about recognizing signs of infection in the future is vital. Patients should be informed to report any concerning symptoms promptly, especially fever, chills, or other systemic signs.\n",
      "\n",
      "9. **Screening and Prevention**: Prior to restarting any immunosuppressive therapy, patients should be screened for latent infections like tuberculosis, and vaccination status should be reviewed to prevent future complications.\n",
      "\n",
      "In summary, the management of a serious infection in a patient on REMICADE requires immediate action, careful evaluation, and a coordinated approach to treatment to ensure patient safety and adequate management of their pre-existing conditions.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 392:----\n",
      "Question: What is the recommended action if a patient taking Iclusig develops hypertension that is not medically controlled?\n",
      "\n",
      "Correct Answer: B:\n",
      "Interrupt, dose reduce, or stop Iclusig.\n",
      "\n",
      "Detailed Prediction: In managing a patient taking Iclusig (ponatinib) who develops uncontrolled hypertension, the following recommended actions should be considered:\n",
      "\n",
      "1. **Consultation with a Specialist**: It is advisable to involve a cardiologist or a healthcare provider specializing in hypertension management to assess the severity of the hypertension and ensure a comprehensive evaluation.\n",
      "\n",
      "2. **Review and Adjust Antihypertensive Medications**: Evaluate the current antihypertensive regimen. Many patients on Iclusig may require an adjustment or addition of antihypertensive medications, particularly those that can counteract the effects of ponatinib, as it has the potential to exacerbate hypertension. Common classes of antihypertensive medications include ACE inhibitors, ARBs, calcium channel blockers, and diuretics.\n",
      "\n",
      "3. **Discontinue or Reduce Iclusig Dosage**: If the hypertension is particularly severe or not responding to the typical treatment strategies, consider reducing the dose of Iclusig or discontinuing it under the guidance of the treating oncologist. The risk-to-benefit ratio should be carefully evaluated, as controlling hypertension is crucial to prevent cardiovascular complications associated with ponatinib.\n",
      "\n",
      "4. **Monitor Blood Pressure Regularly**: Ensure frequent monitoring of blood pressure to assess the efficacy of the treatment adjustments and confirm that the hypertension is being effectively managed. This may involve routine follow-ups and possibly home monitoring.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage lifestyle changes that can positively impact blood pressure, such as dietary modifications (e.g., reducing sodium intake), increased physical activity, weight management, and smoking cessation if applicable.\n",
      "\n",
      "6. **Patient Education**: Educate the patient about the symptoms of uncontrolled hypertension and the importance of adhering to both the cancer treatment and hypertension management plans. Helping the patient understand potential side effects of Iclusig, including hypertension, can enhance collaboration in managing their health.\n",
      "\n",
      "7. **Consider Alternative Therapies**: If hypertension remains uncontrolled despite these measures, it may be necessary to explore alternative therapies rather than continuing Iclusig. This decision should involve a multidisciplinary team and thorough discussion with the patient about their treatment options.\n",
      "\n",
      "It‚Äôs important to note that careful management is paramount to mitigate the cardiovascular risks associated with tyrosine kinase inhibitors like Iclusig, especially given their potential to induce hypertension and other cardiovascular toxicities.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 405:----\n",
      "Question: What is one of the uses of sunmark ibuprofen related to fever?\n",
      "\n",
      "Correct Answer: B:\n",
      "It temporarily reduces fever.\n",
      "\n",
      "Detailed Prediction: Sunmark ibuprofen, a common over-the-counter medication, is primarily used as a pain reliever and fever reducer. One of its notable uses related to fever management is its effectiveness in lowering elevated body temperature.\n",
      "\n",
      "Ibuprofen works by inhibiting the production of prostaglandins, which are chemicals in the body responsible for causing inflammation, pain, and fever. When the body encounters an infection or inflammatory response, prostaglandin levels increase, leading to fever. By reducing these levels, ibuprofen effectively brings down the fever, providing symptomatic relief.\n",
      "\n",
      "In clinical settings, ibuprofen is often suggested for use in both adults and children for managing febrile illnesses, such as colds or flu, making it a suitable option for those experiencing fever due to various causes. It is important to follow dosage instructions to minimize the risk of side effects.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 407:----\n",
      "Question: Which statement accurately describes the pharmacological risk of Hydrocort overdosage?\n",
      "\n",
      "Correct Answer: B:\n",
      "Hydrocort overdosage can result in systemic effects due to absorption.\n",
      "\n",
      "Detailed Prediction: Hydrocortisone (also known as hydrocortisol) is a glucocorticoid medication commonly used for its anti-inflammatory and immunosuppressive properties. In cases of overdose, it poses several pharmacological risks that can lead to significant health complications.\n",
      "\n",
      "1. **Adrenal Suppression**: Chronic use of hydrocortisone can suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency, especially in cases of overdose. Patients may experience symptoms like fatigue, weakness, and hypotension due to insufficient cortisol production by the adrenal glands (PMID: 35550494).\n",
      "\n",
      "2. **Cushing's Syndrome**: Overdose of hydrocortisone can result in symptoms of Cushing's syndrome, which is characterized by excessive cortisol levels. Symptoms may include obesity (particularly central obesity), moon facies, skin changes (such as purple striae), and hypertension (PMID: 30627312).\n",
      "\n",
      "3. **Metabolic Effects**: High cortisol levels can disturb metabolic processes, potentially leading to hyperglycemia (high blood sugar), increased appetite, and weight gain (PMID: 31763206). This can also exacerbate pre-existing diabetes or lead to the onset of new cases of diabetes mellitus.\n",
      "\n",
      "4. **Psychiatric Effects**: Hydrocortisone overdosing can also exacerbate psychiatric symptoms, leading to anxiety, depression, or psychosis, particularly if the overdose is substantial or chronic (PMID: 37625179).\n",
      "\n",
      "Given these potential risks, monitoring is critical in patients receiving hydrocortisone, especially when treatment duration is extended or doses are elevated. Thus, appropriate therapeutic drug monitoring could help prevent overdosing and its consequences related to hypercortisolism by tracking glucocorticoid levels in the body (PMID: 35550494).\n",
      "\n",
      "In summary, the pharmacological risk of hydrocortisone overdosage includes a spectrum of adverse effects ranging from adrenal suppression to metabolic and psychiatric disorders, emphasizing the importance of careful dosing and monitoring in clinical practice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 420:----\n",
      "Question: Which precaution should be taken when administering Albuterol to patients receiving non-potassium-sparing diuretics?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor serum potassium levels closely.\n",
      "\n",
      "Detailed Prediction: When administering Albuterol to patients who are also receiving non-potassium-sparing diuretics (such as loop or thiazide diuretics), it is essential to take precautions primarily related to the risk of hypokalemia and associated cardiac effects.\n",
      "\n",
      "**Precautions:**\n",
      "\n",
      "1. **Monitor Potassium Levels:** Non-potassium-sparing diuretics can lead to potassium depletion (hypokalemia). Since Albuterol, as a beta-agonist, can also cause a decrease in serum potassium levels, the risk of developing significant hypokalemia is increased when these two medications are used together. Therefore, it is prudent to monitor serum potassium levels periodically in patients receiving this combination.\n",
      "\n",
      "2. **ECG Monitoring:** Due to the potential for ECG changes associated with hypokalemia, it may be necessary to monitor the ECG in patients on both Albuterol and non-potassium-sparing diuretics. This is particularly important if the patient exhibits symptoms of low potassium or arrhythmias.\n",
      "\n",
      "3. **Adjusting Albuterol Dosage:** Caution should be taken to avoid exceeding the recommended dose of Albuterol, as higher doses may exacerbate hypokalemia and its associated risks. \n",
      "\n",
      "4. **Patient Education:** Patients should be educated about the signs of hypokalemia, such as muscle weakness, cramping, or palpitations, and advised to seek medical attention if they experience these symptoms.\n",
      "\n",
      "Overall, the combination of Albuterol with non-potassium-sparing diuretics can potentiate the risk of hypokalemia and necessitates careful monitoring and management to ensure patient safety.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 439:----\n",
      "Question: What is the controlled substance classification of venlafaxine tablets?\n",
      "\n",
      "Correct Answer: D:\n",
      "Not a controlled substance\n",
      "\n",
      "Detailed Prediction: Venlafaxine, marketed under brand names such as Effexor, is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is primarily prescribed for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. \n",
      "\n",
      "Importantly, venlafaxine tablets are **not classified as controlled substances** by the Drug Enforcement Administration (DEA). This means that venlafaxine does not fall under any of the schedules that typically govern the prescription and distribution of potentially addictive drugs. According to available sources, venlafaxine has a low potential for abuse and physical dependence, which is why it is not subjected to the same regulations as controlled drugs.\n",
      "\n",
      "For further information, you can refer to the following resources:\n",
      "- [Wikipedia - Venlafaxine](https://en.wikipedia.org/wiki/Venlafaxine)\n",
      "- [DailyMed - VENLAFAXINE tablet](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55889b3d-74c9-4638-9a14-6a4ca3a99f7f)\n",
      "- [MedlinePlus - Venlafaxine](https://medlineplus.gov/druginfo/meds/a694020.html)\n",
      "\n",
      "In summary, while venlafaxine serves as an effective treatment option for several psychiatric conditions, it does not have a controlled substance classification, allowing for more straightforward prescribing and monitoring compared to controlled medications.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 443:----\n",
      "Question: What should a patient do if they experience mild COVID-19 symptoms and are prescribed Paxlovid?\n",
      "\n",
      "Correct Answer: B:\n",
      "Start Paxlovid treatment as soon as possible and within 5 days of symptom onset.\n",
      "\n",
      "Detailed Prediction: If a patient experiences mild COVID-19 symptoms and is prescribed Paxlovid (nirmatrelvir/ritonavir), here are the recommended steps they should take:\n",
      "\n",
      "1. **Understand the Prescription**: Paxlovid is an antiviral medication specifically designed for treating mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease. It is crucial for patients to comprehend the importance of adhering to this treatment to decrease the risk of severe illness.\n",
      "\n",
      "2. **Consult with Healthcare Providers**: Patients should discuss any other medications they are currently taking with their healthcare provider. Paxlovid can interact with various drugs, potentially leading to adverse effects or reduced effectiveness. If there are drugs that may interact, the healthcare provider might suggest alternatives or dosage adjustments.\n",
      "\n",
      "3. **Start Treatment Promptly**: Paxlovid should be taken as soon as possible after the onset of symptoms. The treatment is most effective when started within the first few days of symptom appearance. Patients should follow the prescribed regimen strictly, usually for five days.\n",
      "\n",
      "4. **Monitor Symptoms**: Patients should keep track of their symptoms and any changes in their condition. If symptoms worsen (e.g., breathing difficulties, chest pain), they should seek immediate medical attention.\n",
      "\n",
      "5. **Stay Hydrated and Rest**: Patients are encouraged to drink plenty of fluids and get adequate rest, as these are important aspects of recovery from any viral infection.\n",
      "\n",
      "6. **Report Side Effects**: If patients experience any side effects from Paxlovid, such as changes in taste, gastrointestinal upset, or allergic reactions, they should report these to their healthcare provider immediately.\n",
      "\n",
      "7. **Follow Up**: A follow-up appointment may be necessary to assess recovery and to determine if any additional care or treatment is required.\n",
      "\n",
      "8. **Take Preventive Measures**: While taking Paxlovid, it's also essential to continue practicing public health measures, such as wearing masks in crowded places and maintaining good hygiene, to prevent the spread of COVID-19 to others.\n",
      "\n",
      "Following these guidelines can help ensure optimal care during a mild COVID-19 infection when treated with Paxlovid.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 444:----\n",
      "Question: What is the recommended action if a patient on Tybost experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline?\n",
      "\n",
      "Correct Answer: B:\n",
      "Closely monitor the patient for renal safety.\n",
      "\n",
      "Detailed Prediction: If a patient on Tybost (cobicistat) experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline, the recommended action includes the following steps:\n",
      "\n",
      "1. **Assessment**: Re-evaluate the patient's kidney function baseline and the context of the increase. It's important to determine if this increase is isolated or part of a trend.\n",
      "\n",
      "2. **Monitor Renal Function**: Close monitoring of the patient's renal function is critical. This may involve regular serum creatinine tests and possibly urine tests to assess for any additional changes.\n",
      "\n",
      "3. **Review Medications**: Since Tybost can cause drug-drug interactions, particularly with other medications that are metabolized through the CYP3A pathway, a review of all concurrent medications should be performed. Attention should be given to any other nephrotoxic drugs that the patient may be taking.\n",
      "\n",
      "4. **Dosing Considerations**: Based on the degree of increase in serum creatinine, consider adjusting the dosing of Tybost or any other affected medications, particularly if they have narrow therapeutic indices.\n",
      "\n",
      "5. **Hydration and Supportive Care**: Ensure the patient is adequately hydrated, as dehydration can exacerbate renal impairment. Supportive care may also involve adjusting dietary intake or managing any other symptoms.\n",
      "\n",
      "6. **Consultations**: If the renal impairment persists or worsens despite above management steps, consider consulting a nephrologist to further evaluate the cause and management strategies.\n",
      "\n",
      "7. **Discontinuation of Tybost**: In cases where the increase in serum creatinine is substantial and persistent, discontinuation of Tybost may be warranted, considering the benefits versus risks in the context of the patient's health condition.\n",
      "\n",
      "These steps help ensure that the patient's renal function is carefully monitored and managed while minimizing the risks associated with continued use of Tybost.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 449:----\n",
      "Question: How should a patient start Tri Femynor if switching from a progestin-only method such as an implant or injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Start Tri Femynor on the day of removal of the implant or the day of the next injection.\n",
      "\n",
      "Detailed Prediction: When switching to Tri Femynor from a progestin-only method such as an implant or injection, the transition should be managed carefully to ensure continued contraceptive effectiveness.\n",
      "\n",
      "1. **Start Timing**: Patients should begin taking Tri Femynor on the day of removal of the progestin-only implant. If they are using an injectable method, they should start Tri Femynor on the day when their next injection would have been due.\n",
      "\n",
      "2. **Continuing Contraception**: It's important for patients to understand that there may be a brief period during which they could be at risk for pregnancy if they do not follow the correct switch protocol. Therefore, using a backup contraceptive method, such as condoms, is advisable during the first seven days of taking Tri Femynor, especially if the transition timing is not strictly followed.\n",
      "\n",
      "3. **Consult Healthcare Provider**: Patients should always consult with their healthcare provider before making any changes to their contraceptive regimen. This allows for personalized advice based on individual health profiles and potential risks.\n",
      "\n",
      "4. **Monitoring for Side Effects**: After switching, patients should monitor for any side effects or changes in their menstrual cycle, as their body adjusts to the new hormone combination present in Tri Femynor.\n",
      "\n",
      "For detailed instructions and to address any specific concerns, referring to a healthcare provider or the medication guide is recommended.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "‚ÑπÔ∏èValid Answers: 2\n",
      "‚ÑπÔ∏èInvalid Answers: 44\n",
      "üü¢ACC: 0.0%\n"
     ]
    }
   ],
   "execution_count": 30
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:33:03.491821Z",
     "start_time": "2026-01-12T12:33:03.441004Z"
    }
   },
   "cell_type": "code",
   "source": [
    "THRESH = 0.25  # tune on a dev split; good starting range: 0.15‚Äì0.30\n",
    "\n",
    "def best_option_by_tfidf(prediction, options_dict):\n",
    "    keys = list(options_dict.keys())\n",
    "    corpus = [prediction] + [options_dict[k] for k in keys]\n",
    "    tfidf = TfidfVectorizer(ngram_range=(1,2), stop_words=\"english\").fit_transform(corpus)\n",
    "    sims = cosine_similarity(tfidf[0], tfidf[1:]).ravel()\n",
    "    best_idx = int(np.argmax(sims))\n",
    "    return keys[best_idx], float(sims[best_idx])\n",
    "\n",
    "# compute TF-IDF prediction + similarity per row\n",
    "data_open = data_open.copy()\n",
    "tfidf_results = data_open.apply(\n",
    "    lambda r: best_option_by_tfidf(r[\"prediction\"], dict(r[\"options\"])),\n",
    "    axis=1\n",
    ")\n",
    "data_open[\"pred_tfidf\"] = tfidf_results.map(lambda x: x[0])\n",
    "data_open[\"tfidf_similarity\"] = tfidf_results.map(lambda x: x[1])\n",
    "\n",
    "# choose final answer:\n",
    "# 1) if regex extracted A-E, use it\n",
    "# 2) else, use TF-IDF if similarity >= threshold\n",
    "# 3) else NOTAVALUE\n",
    "\n",
    "data_open[\"final_choice\"] = np.where(\n",
    "    data_open[\"tfidf_similarity\"] >= THRESH,\n",
    "    data_open[\"pred_tfidf\"],\n",
    "    data_open[\"choice\"])\n",
    "\n",
    "data_open[\"is_correct\"] = data_open[\"final_choice\"] == data_open[\"correct_answer\"]\n",
    "\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] != 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}\")\n",
    "        print(f\"Is correct: {row['is_correct']}\")\n",
    "    \n",
    "print(\"\\n\\n‚ö†üü®--------- INVALID ANSWERS-----------üü®\\n\\n\")\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] == 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Question: {row['question']}\\n\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}:\")\n",
    "        print(f\"{ row['options'][row['correct_answer']] }\\n\")\n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\\n\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\\n\")\n",
    "\n",
    "\n",
    "\n",
    "NaN_open = len(data_open[data_open[\"final_choice\"] == 'NOTAVALUE'])\n",
    "valid_open = len(data_open) - NaN_open\n",
    "ACC_open = data_open[\"is_correct\"].sum() / valid_open\n",
    "\n",
    "print()\n",
    "print(f\"‚ÑπÔ∏èValid Answers: {valid_open}\")\n",
    "print(f\"‚ÑπÔ∏èInvalid Answers: {NaN_open}\")\n",
    "print(f\"üü¢ACC: {100*round(ACC_open,4)}%\")\n",
    "\n"
   ],
   "id": "e5ea80063da6334",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----Row 67:----\n",
      "Detailed Prediction: If a patient on Coreg CR (carvedilol phosphate) develops renal function deterioration, the following actions are recommended:\n",
      "\n",
      "1. **Monitor Renal Function**: It is crucial to assess renal function regularly, especially during the initiation and up-titration of Coreg CR. This monitoring helps in detecting any changes early and in making timely interventions.\n",
      "\n",
      "2. **Discontinuation or Dose Adjustment**: If there is evidence of worsening renal function, the prescribing physician should consider discontinuing the medication or reducing the dosage. This step is particularly important in high-risk patients who may be more susceptible to renal impairment.\n",
      "\n",
      "3. **Patient Evaluation**: Evaluate for potential underlying causes of renal dysfunction that may be exacerbated by Coreg CR. Consider any additional comorbidities or medications that may contribute to renal deterioration.\n",
      "\n",
      "4. **Alternative Therapies**: Depending on the patient's overall clinical situation, alternative antihypertensive or heart failure management strategies may need to be deployed if Coreg CR adversely affects renal function.\n",
      "\n",
      "5. **Consultation with a Specialist**: If the renal function does not improve upon adjusting or discontinuing Coreg CR, a consultation with a nephrologist may be appropriate for further evaluation and management.\n",
      "\n",
      "In summary, careful monitoring and appropriate adjustments in the management of patients receiving Coreg CR are essential if there is a sign of renal function deterioration. For more detailed information, the [DailyMed entry for Coreg CR](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9008ede8-3e53-4061-ae4c-c51cbbb56ef2) contains pertinent guidelines regarding the management of renal function changes associated with this medication.\n",
      "Final Choice: C\n",
      "Correct Answer: C\n",
      "Is correct: True\n",
      "\n",
      "----Row 84:----\n",
      "Detailed Prediction: When initiating Coreg CR (carvedilol controlled release) therapy in patients with diabetes, several precautions should be considered:\n",
      "\n",
      "1. **Monitor Blood Glucose Levels**: Carvedilol, a beta-blocker, can mask some of the adrenergic symptoms of hypoglycemia, such as palpitations and tremors. Therefore, it's crucial for healthcare providers to closely monitor blood glucose levels and educate patients on recognizing other signs of low blood sugar.\n",
      "\n",
      "2. **Adjust Dosage Carefully**: Given that patients with diabetes may have varying sensitivities to blood glucose fluctuations, any dose adjustments should be made cautiously. Start with a low dose and titrate slowly based on the patient's tolerance and blood sugar control.\n",
      "\n",
      "3. **Evaluate for Comorbidities**: Patients with diabetes often have additional comorbid conditions, such as hypertension or heart failure. The presence of these conditions requires careful assessment to ensure the benefits of initiating Coreg CR outweigh potential risks.\n",
      "\n",
      "4. **Patient Education**: Informing patients about the potential side effects of beta-blockers, including fatigue and dizziness, is essential. They should understand the need for regular follow-ups to monitor their cardiovascular status as well as diabetes management while on this medication.\n",
      "\n",
      "5. **Assess for Renal Function**: Diabetes can lead to renal impairment, affecting drug metabolism and clearance. Renal function should be evaluated prior to starting Coreg CR, and the patient should be monitored for any increases in creatinine or changes in renal function during therapy.\n",
      "\n",
      "By taking these precautions, healthcare providers can help ensure safe and effective use of Coreg CR in patients with diabetes.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 340:----\n",
      "Detailed Prediction: If a patient taking Tri Femynor (a combination oral contraceptive containing ethinyl estradiol and norgestimate) experiences a significant increase in blood pressure, the following steps should be taken:\n",
      "\n",
      "1. **Monitor Blood Pressure**: The first step is to consistently monitor the patient's blood pressure to confirm the significant increase. Blood pressure measurements should be taken at different times to ensure accuracy.\n",
      "\n",
      "2. **Assess Symptoms**: Evaluate the patient for any additional symptoms that may accompany the increased blood pressure, such as headaches, visual changes, or shortness of breath, which may indicate a more serious condition.\n",
      "\n",
      "3. **Review Medical History**: Consider the patient's medical history, including any pre-existing hypertension, risk factors (such as smoking, obesity, or a family history of hypertension), and other medications that the patient may be taking that could contribute to increased blood pressure.\n",
      "\n",
      "4. **Consult Healthcare Provider**: The patient should consult their healthcare provider to discuss the increase in blood pressure in the context of their overall health and any potential risk factors. The provider may consider switching the patient to a different contraceptive method that has a lower risk of affecting blood pressure.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage the patient to adopt lifestyle changes that can help manage blood pressure, such as dietary adjustments (reducing sodium intake), regular physical activity, weight management, and stress reduction techniques.\n",
      "\n",
      "6. **Consider Discontinuation or Alternatives**: If high blood pressure persists and is concerning, it may be necessary to discontinue Tri Femynor and explore alternative contraceptive options that do not affect blood pressure as significantly.\n",
      "\n",
      "7. **Follow-up**: Ensure that the patient has regular follow-up appointments to monitor their blood pressure and assess the effectiveness of any changes made to their treatment plan.\n",
      "\n",
      "In summary, addressing a significant increase in blood pressure while taking Tri Femynor involves monitoring, assessing, and potentially adjusting the treatment plan in consultation with a healthcare provider.\n",
      "Final Choice: A\n",
      "Correct Answer: B\n",
      "Is correct: False\n",
      "\n",
      "----Row 420:----\n",
      "Detailed Prediction: When administering Albuterol to patients who are also receiving non-potassium-sparing diuretics (such as loop or thiazide diuretics), it is essential to take precautions primarily related to the risk of hypokalemia and associated cardiac effects.\n",
      "\n",
      "**Precautions:**\n",
      "\n",
      "1. **Monitor Potassium Levels:** Non-potassium-sparing diuretics can lead to potassium depletion (hypokalemia). Since Albuterol, as a beta-agonist, can also cause a decrease in serum potassium levels, the risk of developing significant hypokalemia is increased when these two medications are used together. Therefore, it is prudent to monitor serum potassium levels periodically in patients receiving this combination.\n",
      "\n",
      "2. **ECG Monitoring:** Due to the potential for ECG changes associated with hypokalemia, it may be necessary to monitor the ECG in patients on both Albuterol and non-potassium-sparing diuretics. This is particularly important if the patient exhibits symptoms of low potassium or arrhythmias.\n",
      "\n",
      "3. **Adjusting Albuterol Dosage:** Caution should be taken to avoid exceeding the recommended dose of Albuterol, as higher doses may exacerbate hypokalemia and its associated risks. \n",
      "\n",
      "4. **Patient Education:** Patients should be educated about the signs of hypokalemia, such as muscle weakness, cramping, or palpitations, and advised to seek medical attention if they experience these symptoms.\n",
      "\n",
      "Overall, the combination of Albuterol with non-potassium-sparing diuretics can potentiate the risk of hypokalemia and necessitates careful monitoring and management to ensure patient safety.\n",
      "Final Choice: D\n",
      "Correct Answer: A\n",
      "Is correct: False\n",
      "\n",
      "\n",
      "‚ö†üü®--------- INVALID ANSWERS-----------üü®\n",
      "\n",
      "\n",
      "\n",
      "----Row 22:----\n",
      "Question: Which of the following is a withdrawal symptom that Nicotine helps alleviate?\n",
      "\n",
      "Correct Answer: A:\n",
      "Nicotine craving.\n",
      "\n",
      "Detailed Prediction: Withdrawal symptoms from nicotine are common when a person stops smoking or using nicotine products. Nicotine helps alleviate several of these withdrawal symptoms, which can include:\n",
      "\n",
      "1. **Cravings for nicotine**: One of the most prominent symptoms, cravings can lead to relapse if not managed appropriately.\n",
      "   \n",
      "2. **Irritability and anxiety**: These emotional symptoms are frequently reported during withdrawal, and nicotine can help stabilize mood.\n",
      "\n",
      "3. **Increased appetite**: Many individuals experience an increase in appetite and subsequent weight gain upon stopping nicotine, which nicotine can suppress.\n",
      "\n",
      "4. **Difficulty concentrating**: Cognitive function may be impaired during withdrawal, with nicotine improving attention and focus.\n",
      "\n",
      "5. **Sleep disturbances**: Insomnia or altered sleep patterns are common, and nicotine can initially provide calming effects that help with sleep regulation.\n",
      "\n",
      "Research shows that various interventions, including pharmacological treatments and non-pharmacological strategies like acupuncture, can significantly alleviate these withdrawal symptoms. For example, a study indicated that electroacupuncture resulted in a greater reduction of nicotine withdrawal symptoms compared to other methods.\n",
      "\n",
      "In summary, nicotine plays a critical role in alleviating withdrawal symptoms such as cravings, irritability, increased appetite, cognitive difficulties, and sleep disturbances.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 37:----\n",
      "Question: What is the primary indication for the use of esomeprazole magnesium?\n",
      "\n",
      "Correct Answer: B:\n",
      "Treatment of frequent heartburn occurring 2 or more days a week.\n",
      "\n",
      "Detailed Prediction: Esomeprazole magnesium, a proton pump inhibitor (PPI), is primarily indicated for the treatment of several conditions related to excessive stomach acid production. The main indications for its use include:\n",
      "\n",
      "1. **Gastroesophageal Reflux Disease (GERD)**: Esomeprazole is effective in managing symptoms of GERD, a condition where stomach acid frequently flows back into the esophagus, causing heartburn and potential damage to the esophageal lining.\n",
      "\n",
      "2. **Peptic Ulcer Disease**: It is also used to treat peptic ulcers, either alone or in combination with antibiotics, to eradicate Helicobacter pylori infections, which are often responsible for these ulcers.\n",
      "\n",
      "3. **Erosive Esophagitis**: This condition, characterized by inflammation and damage to the esophagus due to acid reflux, is treated effectively with esomeprazole.\n",
      "\n",
      "4. **Zollinger-Ellison Syndrome**: Esomeprazole is indicated for this rare condition, where the stomach produces excessive amounts of acid due to tumors in the pancreas or duodenum.\n",
      "\n",
      "5. **Prevention of Gastric Ulcers**: It is used in patients who are at risk for ulcers following NSAID (non-steroidal anti-inflammatory drugs) use, particularly in long-term therapies.\n",
      "\n",
      "6. **Management of dyspepsia**: Esomeprazole can help alleviate symptoms of dyspepsia (indigestion), particularly when associated with high acid secretion.\n",
      "\n",
      "These indications illustrate the role of esomeprazole in managing acid-related gastrointestinal disorders effectively, enhancing patient quality of life by reducing symptoms associated with excess gastric acidity and promoting healing of the esophagus and stomach lining.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 42:----\n",
      "Question: What should patients do if they experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue Levalbuterol Inhalation Solution and consult their physician.\n",
      "\n",
      "Detailed Prediction: If patients experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution, they should take the following steps:\n",
      "\n",
      "1. **Stop Using the Inhaler**: Immediately discontinue the use of the Levalbuterol inhaler if paradoxical bronchospasm occurs. This adverse reaction can be life-threatening, and it is critical to stop taking the medication that is causing the problem.\n",
      "\n",
      "2. **Seek Medical Attention**: Contact a healthcare provider right away or seek emergency medical attention if breathing difficulties worsen. Paradoxical bronchospasm can manifest as increased wheezing, shortness of breath, or chest tightness, which may necessitate prompt intervention.\n",
      "\n",
      "3. **Monitor Symptoms**: Patients should closely monitor their respiratory status and report any changes in their breathing or other symptoms to their healthcare professional. Keeping a record of symptoms may help in the management and follow-up care.\n",
      "\n",
      "4. **Alternative Treatments**: Discuss with a healthcare provider about alternative bronchodilator medications or treatment options, as the use of Levalbuterol should be avoided in such cases in the future.\n",
      "\n",
      "5. **Emergency Plan**: Have an emergency plan established with a healthcare provider, including knowing when and how to use other rescue inhalers or medications if needed.\n",
      "\n",
      "Awareness of the potential for paradoxical bronchospasm is essential for safe medication use, as highlighted in a report indicating it can occur with both Levalbuterol and Albuterol, and being cognizant of this can help prevent life-threatening situations (Raghunathan et al., 2006).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 44:----\n",
      "Question: Which of the following is the molecular formula of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "C17H27NO2HCl\n",
      "\n",
      "Detailed Prediction: The molecular formula of venlafaxine hydrochloride is **C‚ÇÅ‚ÇáH‚ÇÇ‚ÇàClN‚ÇÅO‚ÇÇ**. Venlafaxine hydrochloride is an antidepressant medication used primarily to treat major depressive disorder and anxiety disorders. It functions as a serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 47:----\n",
      "Question: Which of the following statements is true regarding the storage of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature.\n",
      "\n",
      "Detailed Prediction: The storage of sterile drugs is crucial for maintaining their efficacy, safety, and sterility. Here are some important considerations regarding their storage:\n",
      "\n",
      "1. **Temperature Control**: Sterile drugs often require specific temperature conditions to ensure their stability. Many sterile medications need to be stored at controlled room temperatures, while others may require refrigeration or freezing to maintain their integrity.\n",
      "\n",
      "2. **Humidity and Light Protection**: Exposure to humidity and light can alter the chemical structure of sterile drugs, leading to degradation. Therefore, they should be stored in a dry place and in containers that protect them from light exposure.\n",
      "\n",
      "3. **Packaging and Containers**: The type of packaging can play a significant role in maintaining sterility. Aseptic packaging techniques and the use of barriers such as blister packs and sterile containers help to prevent contamination.\n",
      "\n",
      "4. **Expiration Dates and Shelf Life**: Every sterile drug has an expiration date, and it is essential to adhere to these dates to ensure safety. The storage conditions may also affect the shelf life of sterile medications.\n",
      "\n",
      "5. **Avoiding Contamination**: It is important to ensure that the storage area is clean and that proper hygiene practices are followed when handling sterile drugs, to prevent any form of contamination.\n",
      "\n",
      "In summary, to safely store sterile drugs, it is crucial to maintain appropriate temperature and humidity levels, protect them from light, use proper packaging, adhere to expiration dates, and follow strict hygiene protocols. For detailed guidelines, refer to specialized sources on drug storage and stability. \n",
      "\n",
      "For further reading, you can explore [this article](https://www.em-consulte.com/article/513841/drug-storage-and-stability) on drug storage and stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 61:----\n",
      "Question: For what purpose is the drug Motion Sickness primarily used?\n",
      "\n",
      "Correct Answer: A:\n",
      "To prevent and treat symptoms associated with motion sickness\n",
      "\n",
      "Detailed Prediction: Error\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 83:----\n",
      "Question: Which document should patients read and understand when prescribed venlafaxine tablets?\n",
      "\n",
      "Correct Answer: A:\n",
      "The Medication Guide about 'Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions.'\n",
      "\n",
      "Detailed Prediction: Patients prescribed venlafaxine tablets should read and understand the **Patient Information Leaflet (PIL)** provided with their medication. This document includes essential information about the medication such as its uses, dosage instructions, potential side effects, and precautions. \n",
      "\n",
      "Some key elements that are typically covered in the PIL include:\n",
      "\n",
      "1. **Description of the Drug**: What venlafaxine is, including its classification as a serotonin-norepinephrine reuptake inhibitor (SNRI), and its common uses for treating conditions like depression and anxiety.\n",
      "\n",
      "2. **Dosage and Administration**: Instructions on how to take the medication correctly, including the timing and whether to take it with food.\n",
      "\n",
      "3. **Side Effects**: Common and serious side effects that may occur, such as nausea, dizziness, or increased blood pressure. Important notes about any severe reactions that require immediate medical attention are also included.\n",
      "\n",
      "4. **Warnings and Precautions**: Information about contraindications, what to discuss with healthcare providers (e.g., other medications being taken or existing health issues), and the risk of withdrawal symptoms if the medication is stopped suddenly.\n",
      "\n",
      "5. **Interaction with Other Drugs**: Potential interactions with other medications, which could affect how venlafaxine works or increase the risk of side effects.\n",
      "\n",
      "6. **Storage Instructions**: Guidelines on how to properly store the tablets to maintain their efficacy.\n",
      "\n",
      "Patients may also find the following resources useful:\n",
      "- [Venlafaxine 75 mg tablets - Patient Information Leaflet](https://www.medicines.org.uk/emc/product/764/pil)\n",
      "- [Important Patient Information PDF](https://www.urmc.rochester.edu/medialibraries/urmcmedia/medicine/general-medicine/patientcare/documents/venlafaxine_brochure.pdf)\n",
      "\n",
      "Understanding this information is crucial for the safe and effective use of venlafaxine and for making informed decisions about their treatment.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 102:----\n",
      "Question: In animal studies, what developmental toxicity was observed in rats exposed to lamotrigine during pregnancy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Decreased fetal folate concentrations.\n",
      "\n",
      "Detailed Prediction: In animal studies, particularly those involving pregnant rats, developmental toxicity associated with lamotrigine (LTG) has been observed, highlighting several significant effects on offspring. \n",
      "\n",
      "1. **Study Overview**: Research conducted on Sprague Dawley rats assessed the impact of prenatal exposure to LTG, administered from gestational day 3 until postnatal day 11. The doses used were 11.5, 23, and 46 mg/kg. The study primarily observed postnatal development and behavioral changes in the offspring.\n",
      "\n",
      "2. **Findings**: \n",
      "   - **Maternal Toxicity**: At the highest dosage of 46 mg/kg, signs of severe toxicity were observed in the mother rats, leading to mortality between gestational days 15 and 17.\n",
      "   - **Developmental Effects on Offspring**: Offspring exposed to both 11.5 mg/kg and 23 mg/kg doses showed significant deviations compared to control groups. Notably, there were alterations in milestones such as the eruption of incisors and the timing of vaginal opening, indicating potential disruptions in normal development.\n",
      "   - **Behavioral Changes**: Female offspring exposed to 23 mg/kg exhibited hyperactivity, alongside a decrease in GABA-A receptor expression, which suggests alterations in neural development and functioning.\n",
      "\n",
      "3. **Implications**: These findings indicate that prenatal exposure to lamotrigine can lead to essential developmental issues in rats, including both physical and behavioral alterations that may differ based on sex. Such variations underscore the need for further investigation into the mechanisms behind these effects and their relevance to fetal development in humans.\n",
      "\n",
      "In summary, prenatal exposure to lamotrigine in rats resulted in notable developmental toxicity, including maternal toxicity, altered developmental milestones, and behavioral changes in the offspring, pointing towards potential risks associated with its use during pregnancy.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 104:----\n",
      "Question: What should a user do if they are under 18 years of age and want to use nicotine lozenges?\n",
      "\n",
      "Correct Answer: B:\n",
      "Consult a doctor before use\n",
      "\n",
      "Detailed Prediction: If a user under 18 years of age is considering the use of nicotine lozenges, there are several important steps and considerations to keep in mind:\n",
      "\n",
      "1. **Consult a Healthcare Professional**: The first and most crucial step is to speak with a healthcare provider. A doctor or a trained pharmacist can provide guidance on whether nicotine lozenges are suitable for the individual, considering their age and health status.\n",
      "\n",
      "2. **Consider Alternatives for Smoking Cessation**: Research shows that adolescent-specific smoking cessation programs can be beneficial. A study from T√ºrkiye highlighted the effectiveness of adolescents attending smoking cessation clinics, with various methods including nicotine patches showing positive outcomes (PMID: 41509942). It‚Äôs essential to explore comprehensive smoking cessation plans tailored for young individuals.\n",
      "\n",
      "3. **Understand the Risks and Regulations**: In many regions, the sale and use of nicotine products (including lozenges) are typically restricted for minors. Familiarizing oneself with local laws and regulations is important, as well as understanding the health risks associated with nicotine use, particularly before reaching adulthood. Adolescents are generally more susceptible to addiction and the potential health consequences of nicotine.\n",
      "\n",
      "4. **Explore Ongoing Clinical Trials**: There may be clinical trials assessing the efficacy and safety of nicotine replacement therapies in adolescents, such as the Aggressive Smoking Cessation Trial (NCT05257629). Engaging in a clinical trial might provide access to resources and support designed for young smokers looking to quit.\n",
      "\n",
      "5. **Educate on Smoking Cessation Techniques**: In addition to lozenges, various methods exists for quitting smoking that are safe for adolescents, including behavioral therapies, counseling, and support groups. \n",
      "\n",
      "In summary, the use of nicotine lozenges by individuals under 18 requires careful consideration and guidance from healthcare professionals, alongside understanding the associated risks and exploring alternative cessation methods tailored for young users.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 113:----\n",
      "Question: Which brand produces the Beloved Coconut & Warm Vanilla Hand Sanitizer?\n",
      "\n",
      "Correct Answer: A:\n",
      "Love Beauty and Planet\n",
      "\n",
      "Detailed Prediction: The Beloved Coconut & Warm Vanilla Hand Sanitizer is produced by Love Beauty and Planet. This brand focuses on creating beauty products that are environmentally friendly and incorporate natural ingredients, aligning well with their ethos of sustainability and care for nature. The hand sanitizer combines the tropical scent of coconut with the comforting warmth of vanilla, providing a pleasant user experience while helping to reduce bacteria on the skin.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 114:----\n",
      "Question: For children aged 6 to under 12 years, what is the appropriate dosage of the laxative for women?\n",
      "\n",
      "Correct Answer: A:\n",
      "1 tablet in a single daily dose\n",
      "\n",
      "Detailed Prediction: The appropriate dosage of laxatives for children aged 6 to under 12 years can vary depending on the specific type of laxative used. Here's a general guideline based on various sources:\n",
      "\n",
      "1. **Over-the-counter Laxatives**: \n",
      "   - Most over-the-counter laxatives are not recommended for children under the age of 6 without consulting a healthcare provider.\n",
      "   - For children aged 6 to 11 years, it's typically advised to administer half the adult dosage indicated on the package unless otherwise directed by a healthcare professional.\n",
      "\n",
      "2. **Senna-Based Laxatives** (like Senokot):\n",
      "   - For children aged 6-11 years, the recommendation is usually to use 1 tablet once or twice daily.\n",
      "\n",
      "3. **Dulcolax Suppositories**:\n",
      "   - These are typically not recommended for children under 12 years without medical advice, but if used, a 10 mg suppository may be inserted as needed (usually one suppository for quicker effect).\n",
      "\n",
      "4. **Liquid Laxatives**: \n",
      "   - The dosage may be around 15 to 30 mL for children over 6 years, but this can depend on the formulation and should be guided by a physician.\n",
      "\n",
      "**Important Note**: Consultation with a healthcare provider is crucial before administering any laxative to children for proper dosing and to rule out any underlying health issues causing constipation. It's essential to follow specific product guidance and medical advice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 120:----\n",
      "Question: Why is it recommended not to eat or drink 15 minutes before using or while the NICOTINE lozenge is in the mouth?\n",
      "\n",
      "Correct Answer: B:\n",
      "To ensure proper absorption of nicotine\n",
      "\n",
      "Detailed Prediction: It is recommended not to eat or drink for 15 minutes before using or while the nicotine lozenge is in the mouth due to several reasons related to absorption and effectiveness of the medication:\n",
      "\n",
      "1. **Absorption Mechanism**: Nicotine lozenges are designed to dissolve slowly in the mouth, allowing nicotine to be absorbed through the mucosal membranes. Eating or drinking can interfere with this absorption process. The presence of food or liquids can wash away the lozenge's active ingredients, leading to a reduction in the amount of nicotine that enters the bloodstream.\n",
      "\n",
      "2. **pH Levels**: The pH levels in the mouth can change due to food or beverage consumption. These changes can affect how effectively nicotine is absorbed. For example, acidic foods or drinks may enhance nicotine absorption, but the overall interaction may lead to inconsistent dosing, which is not ideal for someone trying to quit smoking.\n",
      "\n",
      "3. **Maintaining Effectiveness**: For optimal effectiveness in reducing cravings and withdrawal symptoms, it is crucial for the lozenge to provide a steady release of nicotine. Disruption by eating or drinking can lead to fluctuating nicotine levels in the blood, which can undermine the lozenge's intended purpose.\n",
      "\n",
      "4. **Taste and Experience**: Additionally, substances like coffee or acidic drinks can impair the taste of the lozenge, potentially leading to a decreased likelihood of continued use. This sensory experience can influence adherence to using the lozenge as part of a smoking cessation strategy.\n",
      "\n",
      "In summary, avoiding eating and drinking before and during the use of a nicotine lozenge maximizes nicotine absorption, maintains steady blood levels, and helps ensure that the lozenge is effective in curbing smoking urges.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 128:----\n",
      "Question: In which animal model did albuterol sulfate show no evidence of tumorigenicity at dietary doses of up to 50 mg/kg?\n",
      "\n",
      "Correct Answer: C:\n",
      "Golden hamsters\n",
      "\n",
      "Detailed Prediction: Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg in a 22-month study involving **Golden Hamsters**. This study indicated that the doses tested were significantly higher than the maximum recommended daily inhalation doses for both adults and children when adjusted for body surface area. \n",
      "\n",
      "For more detailed information, you can refer to the source [here](https://medlibrary.org/lib/rx/meds/albuterol-sulfate-38/page/3/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 129:----\n",
      "Question: What is the recommended action if a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Prohibit intercourse to avoid hemoperitoneum\n",
      "\n",
      "Detailed Prediction: If a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy, the recommended action is to carefully evaluate the situation for any potential complications, primarily the risk of ovarian hyperstimulation syndrome (OHSS). Here are several key steps to consider:\n",
      "\n",
      "1. **Monitoring and Assessment**: Close monitoring of the patient's symptoms and ovarian size via ultrasound is crucial. Significant enlargement may indicate overstimulation, which can lead to complications.\n",
      "\n",
      "2. **Symptomatic Management**: If the enlargement is accompanied by symptoms such as abdominal pain, shortness of breath, or weight gain, symptomatic treatment may be warranted.\n",
      "\n",
      "3. **Adjustment of Medication**: Depending on the severity of the enlargement, it may be necessary to adjust or even suspend Follistim AQ therapy. This could involve dose reduction or pausing treatment until the patient's condition stabilizes.\n",
      "\n",
      "4. **Consultation**: If there are concerns regarding complications such as OHSS, involve a reproductive endocrinologist for expert management. \n",
      "\n",
      "5. **Patient Education**: Inform the patient about the signs and symptoms of OHSS, emphasizing the importance of reporting any worsening symptoms immediately.\n",
      "\n",
      "6. **Follow-up Care**: Ensure regular follow-up appointments to monitor the patient's ovarian response and overall health. This may involve repeating ultrasound examinations and possibly hormone level testing.\n",
      "\n",
      "Individuals on fertility treatments like Follistim AQ should be monitored closely for responses, and any signs of ovarian enlargement should be managed proactively to prevent complications. \n",
      "\n",
      "For more detailed guidelines, you can refer to the official product information from sources such as [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48489027-e52b-4b10-ae74-4ba03839150c).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 134:----\n",
      "Question: What is a potential risk when Labetalol HCL is used in combination with tricyclic antidepressants?\n",
      "\n",
      "Correct Answer: B:\n",
      "Increased risk of tremor\n",
      "\n",
      "Detailed Prediction: A potential risk when Labetalol HCL is used in combination with tricyclic antidepressants (TCAs) is the inhibition of mIBG (metaiodobenzylguanidine) uptake in cardiac tissues, which could impact cardiac imaging studies. \n",
      "\n",
      "Labetalol, a beta-blocker with alpha-blocking activity, has a strong inhibition effect on mIBG uptake, which is rated as having high evidence. In contrast, tricyclic antidepressants have a medium level of evidence for their impact on mIBG uptake. The combination of these medications may therefore lead to an insufficient uptake of mIBG during imaging, potentially complicating the assessment of cardiac function or disease. This interaction underscores the need for clinicians to reconsider the timing of these medications before conducting mIBG cardiac imaging and may warrant temporary withdrawal to ensure accurate diagnostic results. \n",
      "\n",
      "In summary, the use of Labetalol in conjunction with tricyclic antidepressants can pose significant risks for cardiac imaging accuracy due to their combined effects on mIBG uptake.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 173:----\n",
      "Question: Which of the following symptoms is NOT associated with a lamotrigine overdose?\n",
      "\n",
      "Correct Answer: C:\n",
      "Hypertension\n",
      "\n",
      "Detailed Prediction: Lamotrigine overdose is associated with several symptoms, including seizures, cardiac arrest, and potentially fatal arrhythmias. In clinical findings, patients have presented with significant neurological and cardiovascular instability following an overdose. While activated charcoal and sodium bicarbonate are common treatments, alternative therapies are limited.\n",
      "\n",
      "To conclude, one symptom NOT associated with a lamotrigine overdose is *hypertension*. The primary symptoms remain centered around neurological effects (like seizures) and cardiovascular complications (such as arrhythmias), rather than increases in blood pressure.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 184:----\n",
      "Question: What precaution should be taken for patients with multiple cardiovascular risk factors before administering Sumatriptan injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Perform a cardiovascular evaluation\n",
      "\n",
      "Detailed Prediction: Before administering Sumatriptan injection to patients with multiple cardiovascular risk factors, several precautions should be taken:\n",
      "\n",
      "1. **Cardiovascular Evaluation**: It is crucial to perform a thorough cardiac evaluation for patients with cardiovascular risk factors, such as diabetes, hypertension, smoking history, obesity, or a strong family history of coronary artery disease (CAD). This evaluation helps assess the potential risk of myocardial ischemia or infarction, which can be exacerbated by Sumatriptan.\n",
      "\n",
      "2. **Setting of Administration**: If the patient has significant cardiovascular risk factors, the initial dose of Sumatriptan should ideally be administered in a medically supervised setting, such as a physician‚Äôs office. This precaution allows for immediate medical assistance if any adverse cardiovascular events occur.\n",
      "\n",
      "3. **Monitoring**: Continuous monitoring of cardiovascular status is advisable in patients with a history of cardiovascular disease or risk factors when they receive Sumatriptan. Monitoring helps in the early detection of any complications.\n",
      "\n",
      "4. **Patient Counseling**: Patients should be informed about the signs and symptoms of cardiovascular events, and they should be advised to seek medical attention if they experience chest pain, shortness of breath, or any unusual symptoms following administration.\n",
      "\n",
      "Taking these precautions can help mitigate the risks associated with Sumatriptan in patients with multiple cardiovascular risk factors. For more detailed information about the drug and its precautions, healthcare providers can refer to the official prescribing information available from sources such as [Drugs.com](https://www.drugs.com/pro/sumatriptan-injection.html) and [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a4c0c2f-497d-4c5c-84c4-9ab42780cbde).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 186:----\n",
      "Question: What precaution should be taken when prescribing fluoxetine to a patient with diabetes?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor for hypoglycemia during therapy and hyperglycemia after discontinuation\n",
      "\n",
      "Detailed Prediction: When prescribing fluoxetine to a patient with diabetes, there are several important precautions to consider:\n",
      "\n",
      "1. **Monitoring Blood Sugar Levels**: Fluoxetine can affect glycemic control, which may lead to changes in blood sugar levels. Careful monitoring of blood sugar is essential, especially when beginning treatment or adjusting the dose. \n",
      "\n",
      "2. **Potential Risk of Hypoglycemia**: There is a risk that fluoxetine may increase the effectiveness of insulin or other antidiabetic medications, potentially leading to hypoglycemia (low blood sugar). Symptoms of hypoglycemia include headache, dizziness, drowsiness, confusion, and tremor. Patients should be educated on recognizing these symptoms and advised on how to manage them.\n",
      "\n",
      "3. **Adjustment of Diabetes Medications**: The dosage of insulin or oral hypoglycemic agents may need to be altered when a patient starts fluoxetine. Collaboration with the endocrinologist or the healthcare provider managing the diabetes is advisable to determine appropriate medication adjustments.\n",
      "\n",
      "4. **Patient Education**: Patients should be informed about the potential effects of fluoxetine on their diabetes management, including the signs of hypoglycemia and the importance of adherence to blood glucose monitoring.\n",
      "\n",
      "5. **Close Follow-up**: Regular follow-up appointments should be scheduled to assess the patient's mental health as well as their diabetes control, adjusting treatment as necessary.\n",
      "\n",
      "In summary, careful monitoring, potential medication adjustments, and patient education are critical when prescribing fluoxetine to individuals with diabetes to ensure both their mental health and glycemic control are optimized.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 219:----\n",
      "Question: If a hypersensitivity reaction occurs during TAKHZYRO treatment, what is the primary concern for the healthcare provider?\n",
      "\n",
      "Correct Answer: C:\n",
      "Discontinuing TAKHZYRO and initiating appropriate treatment.\n",
      "\n",
      "Detailed Prediction: If a hypersensitivity reaction occurs during TAKHZYRO (lanadelumab) treatment, the primary concern for the healthcare provider is the potential for serious allergic reactions, which may include anaphylaxis. Healthcare providers must be vigilant in monitoring patients for signs of hypersensitivity after administration, including symptoms like rash, urticaria, difficulty breathing, or gastrointestinal symptoms. Immediate intervention may be required if severe symptoms manifest, including the use of epinephrine in cases of anaphylaxis. It is crucial to have a plan in place for managing such reactions, including the provision of emergency care.\n",
      "\n",
      "In the context of managing patients receiving TAKHZYRO, which is used to prevent attacks of hereditary angioedema, understanding the risk of hypersensitivity is critical as it ensures patient safety and effective management of their condition. Regular assessment and education of the patient about the symptoms of hypersensitivity are essential components of care during treatment with this medication.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 225:----\n",
      "Question: What is the physical appearance of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "White to off-white crystalline powder\n",
      "\n",
      "Detailed Prediction: Venlafaxine hydrochloride is a medication commonly used as an antidepressant and in the treatment of anxiety disorders. \n",
      "\n",
      "In its physical form, venlafaxine hydrochloride is typically presented in the form of tablets or capsules. The appearance of these pharmaceutical forms can vary based on the manufacturer and specific formulation:\n",
      "\n",
      "1. **Tablets**: The extended-release tablets may resemble conventional tablets and typically have a smooth surface with a specific coating for gradual release of the medication. The appearance can be described as circular and may contain specific identifiers such as numbers or letters stamped on them for identification.\n",
      "\n",
      "2. **Capsules**: For the capsule form, venlafaxine hydrochloride might be presented in a hard or soft gelatin shell, generally in colors such as light green or blue, and may be oval or elongated in shape. Each capsule usually contains the active ingredient as well as various inactive ingredients necessary for stability and absorption.\n",
      "\n",
      "3. **Color and Texture**: The color can range from off-white to tan when in solid form (e.g., as a powder before compression into tablets or encapsulation). When describing the physical properties, some studies report the color and texture may vary slightly among different preparations, but they remain within a specific pharmaceutical standard.\n",
      "\n",
      "For specific appearances, more details can be checked through pharmaceutical labels or product descriptions provided by the manufacturers and regulatory bodies (e.g., FDA labels).\n",
      "\n",
      "Overall, the precise physical appearance of venlafaxine hydrochloride can depend on the dosage form and manufacturer but generally conforms to these descriptions. For a more detailed visual reference, you may consult the manufacturer's product label.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 233:----\n",
      "Question: Which of the following is NOT a contraindication for Ciprofloxacin use?\n",
      "\n",
      "Correct Answer: D:\n",
      "A history of hypersensitivity to cephalosporins\n",
      "\n",
      "Detailed Prediction: Ciprofloxacin is an antibiotic that is part of the fluoroquinolone class, and it has several contraindications for its use. The common contraindications include:\n",
      "\n",
      "1. **History of tendon disorders**: Ciprofloxacin has been associated with an increased risk of tendon rupture, especially in patients with a history of tendon disorders, particularly the Achilles tendon.\n",
      "2. **Myasthenia gravis**: The use of ciprofloxacin may exacerbate muscle weakness in patients with myasthenia gravis.\n",
      "3. **Pregnancy**: Ciprofloxacin is generally contraindicated in pregnancy due to the potential risk to the developing fetus.\n",
      "\n",
      "However, there are certain conditions where ciprofloxacin use may not be contraindicated, which might include:\n",
      "\n",
      "- **Mild to moderate renal impairment**, if the dosage is adjusted accordingly.\n",
      "- **Certain types of infections**, where ciprofloxacin is found to be effective despite other risk factors.\n",
      "\n",
      "Thus, it is essential for healthcare providers to carefully assess the risks and benefits before prescribing ciprofloxacin in patients with varying health conditions. Therefore, the answer to the question regarding which is NOT a contraindication for ciprofloxacin would involve identifying a condition that does not fall under the typical contraindications mentioned above.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 250:----\n",
      "Question: What is the recommendation for dosing Lantus Solostar in geriatric patients?\n",
      "\n",
      "Correct Answer: C:\n",
      "Start with conservative dosing to avoid hypoglycemia.\n",
      "\n",
      "Detailed Prediction: In geriatric patients, dosing recommendations for Lantus (insulin glargine) should be approached with caution due to the physiological changes associated with aging, potential comorbidities, and the possibility of polypharmacy effects. \n",
      "\n",
      "1. **Starting Dose**: It is generally recommended to start at a lower dose than in younger patients. A typical initiation dose might range from 0.2 to 0.4 units/kg/day, depending on the individual patient's requirements and current blood glucose levels.\n",
      "\n",
      "2. **Adjustment Based on Glycemic Control**: The dose should then be titrated based on self-monitored blood glucose readings, with adjustments typically made in increments of 2 to 4 units as necessary. \n",
      "\n",
      "3. **Risk of Hypoglycemia**: Geriatric patients are at a higher risk for hypoglycemia due to factors like decreased renal function, altered pharmacokinetics of insulin, and cognitive impairment. Therefore, it is crucial to monitor for signs of hypoglycemia and adjust the dosage accordingly.\n",
      "\n",
      "4. **Consideration for Comorbidities**: Many elderly patients may have comorbid conditions such as renal impairment or cardiovascular diseases that could influence insulin metabolism and action. \n",
      "\n",
      "5. **Regular Monitoring**: Frequent monitoring of glucose levels is recommended to prevent both hyperglycemia and hypoglycemia, especially during dose adjustments.\n",
      "\n",
      "In summary, while using Lantus in geriatric patients, careful consideration of the starting dose, monitoring for hypoglycemia, and adjustment based on individual patient needs are essential for effective and safe management of diabetes in this population.\n",
      "\n",
      "For more detailed clinical guidelines and specific studies, please refer to recent literature from resources such as PubMed.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 256:----\n",
      "Question: What is the recommendation for dose adjustment of Signifor LAR in patients with renal impairment?\n",
      "\n",
      "Correct Answer: A:\n",
      "No dose adjustment is required.\n",
      "\n",
      "Detailed Prediction: The dosing recommendations for Signifor LAR (pasireotide) in patients with renal impairment specifically are not well detailed in available literature. However, it is generally accepted that drugs primarily excreted by the kidneys may require dose adjustments in patients with renal impairment.\n",
      "\n",
      "Based on the information gathered:\n",
      "- **General Dosing**: The standard initial dose of Signifor LAR for the treatment of conditions like acromegaly is typically 40 mg administered by intramuscular injection once every 4 weeks. Adjustments may be considered if the patient experiences side effects or inadequate response.\n",
      "- **Lack of Specific Guidance**: There is limited data directly addressing dosage adjustments for Signifor LAR in patients with renal impairment, which suggests that more individualized assessment may be necessary. \n",
      "\n",
      "For deeper insights, referring to the package insert and consulting a healthcare provider or pharmacist is recommended. Additionally, continuous monitoring is important in any patient with renal impairment receiving this medication. \n",
      "\n",
      "For more detailed information, you can refer to sources such as the [Drugs.com package insert](https://www.drugs.com/pro/signifor-lar-injection.html).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 296:----\n",
      "Question: In which scenario should Lamotrigine not be prescribed?\n",
      "\n",
      "Correct Answer: A:\n",
      "A patient with hypersensitivity to Lamotrigine\n",
      "\n",
      "Detailed Prediction: Lamotrigine is a medication primarily used to treat epilepsy and bipolar disorder. However, there are specific scenarios where its use is contraindicated or should be approached with caution:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Individuals who have a known hypersensitivity to lamotrigine or any of its components should not be prescribed this medication. Rash or other allergic reactions can occur, and in some cases, they may lead to severe conditions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).\n",
      "\n",
      "2. **History of Serious Skin Reactions**: Patients who have experienced severe skin reactions from lamotrigine in the past should avoid its use. This includes cases of SJS, TEN, or other serious cutaneous adverse drug reactions.\n",
      "\n",
      "3. **Concurrent Use with Valproate**: Lamotrigine metabolism can be significantly affected by the concomitant use of valproate (valproic acid), leading to increased levels of lamotrigine and a higher risk of serious side effects, particularly skin rashes. Caution is needed when these medications are used together, and dosage adjustments may be necessary.\n",
      "\n",
      "4. **Pregnancy and Lactation**: While lamotrigine can be used in pregnancy under careful monitoring, potential risks to the fetus exist, particularly regarding neural tube defects if used at high doses. Pregnant individuals or those planning to become pregnant should consult healthcare providers to evaluate risks versus benefits.\n",
      "\n",
      "5. **Renal or Hepatic Impairment**: Patients with significant renal or hepatic impairment may require dosage adjustments, and potential risks associated with lamotrigine should be considered carefully.\n",
      "\n",
      "6. **Non-dystrophic Myotonia**: While there have been studies showing efficacy, patients with specific neuromuscular disorders where muscle relaxation is significantly impaired should be evaluated carefully due to potential unusual responses (as per the findings observed in real-world cases).\n",
      "\n",
      "In summary, lamotrigine should not be prescribed in cases of hypersensitivity to the drug or its components, in patients with a history of severe skin reactions caused by lamotrigine, when used in conjunction with valproate without careful monitoring, during pregnancy (without a thorough risk assessment), in significant renal or hepatic impairment, and with caution in patients with certain neuromuscular disorders. Always consulting with a healthcare provider for individualized assessment is essential.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 321:----\n",
      "Question: What action should patients take if they develop signs of heart failure while on REMICADE?\n",
      "\n",
      "Correct Answer: B:\n",
      "Seek medical attention and consult their prescriber.\n",
      "\n",
      "Detailed Prediction: If a patient develops signs of heart failure while on REMICADE (infliximab), they should take the following actions:\n",
      "\n",
      "1. **Immediate Consultation**: Patients are advised to seek immediate medical attention. Heart failure can manifest as symptoms like shortness of breath, swelling in the legs or abdomen, fatigue, and rapid or irregular heartbeat. Recognizing these signs and acting promptly is vital.\n",
      "\n",
      "2. **Discontinuation of REMICADE**: Upon presentation with symptoms suggestive of heart failure, healthcare providers may recommend discontinuing REMICADE, as it has been associated with cardiovascular issues in some patients.\n",
      "\n",
      "3. **Comprehensive Evaluation**: The healthcare provider will likely conduct a thorough evaluation, including physical exams and diagnostic tests such as echocardiograms and EKGs, to assess cardiovascular function and rule out other possible causes of heart failure.\n",
      "\n",
      "4. **Management of Heart Failure**: If diagnosed, treatment may include medication to help manage heart failure symptoms such as diuretics to reduce fluid overload, ACE inhibitors, or beta-blockers to improve heart function.\n",
      "\n",
      "5. **Monitoring and Follow-Up**: Close monitoring by a cardiologist or primary care provider is crucial to manage heart health effectively. Follow-up visits and adjustments to medication and treatment plans may be necessary based on the patient's response.\n",
      "\n",
      "It is essential for patients to communicate openly with their healthcare team regarding any symptoms experienced while on immunotherapy treatments like REMICADE, as timely intervention can significantly improve outcomes.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 338:----\n",
      "Question: If a user requires higher sunburn protection than Arizona Sun Sunscreen SPF15, what should they consider?\n",
      "\n",
      "Correct Answer: A:\n",
      "Using a sunscreen with a higher SPF\n",
      "\n",
      "Detailed Prediction: When considering higher sunburn protection than Arizona Sun Sunscreen SPF 15, users should keep the following factors in mind:\n",
      "\n",
      "1. **Higher SPF Values**: Choose sunscreens with higher SPF ratings. The SPF (Sun Protection Factor) indicates the level of protection from UVB rays. For instance, products with SPF 30 to SPF 50 provide significantly better protection. It's important to note that SPF values above 50 offer diminishing returns in terms of protection.\n",
      "\n",
      "2. **Broad-Spectrum Protection**: Ensure that the sunscreen provides broad-spectrum protection against both UVA and UVB rays. UVB rays cause sunburn and contribute to skin cancer, while UVA rays penetrate the skin more deeply and can cause aging and also contribute to skin cancer.\n",
      "\n",
      "3. **Water Resistance**: Consider water-resistant formulations if engaging in activities that involve swimming or sweating. Look for products labeled as \"water-resistant\" for 40 or 80 minutes, as these can retain their SPF for that duration even when exposed to water.\n",
      "\n",
      "4. **Active Ingredients**: The effectiveness of sunscreens can vary based on their active ingredients. Common ingredients include:\n",
      "   - **Chemical Filters**: Such as avobenzone, octisalate, and octocrylene, which absorb UV radiation.\n",
      "   - **Physical (Mineral) Filters**: Such as zinc oxide or titanium dioxide, which reflect UV rays and are often recommended for sensitive skin.\n",
      "\n",
      "5. **Formulation and Application**: Choose a formulation that suits the user's skin type and preference (gel, cream, lotion, spray, etc.). It's essential to apply sunscreen generously and evenly to all exposed skin, using about an ounce (a shot glass full) for full body coverage.\n",
      "\n",
      "6. **Reapplication**: Reapply sunscreen every two hours, or more frequently if swimming or sweating. This is critical for maintaining effective protection.\n",
      "\n",
      "7. **Additional Protective Measures**: Along with using high SPF sunscreen, users should consider other protective measures such as wearing protective clothing, sunglasses, and seeking shade during peak sun hours (10 a.m. to 4 p.m.).\n",
      "\n",
      "8. **New Innovations**: Recent developments in sunscreen technology, like the use of bilayer hydrogels with exceptional UV absorption and enhanced skin adhesion, offer promising advancements for sun protection. These formulations can significantly exceed traditional SPF levels, providing better protection and therapeutic benefits to the skin (as noted in recent studies).\n",
      "\n",
      "In summary, when seeking higher sunburn protection, users should opt for a higher SPF, ensure broad-spectrum coverage, choose suitable formulations, and incorporate additional protective practices to effectively safeguard their skin from UV damage.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 348:----\n",
      "Question: What is the approximate incidence rate of serious rashes, including Stevens-Johnson syndrome, in pediatric patients aged 2 to 17 years taking lamotrigine?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.3% to 0.8%\n",
      "\n",
      "Detailed Prediction: The incidence rate of serious rashes, including Stevens-Johnson syndrome (SJS), in pediatric patients aged 2 to 17 years taking lamotrigine is relatively low. A retrospective cohort study involving adolescents aged 13 to 20 years treated with lamotrigine reported that out of 102 patients, 23 developed a skin rash, leading to an incidence of approximately 22.5%. However, only one patient developed a serious rash classified as Stevens-Johnson syndrome. This indicates that while skin rashes are not uncommon, serious adverse reactions such as SJS are rare, highlighting an incidence rate of about 1% for severe rashes in this specific demographic.\n",
      "\n",
      "Additional studies support that the overall risk of developing serious skin reactions with lamotrigine, particularly when introduced at higher doses or more rapidly, has potential to increase, but careful dosing and monitoring can mitigate risks. Therefore, healthcare providers often recommend gradually titrating the dosage of lamotrigine to lower the likelihood of rash development. \n",
      "\n",
      "In summary, while rashes are a common side effect of lamotrigine treatment in pediatric patients, serious complications such as Stevens-Johnson syndrome occur infrequently, emphasizing the importance of careful clinical monitoring.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 353:----\n",
      "Question: What monitoring is recommended for patients on chronic warfarin therapy who are administered FOSAPREPITANT?\n",
      "\n",
      "Correct Answer: B:\n",
      "Monitor INR in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant.\n",
      "\n",
      "Detailed Prediction: The interaction between warfarin and fosaprepitant necessitates careful monitoring due to the potential for altered anticoagulation effects. Here are some considerations and recommendations for monitoring patients on chronic warfarin therapy who are administered fosaprepitant:\n",
      "\n",
      "1. **INR Monitoring**: Regular INR (International Normalized Ratio) tests are crucial. Patients should have their INR checked more frequently (at least once a week) after initiating fosaprepitant, as it may affect warfarin metabolism due to its influence on CYP3A4.\n",
      "\n",
      "2. **Clinical Assessment**: Monitor for signs of bleeding or thrombosis closely. Increased vigilance is warranted during the initial days of therapy with fosaprepitant as it may interact with the pharmacokinetics of warfarin.\n",
      "\n",
      "3. **Dosage Adjustment**: Be prepared to adjust the dose of warfarin based on INR results. If significant changes in INR occur, modifications to the warfarin regimen should be done cautiously.\n",
      "\n",
      "4. **Patient Education**: Educate patients about the signs of bleeding, such as unusual bruising, blood in urine or stool, and prolonged bleeding from cuts. They should also be informed about the importance of adherence to follow-up INR checks.\n",
      "\n",
      "5. **Duration of Monitoring**: The adjustments and increased monitoring should continue until the INR stabilizes at the desired therapeutic range post-initiation of fosaprepitant therapy.\n",
      "\n",
      "6. **Professional Collaboration**: Consider involving a pharmacist or anticoagulation management service for optimal management strategies during this concurrent therapy.\n",
      "\n",
      "Due to the lack of specific clinical trials currently linking these therapies directly, healthcare providers should base their decisions on pharmacological principles and existing guidelines on warfarin management and the effects of CYP3A4 inhibitors. Always assess the individual patient's risk factors and clinical scenario when determining monitoring strategies.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 361:----\n",
      "Question: What should a user do if irritation or sensitivity develops while using BP Wash?\n",
      "\n",
      "Correct Answer: B:\n",
      "Stop using BP Wash and consult a doctor.\n",
      "\n",
      "Detailed Prediction: If irritation or sensitivity develops while using BP (benzoyl peroxide) Wash, here are some recommended steps to manage the situation:\n",
      "\n",
      "1. **Discontinue Use**: Immediately stop using the BP Wash to prevent further irritation. Continuing to use the product can worsen the sensitivity and delay healing.\n",
      "\n",
      "2. **Rinse Thoroughly**: Gently rinse your skin with lukewarm water to remove any residual product. This helps to soothe the skin and reduce the irritation.\n",
      "\n",
      "3. **Use a Gentle Cleanser**: Switch to a mild, non-irritating cleanser for your regular skin care routine. Look for products that are fragrance-free and formulated for sensitive skin.\n",
      "\n",
      "4. **Apply Soothing Agents**: Consider applying soothing agents such as aloe vera gel or hydrocortisone cream (if approved by a healthcare professional) to alleviate irritation. These products can help calm the skin and reduce redness.\n",
      "\n",
      "5. **Moisturize**: Use a gentle, non-comedogenic moisturizer to help restore the skin barrier. Keeping your skin hydrated can reduce dryness and irritation.\n",
      "\n",
      "6. **Avoid Active Ingredients**: While your skin is healing, avoid using other active ingredients that may irritate the skin, such as salicylic acid, retinoids, or other exfoliants.\n",
      "\n",
      "7. **Gradual Reintroduction**: Once the irritation has resolved, if you wish to continue using benzoyl peroxide, consider reintroducing it slowly. You can start with a lower concentration and use it less frequently (e.g., every other day) to see how your skin reacts.\n",
      "\n",
      "8. **Consult a Healthcare Professional**: If irritation persists or worsens, consult a dermatologist or healthcare provider for tailored advice and possible alternative treatments.\n",
      "\n",
      "For more detailed information on managing skin irritation while using benzoyl peroxide, you can refer to [this article](https://viraltrench.com/reduce-irritation-using-benzoyl-peroxide-wash/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 366:----\n",
      "Question: What is the incidence of infusion-site erythema in patients receiving FOSAPREPITANT for HEC compared to oral aprepitant?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.5% in FOSAPREPITANT group and 0.1% in oral aprepitant group\n",
      "\n",
      "Detailed Prediction: The incidence of infusion-site erythema in patients receiving FOSAPREPITANT has been reported to be significant. In a study that evaluated symptoms from 61 injections of Fosaprepitant, erythema was observed in 10 patients, representing approximately 16% of the injections. Pain at the injection site was noted in 23% of cases, further indicating that injection-site reactions can be prevalent. \n",
      "\n",
      "Currently, specific comparative data for the incidence of infusion-site erythema between FOSAPREPITANT and oral aprepitant is limited, but the infusion-related reactions to FOSAPREPITANT appear to be notable. Oral aprepitant typically does not involve injection-site reactions as it is administered orally; thus, it offers a different route of administration that may mitigate such local reactions, but direct comparative incidence rates remain to be elucidated in research. \n",
      "\n",
      "For further details, you can refer to the relevant study discussing these findings [here](https://www.jcancer.org/v05p0390.htm).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 371:----\n",
      "Question: In the trial comparing Ondansetron to metoclopramide for single high-dose fraction radiotherapy, which drug was more effective in achieving complete control of emesis?\n",
      "\n",
      "Correct Answer: A:\n",
      "Ondansetron\n",
      "\n",
      "Detailed Prediction: In the context of treating radiation-induced emesis (RIE) during single high-dose fraction radiotherapy, Ondansetron has been shown to be effective. According to a study published in *Seminars in Oncology*, the incidence and severity of RIE can significantly vary based on factors such as radiation dose and field size.\n",
      "\n",
      "Although the specific trial directly comparing Ondansetron and metoclopramide for this purpose was not found in the clinical trials database, existing literature indicates that Ondansetron, a 5-HT3 receptor antagonist, may provide better control of emesis compared to traditional antiemetics like metoclopramide, especially in cases of high radiation doses over 500 cGy. The effectiveness of Ondansetron relates to its mechanism of action in blocking the serotonin receptors involved in the emetic response.\n",
      "\n",
      "The reported data indicate that radiation-induced emesis occurs in a high percentage of patients receiving high-dose hemibody irradiation, which suggests that administering antiemetics prior to treatment can be beneficial. In summary, while a direct comparative study between the two drugs for RIE was not located, Ondansetron is generally recognized as more effective for controlling emesis in patients undergoing high-dose radiotherapy.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 381:----\n",
      "Question: Based on animal studies, what is the role of leucovorin in the context of Pemetrexed for injection overdose?\n",
      "\n",
      "Correct Answer: B:\n",
      "It mitigates the toxicities of Pemetrexed\n",
      "\n",
      "Detailed Prediction: Leucovorin, also known as folinic acid, is a medication primarily used to mitigate the toxic effects of certain drugs, particularly methotrexate, and can play a supportive role in chemotherapy regimens. In the context of pemetrexed (a chemotherapy agent used to treat certain types of cancer), animal studies suggest that leucovorin may indeed help to reduce the toxicities associated with pemetrexed overdose.\n",
      "\n",
      "The mechanism thought to underlie the protective role of leucovorin involves its function as a reduced form of folate, which can help to replenish folate levels in the body. Pemetrexed exerts its effects by inhibiting several enzymes involved in folate metabolism, leading to a potential depletion of folates and resultant toxicity. By administering leucovorin, the goal is to provide the body with a source of folate that can help counteract this depletion and mitigate side effects.\n",
      "\n",
      "According to resources, the specific finding is that in animal studies, administration of leucovorin can alleviate the toxic effects seen during pemetrexed overdose, although the precise dosing and efficacy may vary based on animal models and individual responses. It is important to note, however, that while the animal models provide useful insights, clinical protocols for overdose management in humans must always integrate comprehensive clinical judgment and adhere to established medical guidelines. \n",
      "\n",
      "In conclusion, leucovorin appears to play a beneficial role in scenarios of Pemtrexed overdose based on animal studies, primarily by counteracting the drug's toxicity through folate replenishment. Further research and clinical studies are, however, essential to fully understand this interaction and guidelines for application in human cases.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 386:----\n",
      "Question: Which of the following statements is true regarding the storage conditions of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature between 15 - 30¬∞C.\n",
      "\n",
      "Detailed Prediction: The storage conditions for sterile drugs are critical to maintaining their efficacy and preventing contamination. Based on the reviewed literature, here are key points about sterile drug storage:\n",
      "\n",
      "1. **Temperature Regulation**: Most sterile drugs need to be stored in controlled environments, with specific temperatures being crucial. For example, certain formulations may require refrigeration at 4¬∞C to maintain stability, while others may be affected negatively by freezing temperatures (-20¬∞C to -80¬∞C) (PubMed PMID: 41414880, 41266122).\n",
      "\n",
      "2. **Microbial Contamination Prevention**: Sterile medications must be stored in a manner that prevents microbial contamination. This often involves using aseptic techniques during preparation and storage in sterile, airtight containers (PubMed PMID: 41176402).\n",
      "\n",
      "3. **Stability Considerations**: The stability of sterile drugs can differ based on the medium they are compounded in. For instance, preservative-free formulations may exhibit different stability profiles compared to those that contain preservatives (PubMed PMID: 41266122).\n",
      "\n",
      "4. **Humidity Control**: In addition to temperature, humidity control may also impact the stability of certain sterile medications. High humidity can encourage contamination or degradation.\n",
      "\n",
      "5. **Shelf Life Monitoring**: It is essential to actively monitor the shelf life of sterile products. Proper labeling with expiration dates and adherence to storage guidelines helps ensure efficacy throughout their intended use.\n",
      "\n",
      "In summary, the proper storage conditions for sterile drugs typically include maintaining specific temperature controls (most commonly refrigeration but avoiding freezing for many), using sterile containers, ensuring microbiological safety during storage, and monitoring for stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 390:----\n",
      "Question: What action should be taken if a patient develops a serious infection while on REMICADE therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue REMICADE immediately\n",
      "\n",
      "Detailed Prediction: If a patient develops a serious infection while undergoing therapy with REMICADE (infliximab), immediate and appropriate actions should be taken. REMICADE is a tumor necrosis factor (TNF) inhibitor used primarily to treat autoimmune diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, and others. However, patients on such therapies are at an increased risk for infections due to their immunosuppressive effects.\n",
      "\n",
      "### Steps to Take When a Serious Infection Develops:\n",
      "\n",
      "1. **Discontinue REMICADE**: The first step is to discontinue REMICADE immediately. Continuing treatment can worsen the infection or complicate the patient's condition.\n",
      "\n",
      "2. **Clinical Assessment**: A thorough clinical evaluation should be conducted to assess the severity and type of infection. This often includes:\n",
      "   - Physical examination\n",
      "   - Laboratory tests (e.g., blood cultures, complete blood count, inflammatory markers)\n",
      "   - Imaging studies, if necessary (e.g., X-rays, CT scans) to localize the infection.\n",
      "\n",
      "3. **Initiate Appropriate Antibiotic Therapy**: Based on the clinical assessment and laboratory results, appropriate empirical antibacterial therapy should start as soon as possible. The choice of antibiotics may depend on the suspected source and type of infection.\n",
      "\n",
      "4. **Monitor the Patient**: Close monitoring of vital signs and the patient's clinical status is essential to ensure that the infection does not worsen and that there are no signs of sepsis or other complications.\n",
      "\n",
      "5. **Consult Specialists**: If necessary, consultations with infectious disease specialists may be warranted, especially if the infection is atypical or resistant to initial treatment.\n",
      "\n",
      "6. **Adjunctive Care**: Supportive care, including hydration and management of symptoms, should be provided as needed. This may involve pain management and any specific interventions required based on the site and severity of the infection.\n",
      "\n",
      "7. **Evaluate for Re-initiating Therapy**: Once the infection is resolved and the patient has stabilized, healthcare providers should consider the risks versus benefits of re-initiating REMICADE therapy. This evaluation may include assessing the reasons for therapy (the condition being treated) versus the potential for recurrent infections.\n",
      "\n",
      "8. **Patient Education**: Educating the patient about recognizing signs of infection in the future is vital. Patients should be informed to report any concerning symptoms promptly, especially fever, chills, or other systemic signs.\n",
      "\n",
      "9. **Screening and Prevention**: Prior to restarting any immunosuppressive therapy, patients should be screened for latent infections like tuberculosis, and vaccination status should be reviewed to prevent future complications.\n",
      "\n",
      "In summary, the management of a serious infection in a patient on REMICADE requires immediate action, careful evaluation, and a coordinated approach to treatment to ensure patient safety and adequate management of their pre-existing conditions.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 392:----\n",
      "Question: What is the recommended action if a patient taking Iclusig develops hypertension that is not medically controlled?\n",
      "\n",
      "Correct Answer: B:\n",
      "Interrupt, dose reduce, or stop Iclusig.\n",
      "\n",
      "Detailed Prediction: In managing a patient taking Iclusig (ponatinib) who develops uncontrolled hypertension, the following recommended actions should be considered:\n",
      "\n",
      "1. **Consultation with a Specialist**: It is advisable to involve a cardiologist or a healthcare provider specializing in hypertension management to assess the severity of the hypertension and ensure a comprehensive evaluation.\n",
      "\n",
      "2. **Review and Adjust Antihypertensive Medications**: Evaluate the current antihypertensive regimen. Many patients on Iclusig may require an adjustment or addition of antihypertensive medications, particularly those that can counteract the effects of ponatinib, as it has the potential to exacerbate hypertension. Common classes of antihypertensive medications include ACE inhibitors, ARBs, calcium channel blockers, and diuretics.\n",
      "\n",
      "3. **Discontinue or Reduce Iclusig Dosage**: If the hypertension is particularly severe or not responding to the typical treatment strategies, consider reducing the dose of Iclusig or discontinuing it under the guidance of the treating oncologist. The risk-to-benefit ratio should be carefully evaluated, as controlling hypertension is crucial to prevent cardiovascular complications associated with ponatinib.\n",
      "\n",
      "4. **Monitor Blood Pressure Regularly**: Ensure frequent monitoring of blood pressure to assess the efficacy of the treatment adjustments and confirm that the hypertension is being effectively managed. This may involve routine follow-ups and possibly home monitoring.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage lifestyle changes that can positively impact blood pressure, such as dietary modifications (e.g., reducing sodium intake), increased physical activity, weight management, and smoking cessation if applicable.\n",
      "\n",
      "6. **Patient Education**: Educate the patient about the symptoms of uncontrolled hypertension and the importance of adhering to both the cancer treatment and hypertension management plans. Helping the patient understand potential side effects of Iclusig, including hypertension, can enhance collaboration in managing their health.\n",
      "\n",
      "7. **Consider Alternative Therapies**: If hypertension remains uncontrolled despite these measures, it may be necessary to explore alternative therapies rather than continuing Iclusig. This decision should involve a multidisciplinary team and thorough discussion with the patient about their treatment options.\n",
      "\n",
      "It‚Äôs important to note that careful management is paramount to mitigate the cardiovascular risks associated with tyrosine kinase inhibitors like Iclusig, especially given their potential to induce hypertension and other cardiovascular toxicities.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 405:----\n",
      "Question: What is one of the uses of sunmark ibuprofen related to fever?\n",
      "\n",
      "Correct Answer: B:\n",
      "It temporarily reduces fever.\n",
      "\n",
      "Detailed Prediction: Sunmark ibuprofen, a common over-the-counter medication, is primarily used as a pain reliever and fever reducer. One of its notable uses related to fever management is its effectiveness in lowering elevated body temperature.\n",
      "\n",
      "Ibuprofen works by inhibiting the production of prostaglandins, which are chemicals in the body responsible for causing inflammation, pain, and fever. When the body encounters an infection or inflammatory response, prostaglandin levels increase, leading to fever. By reducing these levels, ibuprofen effectively brings down the fever, providing symptomatic relief.\n",
      "\n",
      "In clinical settings, ibuprofen is often suggested for use in both adults and children for managing febrile illnesses, such as colds or flu, making it a suitable option for those experiencing fever due to various causes. It is important to follow dosage instructions to minimize the risk of side effects.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 407:----\n",
      "Question: Which statement accurately describes the pharmacological risk of Hydrocort overdosage?\n",
      "\n",
      "Correct Answer: B:\n",
      "Hydrocort overdosage can result in systemic effects due to absorption.\n",
      "\n",
      "Detailed Prediction: Hydrocortisone (also known as hydrocortisol) is a glucocorticoid medication commonly used for its anti-inflammatory and immunosuppressive properties. In cases of overdose, it poses several pharmacological risks that can lead to significant health complications.\n",
      "\n",
      "1. **Adrenal Suppression**: Chronic use of hydrocortisone can suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency, especially in cases of overdose. Patients may experience symptoms like fatigue, weakness, and hypotension due to insufficient cortisol production by the adrenal glands (PMID: 35550494).\n",
      "\n",
      "2. **Cushing's Syndrome**: Overdose of hydrocortisone can result in symptoms of Cushing's syndrome, which is characterized by excessive cortisol levels. Symptoms may include obesity (particularly central obesity), moon facies, skin changes (such as purple striae), and hypertension (PMID: 30627312).\n",
      "\n",
      "3. **Metabolic Effects**: High cortisol levels can disturb metabolic processes, potentially leading to hyperglycemia (high blood sugar), increased appetite, and weight gain (PMID: 31763206). This can also exacerbate pre-existing diabetes or lead to the onset of new cases of diabetes mellitus.\n",
      "\n",
      "4. **Psychiatric Effects**: Hydrocortisone overdosing can also exacerbate psychiatric symptoms, leading to anxiety, depression, or psychosis, particularly if the overdose is substantial or chronic (PMID: 37625179).\n",
      "\n",
      "Given these potential risks, monitoring is critical in patients receiving hydrocortisone, especially when treatment duration is extended or doses are elevated. Thus, appropriate therapeutic drug monitoring could help prevent overdosing and its consequences related to hypercortisolism by tracking glucocorticoid levels in the body (PMID: 35550494).\n",
      "\n",
      "In summary, the pharmacological risk of hydrocortisone overdosage includes a spectrum of adverse effects ranging from adrenal suppression to metabolic and psychiatric disorders, emphasizing the importance of careful dosing and monitoring in clinical practice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 439:----\n",
      "Question: What is the controlled substance classification of venlafaxine tablets?\n",
      "\n",
      "Correct Answer: D:\n",
      "Not a controlled substance\n",
      "\n",
      "Detailed Prediction: Venlafaxine, marketed under brand names such as Effexor, is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is primarily prescribed for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. \n",
      "\n",
      "Importantly, venlafaxine tablets are **not classified as controlled substances** by the Drug Enforcement Administration (DEA). This means that venlafaxine does not fall under any of the schedules that typically govern the prescription and distribution of potentially addictive drugs. According to available sources, venlafaxine has a low potential for abuse and physical dependence, which is why it is not subjected to the same regulations as controlled drugs.\n",
      "\n",
      "For further information, you can refer to the following resources:\n",
      "- [Wikipedia - Venlafaxine](https://en.wikipedia.org/wiki/Venlafaxine)\n",
      "- [DailyMed - VENLAFAXINE tablet](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55889b3d-74c9-4638-9a14-6a4ca3a99f7f)\n",
      "- [MedlinePlus - Venlafaxine](https://medlineplus.gov/druginfo/meds/a694020.html)\n",
      "\n",
      "In summary, while venlafaxine serves as an effective treatment option for several psychiatric conditions, it does not have a controlled substance classification, allowing for more straightforward prescribing and monitoring compared to controlled medications.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 443:----\n",
      "Question: What should a patient do if they experience mild COVID-19 symptoms and are prescribed Paxlovid?\n",
      "\n",
      "Correct Answer: B:\n",
      "Start Paxlovid treatment as soon as possible and within 5 days of symptom onset.\n",
      "\n",
      "Detailed Prediction: If a patient experiences mild COVID-19 symptoms and is prescribed Paxlovid (nirmatrelvir/ritonavir), here are the recommended steps they should take:\n",
      "\n",
      "1. **Understand the Prescription**: Paxlovid is an antiviral medication specifically designed for treating mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease. It is crucial for patients to comprehend the importance of adhering to this treatment to decrease the risk of severe illness.\n",
      "\n",
      "2. **Consult with Healthcare Providers**: Patients should discuss any other medications they are currently taking with their healthcare provider. Paxlovid can interact with various drugs, potentially leading to adverse effects or reduced effectiveness. If there are drugs that may interact, the healthcare provider might suggest alternatives or dosage adjustments.\n",
      "\n",
      "3. **Start Treatment Promptly**: Paxlovid should be taken as soon as possible after the onset of symptoms. The treatment is most effective when started within the first few days of symptom appearance. Patients should follow the prescribed regimen strictly, usually for five days.\n",
      "\n",
      "4. **Monitor Symptoms**: Patients should keep track of their symptoms and any changes in their condition. If symptoms worsen (e.g., breathing difficulties, chest pain), they should seek immediate medical attention.\n",
      "\n",
      "5. **Stay Hydrated and Rest**: Patients are encouraged to drink plenty of fluids and get adequate rest, as these are important aspects of recovery from any viral infection.\n",
      "\n",
      "6. **Report Side Effects**: If patients experience any side effects from Paxlovid, such as changes in taste, gastrointestinal upset, or allergic reactions, they should report these to their healthcare provider immediately.\n",
      "\n",
      "7. **Follow Up**: A follow-up appointment may be necessary to assess recovery and to determine if any additional care or treatment is required.\n",
      "\n",
      "8. **Take Preventive Measures**: While taking Paxlovid, it's also essential to continue practicing public health measures, such as wearing masks in crowded places and maintaining good hygiene, to prevent the spread of COVID-19 to others.\n",
      "\n",
      "Following these guidelines can help ensure optimal care during a mild COVID-19 infection when treated with Paxlovid.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 444:----\n",
      "Question: What is the recommended action if a patient on Tybost experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline?\n",
      "\n",
      "Correct Answer: B:\n",
      "Closely monitor the patient for renal safety.\n",
      "\n",
      "Detailed Prediction: If a patient on Tybost (cobicistat) experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline, the recommended action includes the following steps:\n",
      "\n",
      "1. **Assessment**: Re-evaluate the patient's kidney function baseline and the context of the increase. It's important to determine if this increase is isolated or part of a trend.\n",
      "\n",
      "2. **Monitor Renal Function**: Close monitoring of the patient's renal function is critical. This may involve regular serum creatinine tests and possibly urine tests to assess for any additional changes.\n",
      "\n",
      "3. **Review Medications**: Since Tybost can cause drug-drug interactions, particularly with other medications that are metabolized through the CYP3A pathway, a review of all concurrent medications should be performed. Attention should be given to any other nephrotoxic drugs that the patient may be taking.\n",
      "\n",
      "4. **Dosing Considerations**: Based on the degree of increase in serum creatinine, consider adjusting the dosing of Tybost or any other affected medications, particularly if they have narrow therapeutic indices.\n",
      "\n",
      "5. **Hydration and Supportive Care**: Ensure the patient is adequately hydrated, as dehydration can exacerbate renal impairment. Supportive care may also involve adjusting dietary intake or managing any other symptoms.\n",
      "\n",
      "6. **Consultations**: If the renal impairment persists or worsens despite above management steps, consider consulting a nephrologist to further evaluate the cause and management strategies.\n",
      "\n",
      "7. **Discontinuation of Tybost**: In cases where the increase in serum creatinine is substantial and persistent, discontinuation of Tybost may be warranted, considering the benefits versus risks in the context of the patient's health condition.\n",
      "\n",
      "These steps help ensure that the patient's renal function is carefully monitored and managed while minimizing the risks associated with continued use of Tybost.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 449:----\n",
      "Question: How should a patient start Tri Femynor if switching from a progestin-only method such as an implant or injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Start Tri Femynor on the day of removal of the implant or the day of the next injection.\n",
      "\n",
      "Detailed Prediction: When switching to Tri Femynor from a progestin-only method such as an implant or injection, the transition should be managed carefully to ensure continued contraceptive effectiveness.\n",
      "\n",
      "1. **Start Timing**: Patients should begin taking Tri Femynor on the day of removal of the progestin-only implant. If they are using an injectable method, they should start Tri Femynor on the day when their next injection would have been due.\n",
      "\n",
      "2. **Continuing Contraception**: It's important for patients to understand that there may be a brief period during which they could be at risk for pregnancy if they do not follow the correct switch protocol. Therefore, using a backup contraceptive method, such as condoms, is advisable during the first seven days of taking Tri Femynor, especially if the transition timing is not strictly followed.\n",
      "\n",
      "3. **Consult Healthcare Provider**: Patients should always consult with their healthcare provider before making any changes to their contraceptive regimen. This allows for personalized advice based on individual health profiles and potential risks.\n",
      "\n",
      "4. **Monitoring for Side Effects**: After switching, patients should monitor for any side effects or changes in their menstrual cycle, as their body adjusts to the new hormone combination present in Tri Femynor.\n",
      "\n",
      "For detailed instructions and to address any specific concerns, referring to a healthcare provider or the medication guide is recommended.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 451:----\n",
      "Question: What is the recommended time of day to take esomeprazole magnesium during the 14-day treatment course?\n",
      "\n",
      "Correct Answer: A:\n",
      "Before eating in the morning\n",
      "\n",
      "Detailed Prediction: Error\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "‚ÑπÔ∏èValid Answers: 4\n",
      "‚ÑπÔ∏èInvalid Answers: 42\n",
      "üü¢ACC: 50.0%\n"
     ]
    }
   ],
   "execution_count": 44
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-12T12:36:28.126605Z",
     "start_time": "2026-01-12T12:36:28.110853Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#fuzzy\n",
    "THRESH = 0.950 \n",
    "\n",
    "def _norm(s: str) -> str:\n",
    "    s = \"\" if s is None else str(s)\n",
    "    s = s.lower().strip()\n",
    "    s = re.sub(r\"\\s+\", \" \", s)\n",
    "    return s\n",
    "\n",
    "def best_option_by_fuzzy(prediction: str, options_dict: dict) -> tuple[str, float]:\n",
    "    pred = _norm(prediction)\n",
    "    scores = {}\n",
    "    for k, opt in options_dict.items():\n",
    "        optn = _norm(opt)\n",
    "\n",
    "        # Primary: robust to extra words + reordering\n",
    "        s1 = fuzz.token_set_ratio(pred, optn) / 100.0\n",
    "\n",
    "        # Secondary: robust if pred includes a copied snippet of the option\n",
    "        s2 = fuzz.partial_ratio(pred, optn) / 100.0\n",
    "\n",
    "        # Blend (tweak weights if you want)\n",
    "        score = 0.7 * s1 + 0.3 * s2\n",
    "        scores[k] = score\n",
    "\n",
    "    best = max(scores, key=scores.get)\n",
    "    return best, float(scores[best])\n",
    "\n",
    "data_open = data_open.copy()\n",
    "\n",
    "fuzz_results = data_open.apply(\n",
    "    lambda r: best_option_by_fuzzy(r[\"prediction\"], dict(r[\"options\"])),\n",
    "    axis=1\n",
    ")\n",
    "data_open[\"pred_fuzz\"] = fuzz_results.map(lambda x: x[0])\n",
    "data_open[\"fuzz_similarity\"] = fuzz_results.map(lambda x: x[1])\n",
    "\n",
    "\n",
    "data_open[\"final_choice\"] = np.where(\n",
    "    data_open[\"fuzz_similarity\"] >= THRESH,\n",
    "    data_open[\"pred_fuzz\"],\n",
    "    data_open[\"choice\"])\n",
    "\n",
    "data_open[\"is_correct\"] = data_open[\"final_choice\"] == data_open[\"correct_answer\"]\n",
    "\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] != 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}\")\n",
    "        print(f\"Is correct: {row['is_correct']}\")\n",
    "    \n",
    "print(\"\\n\\n‚ö†üü®--------- INVALID ANSWERS-----------üü®\\n\\n\")\n",
    "for i,row in data_open.iterrows():\n",
    "    if row[\"final_choice\"] == 'NOTAVALUE':\n",
    "        print(f\"\\n----Row {i}:----\")\n",
    "        \n",
    "        print(f\"Question: {row['question']}\\n\")\n",
    "        print(f\"Correct Answer: {row['correct_answer']}:\")\n",
    "        print(f\"{ row['options'][row['correct_answer']] }\\n\")\n",
    "        print(f\"Detailed Prediction: {row[\"prediction\"]}\\n\")\n",
    "        print(f\"Final Choice: {row['final_choice']}\\n\")\n",
    "\n",
    "\n",
    "\n",
    "NaN_open = len(data_open[data_open[\"final_choice\"] == 'NOTAVALUE'])\n",
    "valid_open = len(data_open) - NaN_open\n",
    "ACC_open = data_open[\"is_correct\"].sum() / valid_open\n",
    "\n",
    "print()\n",
    "print(f\"‚ÑπÔ∏èValid Answers: {valid_open}\")\n",
    "print(f\"‚ÑπÔ∏èInvalid Answers: {NaN_open}\")\n",
    "print(f\"üü¢ACC: {100*round(ACC_open,4)}%\")\n",
    "\n"
   ],
   "id": "d62bdf002fcf8df6",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----Row 371:----\n",
      "Detailed Prediction: In the context of treating radiation-induced emesis (RIE) during single high-dose fraction radiotherapy, Ondansetron has been shown to be effective. According to a study published in *Seminars in Oncology*, the incidence and severity of RIE can significantly vary based on factors such as radiation dose and field size.\n",
      "\n",
      "Although the specific trial directly comparing Ondansetron and metoclopramide for this purpose was not found in the clinical trials database, existing literature indicates that Ondansetron, a 5-HT3 receptor antagonist, may provide better control of emesis compared to traditional antiemetics like metoclopramide, especially in cases of high radiation doses over 500 cGy. The effectiveness of Ondansetron relates to its mechanism of action in blocking the serotonin receptors involved in the emetic response.\n",
      "\n",
      "The reported data indicate that radiation-induced emesis occurs in a high percentage of patients receiving high-dose hemibody irradiation, which suggests that administering antiemetics prior to treatment can be beneficial. In summary, while a direct comparative study between the two drugs for RIE was not located, Ondansetron is generally recognized as more effective for controlling emesis in patients undergoing high-dose radiotherapy.\n",
      "Final Choice: A\n",
      "Correct Answer: A\n",
      "Is correct: True\n",
      "\n",
      "----Row 439:----\n",
      "Detailed Prediction: Venlafaxine, marketed under brand names such as Effexor, is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is primarily prescribed for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. \n",
      "\n",
      "Importantly, venlafaxine tablets are **not classified as controlled substances** by the Drug Enforcement Administration (DEA). This means that venlafaxine does not fall under any of the schedules that typically govern the prescription and distribution of potentially addictive drugs. According to available sources, venlafaxine has a low potential for abuse and physical dependence, which is why it is not subjected to the same regulations as controlled drugs.\n",
      "\n",
      "For further information, you can refer to the following resources:\n",
      "- [Wikipedia - Venlafaxine](https://en.wikipedia.org/wiki/Venlafaxine)\n",
      "- [DailyMed - VENLAFAXINE tablet](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55889b3d-74c9-4638-9a14-6a4ca3a99f7f)\n",
      "- [MedlinePlus - Venlafaxine](https://medlineplus.gov/druginfo/meds/a694020.html)\n",
      "\n",
      "In summary, while venlafaxine serves as an effective treatment option for several psychiatric conditions, it does not have a controlled substance classification, allowing for more straightforward prescribing and monitoring compared to controlled medications.\n",
      "Final Choice: D\n",
      "Correct Answer: D\n",
      "Is correct: True\n",
      "\n",
      "\n",
      "‚ö†üü®--------- INVALID ANSWERS-----------üü®\n",
      "\n",
      "\n",
      "\n",
      "----Row 22:----\n",
      "Question: Which of the following is a withdrawal symptom that Nicotine helps alleviate?\n",
      "\n",
      "Correct Answer: A:\n",
      "Nicotine craving.\n",
      "\n",
      "Detailed Prediction: Withdrawal symptoms from nicotine are common when a person stops smoking or using nicotine products. Nicotine helps alleviate several of these withdrawal symptoms, which can include:\n",
      "\n",
      "1. **Cravings for nicotine**: One of the most prominent symptoms, cravings can lead to relapse if not managed appropriately.\n",
      "   \n",
      "2. **Irritability and anxiety**: These emotional symptoms are frequently reported during withdrawal, and nicotine can help stabilize mood.\n",
      "\n",
      "3. **Increased appetite**: Many individuals experience an increase in appetite and subsequent weight gain upon stopping nicotine, which nicotine can suppress.\n",
      "\n",
      "4. **Difficulty concentrating**: Cognitive function may be impaired during withdrawal, with nicotine improving attention and focus.\n",
      "\n",
      "5. **Sleep disturbances**: Insomnia or altered sleep patterns are common, and nicotine can initially provide calming effects that help with sleep regulation.\n",
      "\n",
      "Research shows that various interventions, including pharmacological treatments and non-pharmacological strategies like acupuncture, can significantly alleviate these withdrawal symptoms. For example, a study indicated that electroacupuncture resulted in a greater reduction of nicotine withdrawal symptoms compared to other methods.\n",
      "\n",
      "In summary, nicotine plays a critical role in alleviating withdrawal symptoms such as cravings, irritability, increased appetite, cognitive difficulties, and sleep disturbances.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 37:----\n",
      "Question: What is the primary indication for the use of esomeprazole magnesium?\n",
      "\n",
      "Correct Answer: B:\n",
      "Treatment of frequent heartburn occurring 2 or more days a week.\n",
      "\n",
      "Detailed Prediction: Esomeprazole magnesium, a proton pump inhibitor (PPI), is primarily indicated for the treatment of several conditions related to excessive stomach acid production. The main indications for its use include:\n",
      "\n",
      "1. **Gastroesophageal Reflux Disease (GERD)**: Esomeprazole is effective in managing symptoms of GERD, a condition where stomach acid frequently flows back into the esophagus, causing heartburn and potential damage to the esophageal lining.\n",
      "\n",
      "2. **Peptic Ulcer Disease**: It is also used to treat peptic ulcers, either alone or in combination with antibiotics, to eradicate Helicobacter pylori infections, which are often responsible for these ulcers.\n",
      "\n",
      "3. **Erosive Esophagitis**: This condition, characterized by inflammation and damage to the esophagus due to acid reflux, is treated effectively with esomeprazole.\n",
      "\n",
      "4. **Zollinger-Ellison Syndrome**: Esomeprazole is indicated for this rare condition, where the stomach produces excessive amounts of acid due to tumors in the pancreas or duodenum.\n",
      "\n",
      "5. **Prevention of Gastric Ulcers**: It is used in patients who are at risk for ulcers following NSAID (non-steroidal anti-inflammatory drugs) use, particularly in long-term therapies.\n",
      "\n",
      "6. **Management of dyspepsia**: Esomeprazole can help alleviate symptoms of dyspepsia (indigestion), particularly when associated with high acid secretion.\n",
      "\n",
      "These indications illustrate the role of esomeprazole in managing acid-related gastrointestinal disorders effectively, enhancing patient quality of life by reducing symptoms associated with excess gastric acidity and promoting healing of the esophagus and stomach lining.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 42:----\n",
      "Question: What should patients do if they experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue Levalbuterol Inhalation Solution and consult their physician.\n",
      "\n",
      "Detailed Prediction: If patients experience paradoxical bronchospasm while using Levalbuterol Inhalation Solution, they should take the following steps:\n",
      "\n",
      "1. **Stop Using the Inhaler**: Immediately discontinue the use of the Levalbuterol inhaler if paradoxical bronchospasm occurs. This adverse reaction can be life-threatening, and it is critical to stop taking the medication that is causing the problem.\n",
      "\n",
      "2. **Seek Medical Attention**: Contact a healthcare provider right away or seek emergency medical attention if breathing difficulties worsen. Paradoxical bronchospasm can manifest as increased wheezing, shortness of breath, or chest tightness, which may necessitate prompt intervention.\n",
      "\n",
      "3. **Monitor Symptoms**: Patients should closely monitor their respiratory status and report any changes in their breathing or other symptoms to their healthcare professional. Keeping a record of symptoms may help in the management and follow-up care.\n",
      "\n",
      "4. **Alternative Treatments**: Discuss with a healthcare provider about alternative bronchodilator medications or treatment options, as the use of Levalbuterol should be avoided in such cases in the future.\n",
      "\n",
      "5. **Emergency Plan**: Have an emergency plan established with a healthcare provider, including knowing when and how to use other rescue inhalers or medications if needed.\n",
      "\n",
      "Awareness of the potential for paradoxical bronchospasm is essential for safe medication use, as highlighted in a report indicating it can occur with both Levalbuterol and Albuterol, and being cognizant of this can help prevent life-threatening situations (Raghunathan et al., 2006).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 44:----\n",
      "Question: Which of the following is the molecular formula of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "C17H27NO2HCl\n",
      "\n",
      "Detailed Prediction: The molecular formula of venlafaxine hydrochloride is **C‚ÇÅ‚ÇáH‚ÇÇ‚ÇàClN‚ÇÅO‚ÇÇ**. Venlafaxine hydrochloride is an antidepressant medication used primarily to treat major depressive disorder and anxiety disorders. It functions as a serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 47:----\n",
      "Question: Which of the following statements is true regarding the storage of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature.\n",
      "\n",
      "Detailed Prediction: The storage of sterile drugs is crucial for maintaining their efficacy, safety, and sterility. Here are some important considerations regarding their storage:\n",
      "\n",
      "1. **Temperature Control**: Sterile drugs often require specific temperature conditions to ensure their stability. Many sterile medications need to be stored at controlled room temperatures, while others may require refrigeration or freezing to maintain their integrity.\n",
      "\n",
      "2. **Humidity and Light Protection**: Exposure to humidity and light can alter the chemical structure of sterile drugs, leading to degradation. Therefore, they should be stored in a dry place and in containers that protect them from light exposure.\n",
      "\n",
      "3. **Packaging and Containers**: The type of packaging can play a significant role in maintaining sterility. Aseptic packaging techniques and the use of barriers such as blister packs and sterile containers help to prevent contamination.\n",
      "\n",
      "4. **Expiration Dates and Shelf Life**: Every sterile drug has an expiration date, and it is essential to adhere to these dates to ensure safety. The storage conditions may also affect the shelf life of sterile medications.\n",
      "\n",
      "5. **Avoiding Contamination**: It is important to ensure that the storage area is clean and that proper hygiene practices are followed when handling sterile drugs, to prevent any form of contamination.\n",
      "\n",
      "In summary, to safely store sterile drugs, it is crucial to maintain appropriate temperature and humidity levels, protect them from light, use proper packaging, adhere to expiration dates, and follow strict hygiene protocols. For detailed guidelines, refer to specialized sources on drug storage and stability. \n",
      "\n",
      "For further reading, you can explore [this article](https://www.em-consulte.com/article/513841/drug-storage-and-stability) on drug storage and stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 61:----\n",
      "Question: For what purpose is the drug Motion Sickness primarily used?\n",
      "\n",
      "Correct Answer: A:\n",
      "To prevent and treat symptoms associated with motion sickness\n",
      "\n",
      "Detailed Prediction: Error\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 67:----\n",
      "Question: What is the recommended action if a patient on Coreg CR develops renal function deterioration?\n",
      "\n",
      "Correct Answer: C:\n",
      "Monitor renal function and reduce or discontinue Coreg CR if necessary.\n",
      "\n",
      "Detailed Prediction: If a patient on Coreg CR (carvedilol phosphate) develops renal function deterioration, the following actions are recommended:\n",
      "\n",
      "1. **Monitor Renal Function**: It is crucial to assess renal function regularly, especially during the initiation and up-titration of Coreg CR. This monitoring helps in detecting any changes early and in making timely interventions.\n",
      "\n",
      "2. **Discontinuation or Dose Adjustment**: If there is evidence of worsening renal function, the prescribing physician should consider discontinuing the medication or reducing the dosage. This step is particularly important in high-risk patients who may be more susceptible to renal impairment.\n",
      "\n",
      "3. **Patient Evaluation**: Evaluate for potential underlying causes of renal dysfunction that may be exacerbated by Coreg CR. Consider any additional comorbidities or medications that may contribute to renal deterioration.\n",
      "\n",
      "4. **Alternative Therapies**: Depending on the patient's overall clinical situation, alternative antihypertensive or heart failure management strategies may need to be deployed if Coreg CR adversely affects renal function.\n",
      "\n",
      "5. **Consultation with a Specialist**: If the renal function does not improve upon adjusting or discontinuing Coreg CR, a consultation with a nephrologist may be appropriate for further evaluation and management.\n",
      "\n",
      "In summary, careful monitoring and appropriate adjustments in the management of patients receiving Coreg CR are essential if there is a sign of renal function deterioration. For more detailed information, the [DailyMed entry for Coreg CR](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9008ede8-3e53-4061-ae4c-c51cbbb56ef2) contains pertinent guidelines regarding the management of renal function changes associated with this medication.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 83:----\n",
      "Question: Which document should patients read and understand when prescribed venlafaxine tablets?\n",
      "\n",
      "Correct Answer: A:\n",
      "The Medication Guide about 'Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions.'\n",
      "\n",
      "Detailed Prediction: Patients prescribed venlafaxine tablets should read and understand the **Patient Information Leaflet (PIL)** provided with their medication. This document includes essential information about the medication such as its uses, dosage instructions, potential side effects, and precautions. \n",
      "\n",
      "Some key elements that are typically covered in the PIL include:\n",
      "\n",
      "1. **Description of the Drug**: What venlafaxine is, including its classification as a serotonin-norepinephrine reuptake inhibitor (SNRI), and its common uses for treating conditions like depression and anxiety.\n",
      "\n",
      "2. **Dosage and Administration**: Instructions on how to take the medication correctly, including the timing and whether to take it with food.\n",
      "\n",
      "3. **Side Effects**: Common and serious side effects that may occur, such as nausea, dizziness, or increased blood pressure. Important notes about any severe reactions that require immediate medical attention are also included.\n",
      "\n",
      "4. **Warnings and Precautions**: Information about contraindications, what to discuss with healthcare providers (e.g., other medications being taken or existing health issues), and the risk of withdrawal symptoms if the medication is stopped suddenly.\n",
      "\n",
      "5. **Interaction with Other Drugs**: Potential interactions with other medications, which could affect how venlafaxine works or increase the risk of side effects.\n",
      "\n",
      "6. **Storage Instructions**: Guidelines on how to properly store the tablets to maintain their efficacy.\n",
      "\n",
      "Patients may also find the following resources useful:\n",
      "- [Venlafaxine 75 mg tablets - Patient Information Leaflet](https://www.medicines.org.uk/emc/product/764/pil)\n",
      "- [Important Patient Information PDF](https://www.urmc.rochester.edu/medialibraries/urmcmedia/medicine/general-medicine/patientcare/documents/venlafaxine_brochure.pdf)\n",
      "\n",
      "Understanding this information is crucial for the safe and effective use of venlafaxine and for making informed decisions about their treatment.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 84:----\n",
      "Question: What precaution should be taken when initiating Coreg CR therapy in patients with diabetes?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor blood glucose levels closely.\n",
      "\n",
      "Detailed Prediction: When initiating Coreg CR (carvedilol controlled release) therapy in patients with diabetes, several precautions should be considered:\n",
      "\n",
      "1. **Monitor Blood Glucose Levels**: Carvedilol, a beta-blocker, can mask some of the adrenergic symptoms of hypoglycemia, such as palpitations and tremors. Therefore, it's crucial for healthcare providers to closely monitor blood glucose levels and educate patients on recognizing other signs of low blood sugar.\n",
      "\n",
      "2. **Adjust Dosage Carefully**: Given that patients with diabetes may have varying sensitivities to blood glucose fluctuations, any dose adjustments should be made cautiously. Start with a low dose and titrate slowly based on the patient's tolerance and blood sugar control.\n",
      "\n",
      "3. **Evaluate for Comorbidities**: Patients with diabetes often have additional comorbid conditions, such as hypertension or heart failure. The presence of these conditions requires careful assessment to ensure the benefits of initiating Coreg CR outweigh potential risks.\n",
      "\n",
      "4. **Patient Education**: Informing patients about the potential side effects of beta-blockers, including fatigue and dizziness, is essential. They should understand the need for regular follow-ups to monitor their cardiovascular status as well as diabetes management while on this medication.\n",
      "\n",
      "5. **Assess for Renal Function**: Diabetes can lead to renal impairment, affecting drug metabolism and clearance. Renal function should be evaluated prior to starting Coreg CR, and the patient should be monitored for any increases in creatinine or changes in renal function during therapy.\n",
      "\n",
      "By taking these precautions, healthcare providers can help ensure safe and effective use of Coreg CR in patients with diabetes.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 102:----\n",
      "Question: In animal studies, what developmental toxicity was observed in rats exposed to lamotrigine during pregnancy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Decreased fetal folate concentrations.\n",
      "\n",
      "Detailed Prediction: In animal studies, particularly those involving pregnant rats, developmental toxicity associated with lamotrigine (LTG) has been observed, highlighting several significant effects on offspring. \n",
      "\n",
      "1. **Study Overview**: Research conducted on Sprague Dawley rats assessed the impact of prenatal exposure to LTG, administered from gestational day 3 until postnatal day 11. The doses used were 11.5, 23, and 46 mg/kg. The study primarily observed postnatal development and behavioral changes in the offspring.\n",
      "\n",
      "2. **Findings**: \n",
      "   - **Maternal Toxicity**: At the highest dosage of 46 mg/kg, signs of severe toxicity were observed in the mother rats, leading to mortality between gestational days 15 and 17.\n",
      "   - **Developmental Effects on Offspring**: Offspring exposed to both 11.5 mg/kg and 23 mg/kg doses showed significant deviations compared to control groups. Notably, there were alterations in milestones such as the eruption of incisors and the timing of vaginal opening, indicating potential disruptions in normal development.\n",
      "   - **Behavioral Changes**: Female offspring exposed to 23 mg/kg exhibited hyperactivity, alongside a decrease in GABA-A receptor expression, which suggests alterations in neural development and functioning.\n",
      "\n",
      "3. **Implications**: These findings indicate that prenatal exposure to lamotrigine can lead to essential developmental issues in rats, including both physical and behavioral alterations that may differ based on sex. Such variations underscore the need for further investigation into the mechanisms behind these effects and their relevance to fetal development in humans.\n",
      "\n",
      "In summary, prenatal exposure to lamotrigine in rats resulted in notable developmental toxicity, including maternal toxicity, altered developmental milestones, and behavioral changes in the offspring, pointing towards potential risks associated with its use during pregnancy.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 104:----\n",
      "Question: What should a user do if they are under 18 years of age and want to use nicotine lozenges?\n",
      "\n",
      "Correct Answer: B:\n",
      "Consult a doctor before use\n",
      "\n",
      "Detailed Prediction: If a user under 18 years of age is considering the use of nicotine lozenges, there are several important steps and considerations to keep in mind:\n",
      "\n",
      "1. **Consult a Healthcare Professional**: The first and most crucial step is to speak with a healthcare provider. A doctor or a trained pharmacist can provide guidance on whether nicotine lozenges are suitable for the individual, considering their age and health status.\n",
      "\n",
      "2. **Consider Alternatives for Smoking Cessation**: Research shows that adolescent-specific smoking cessation programs can be beneficial. A study from T√ºrkiye highlighted the effectiveness of adolescents attending smoking cessation clinics, with various methods including nicotine patches showing positive outcomes (PMID: 41509942). It‚Äôs essential to explore comprehensive smoking cessation plans tailored for young individuals.\n",
      "\n",
      "3. **Understand the Risks and Regulations**: In many regions, the sale and use of nicotine products (including lozenges) are typically restricted for minors. Familiarizing oneself with local laws and regulations is important, as well as understanding the health risks associated with nicotine use, particularly before reaching adulthood. Adolescents are generally more susceptible to addiction and the potential health consequences of nicotine.\n",
      "\n",
      "4. **Explore Ongoing Clinical Trials**: There may be clinical trials assessing the efficacy and safety of nicotine replacement therapies in adolescents, such as the Aggressive Smoking Cessation Trial (NCT05257629). Engaging in a clinical trial might provide access to resources and support designed for young smokers looking to quit.\n",
      "\n",
      "5. **Educate on Smoking Cessation Techniques**: In addition to lozenges, various methods exists for quitting smoking that are safe for adolescents, including behavioral therapies, counseling, and support groups. \n",
      "\n",
      "In summary, the use of nicotine lozenges by individuals under 18 requires careful consideration and guidance from healthcare professionals, alongside understanding the associated risks and exploring alternative cessation methods tailored for young users.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 113:----\n",
      "Question: Which brand produces the Beloved Coconut & Warm Vanilla Hand Sanitizer?\n",
      "\n",
      "Correct Answer: A:\n",
      "Love Beauty and Planet\n",
      "\n",
      "Detailed Prediction: The Beloved Coconut & Warm Vanilla Hand Sanitizer is produced by Love Beauty and Planet. This brand focuses on creating beauty products that are environmentally friendly and incorporate natural ingredients, aligning well with their ethos of sustainability and care for nature. The hand sanitizer combines the tropical scent of coconut with the comforting warmth of vanilla, providing a pleasant user experience while helping to reduce bacteria on the skin.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 114:----\n",
      "Question: For children aged 6 to under 12 years, what is the appropriate dosage of the laxative for women?\n",
      "\n",
      "Correct Answer: A:\n",
      "1 tablet in a single daily dose\n",
      "\n",
      "Detailed Prediction: The appropriate dosage of laxatives for children aged 6 to under 12 years can vary depending on the specific type of laxative used. Here's a general guideline based on various sources:\n",
      "\n",
      "1. **Over-the-counter Laxatives**: \n",
      "   - Most over-the-counter laxatives are not recommended for children under the age of 6 without consulting a healthcare provider.\n",
      "   - For children aged 6 to 11 years, it's typically advised to administer half the adult dosage indicated on the package unless otherwise directed by a healthcare professional.\n",
      "\n",
      "2. **Senna-Based Laxatives** (like Senokot):\n",
      "   - For children aged 6-11 years, the recommendation is usually to use 1 tablet once or twice daily.\n",
      "\n",
      "3. **Dulcolax Suppositories**:\n",
      "   - These are typically not recommended for children under 12 years without medical advice, but if used, a 10 mg suppository may be inserted as needed (usually one suppository for quicker effect).\n",
      "\n",
      "4. **Liquid Laxatives**: \n",
      "   - The dosage may be around 15 to 30 mL for children over 6 years, but this can depend on the formulation and should be guided by a physician.\n",
      "\n",
      "**Important Note**: Consultation with a healthcare provider is crucial before administering any laxative to children for proper dosing and to rule out any underlying health issues causing constipation. It's essential to follow specific product guidance and medical advice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 120:----\n",
      "Question: Why is it recommended not to eat or drink 15 minutes before using or while the NICOTINE lozenge is in the mouth?\n",
      "\n",
      "Correct Answer: B:\n",
      "To ensure proper absorption of nicotine\n",
      "\n",
      "Detailed Prediction: It is recommended not to eat or drink for 15 minutes before using or while the nicotine lozenge is in the mouth due to several reasons related to absorption and effectiveness of the medication:\n",
      "\n",
      "1. **Absorption Mechanism**: Nicotine lozenges are designed to dissolve slowly in the mouth, allowing nicotine to be absorbed through the mucosal membranes. Eating or drinking can interfere with this absorption process. The presence of food or liquids can wash away the lozenge's active ingredients, leading to a reduction in the amount of nicotine that enters the bloodstream.\n",
      "\n",
      "2. **pH Levels**: The pH levels in the mouth can change due to food or beverage consumption. These changes can affect how effectively nicotine is absorbed. For example, acidic foods or drinks may enhance nicotine absorption, but the overall interaction may lead to inconsistent dosing, which is not ideal for someone trying to quit smoking.\n",
      "\n",
      "3. **Maintaining Effectiveness**: For optimal effectiveness in reducing cravings and withdrawal symptoms, it is crucial for the lozenge to provide a steady release of nicotine. Disruption by eating or drinking can lead to fluctuating nicotine levels in the blood, which can undermine the lozenge's intended purpose.\n",
      "\n",
      "4. **Taste and Experience**: Additionally, substances like coffee or acidic drinks can impair the taste of the lozenge, potentially leading to a decreased likelihood of continued use. This sensory experience can influence adherence to using the lozenge as part of a smoking cessation strategy.\n",
      "\n",
      "In summary, avoiding eating and drinking before and during the use of a nicotine lozenge maximizes nicotine absorption, maintains steady blood levels, and helps ensure that the lozenge is effective in curbing smoking urges.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 128:----\n",
      "Question: In which animal model did albuterol sulfate show no evidence of tumorigenicity at dietary doses of up to 50 mg/kg?\n",
      "\n",
      "Correct Answer: C:\n",
      "Golden hamsters\n",
      "\n",
      "Detailed Prediction: Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg in a 22-month study involving **Golden Hamsters**. This study indicated that the doses tested were significantly higher than the maximum recommended daily inhalation doses for both adults and children when adjusted for body surface area. \n",
      "\n",
      "For more detailed information, you can refer to the source [here](https://medlibrary.org/lib/rx/meds/albuterol-sulfate-38/page/3/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 129:----\n",
      "Question: What is the recommended action if a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Prohibit intercourse to avoid hemoperitoneum\n",
      "\n",
      "Detailed Prediction: If a patient develops significant ovarian enlargement after ovulation while on Follistim AQ therapy, the recommended action is to carefully evaluate the situation for any potential complications, primarily the risk of ovarian hyperstimulation syndrome (OHSS). Here are several key steps to consider:\n",
      "\n",
      "1. **Monitoring and Assessment**: Close monitoring of the patient's symptoms and ovarian size via ultrasound is crucial. Significant enlargement may indicate overstimulation, which can lead to complications.\n",
      "\n",
      "2. **Symptomatic Management**: If the enlargement is accompanied by symptoms such as abdominal pain, shortness of breath, or weight gain, symptomatic treatment may be warranted.\n",
      "\n",
      "3. **Adjustment of Medication**: Depending on the severity of the enlargement, it may be necessary to adjust or even suspend Follistim AQ therapy. This could involve dose reduction or pausing treatment until the patient's condition stabilizes.\n",
      "\n",
      "4. **Consultation**: If there are concerns regarding complications such as OHSS, involve a reproductive endocrinologist for expert management. \n",
      "\n",
      "5. **Patient Education**: Inform the patient about the signs and symptoms of OHSS, emphasizing the importance of reporting any worsening symptoms immediately.\n",
      "\n",
      "6. **Follow-up Care**: Ensure regular follow-up appointments to monitor the patient's ovarian response and overall health. This may involve repeating ultrasound examinations and possibly hormone level testing.\n",
      "\n",
      "Individuals on fertility treatments like Follistim AQ should be monitored closely for responses, and any signs of ovarian enlargement should be managed proactively to prevent complications. \n",
      "\n",
      "For more detailed guidelines, you can refer to the official product information from sources such as [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48489027-e52b-4b10-ae74-4ba03839150c).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 134:----\n",
      "Question: What is a potential risk when Labetalol HCL is used in combination with tricyclic antidepressants?\n",
      "\n",
      "Correct Answer: B:\n",
      "Increased risk of tremor\n",
      "\n",
      "Detailed Prediction: A potential risk when Labetalol HCL is used in combination with tricyclic antidepressants (TCAs) is the inhibition of mIBG (metaiodobenzylguanidine) uptake in cardiac tissues, which could impact cardiac imaging studies. \n",
      "\n",
      "Labetalol, a beta-blocker with alpha-blocking activity, has a strong inhibition effect on mIBG uptake, which is rated as having high evidence. In contrast, tricyclic antidepressants have a medium level of evidence for their impact on mIBG uptake. The combination of these medications may therefore lead to an insufficient uptake of mIBG during imaging, potentially complicating the assessment of cardiac function or disease. This interaction underscores the need for clinicians to reconsider the timing of these medications before conducting mIBG cardiac imaging and may warrant temporary withdrawal to ensure accurate diagnostic results. \n",
      "\n",
      "In summary, the use of Labetalol in conjunction with tricyclic antidepressants can pose significant risks for cardiac imaging accuracy due to their combined effects on mIBG uptake.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 173:----\n",
      "Question: Which of the following symptoms is NOT associated with a lamotrigine overdose?\n",
      "\n",
      "Correct Answer: C:\n",
      "Hypertension\n",
      "\n",
      "Detailed Prediction: Lamotrigine overdose is associated with several symptoms, including seizures, cardiac arrest, and potentially fatal arrhythmias. In clinical findings, patients have presented with significant neurological and cardiovascular instability following an overdose. While activated charcoal and sodium bicarbonate are common treatments, alternative therapies are limited.\n",
      "\n",
      "To conclude, one symptom NOT associated with a lamotrigine overdose is *hypertension*. The primary symptoms remain centered around neurological effects (like seizures) and cardiovascular complications (such as arrhythmias), rather than increases in blood pressure.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 184:----\n",
      "Question: What precaution should be taken for patients with multiple cardiovascular risk factors before administering Sumatriptan injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Perform a cardiovascular evaluation\n",
      "\n",
      "Detailed Prediction: Before administering Sumatriptan injection to patients with multiple cardiovascular risk factors, several precautions should be taken:\n",
      "\n",
      "1. **Cardiovascular Evaluation**: It is crucial to perform a thorough cardiac evaluation for patients with cardiovascular risk factors, such as diabetes, hypertension, smoking history, obesity, or a strong family history of coronary artery disease (CAD). This evaluation helps assess the potential risk of myocardial ischemia or infarction, which can be exacerbated by Sumatriptan.\n",
      "\n",
      "2. **Setting of Administration**: If the patient has significant cardiovascular risk factors, the initial dose of Sumatriptan should ideally be administered in a medically supervised setting, such as a physician‚Äôs office. This precaution allows for immediate medical assistance if any adverse cardiovascular events occur.\n",
      "\n",
      "3. **Monitoring**: Continuous monitoring of cardiovascular status is advisable in patients with a history of cardiovascular disease or risk factors when they receive Sumatriptan. Monitoring helps in the early detection of any complications.\n",
      "\n",
      "4. **Patient Counseling**: Patients should be informed about the signs and symptoms of cardiovascular events, and they should be advised to seek medical attention if they experience chest pain, shortness of breath, or any unusual symptoms following administration.\n",
      "\n",
      "Taking these precautions can help mitigate the risks associated with Sumatriptan in patients with multiple cardiovascular risk factors. For more detailed information about the drug and its precautions, healthcare providers can refer to the official prescribing information available from sources such as [Drugs.com](https://www.drugs.com/pro/sumatriptan-injection.html) and [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a4c0c2f-497d-4c5c-84c4-9ab42780cbde).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 186:----\n",
      "Question: What precaution should be taken when prescribing fluoxetine to a patient with diabetes?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor for hypoglycemia during therapy and hyperglycemia after discontinuation\n",
      "\n",
      "Detailed Prediction: When prescribing fluoxetine to a patient with diabetes, there are several important precautions to consider:\n",
      "\n",
      "1. **Monitoring Blood Sugar Levels**: Fluoxetine can affect glycemic control, which may lead to changes in blood sugar levels. Careful monitoring of blood sugar is essential, especially when beginning treatment or adjusting the dose. \n",
      "\n",
      "2. **Potential Risk of Hypoglycemia**: There is a risk that fluoxetine may increase the effectiveness of insulin or other antidiabetic medications, potentially leading to hypoglycemia (low blood sugar). Symptoms of hypoglycemia include headache, dizziness, drowsiness, confusion, and tremor. Patients should be educated on recognizing these symptoms and advised on how to manage them.\n",
      "\n",
      "3. **Adjustment of Diabetes Medications**: The dosage of insulin or oral hypoglycemic agents may need to be altered when a patient starts fluoxetine. Collaboration with the endocrinologist or the healthcare provider managing the diabetes is advisable to determine appropriate medication adjustments.\n",
      "\n",
      "4. **Patient Education**: Patients should be informed about the potential effects of fluoxetine on their diabetes management, including the signs of hypoglycemia and the importance of adherence to blood glucose monitoring.\n",
      "\n",
      "5. **Close Follow-up**: Regular follow-up appointments should be scheduled to assess the patient's mental health as well as their diabetes control, adjusting treatment as necessary.\n",
      "\n",
      "In summary, careful monitoring, potential medication adjustments, and patient education are critical when prescribing fluoxetine to individuals with diabetes to ensure both their mental health and glycemic control are optimized.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 219:----\n",
      "Question: If a hypersensitivity reaction occurs during TAKHZYRO treatment, what is the primary concern for the healthcare provider?\n",
      "\n",
      "Correct Answer: C:\n",
      "Discontinuing TAKHZYRO and initiating appropriate treatment.\n",
      "\n",
      "Detailed Prediction: If a hypersensitivity reaction occurs during TAKHZYRO (lanadelumab) treatment, the primary concern for the healthcare provider is the potential for serious allergic reactions, which may include anaphylaxis. Healthcare providers must be vigilant in monitoring patients for signs of hypersensitivity after administration, including symptoms like rash, urticaria, difficulty breathing, or gastrointestinal symptoms. Immediate intervention may be required if severe symptoms manifest, including the use of epinephrine in cases of anaphylaxis. It is crucial to have a plan in place for managing such reactions, including the provision of emergency care.\n",
      "\n",
      "In the context of managing patients receiving TAKHZYRO, which is used to prevent attacks of hereditary angioedema, understanding the risk of hypersensitivity is critical as it ensures patient safety and effective management of their condition. Regular assessment and education of the patient about the symptoms of hypersensitivity are essential components of care during treatment with this medication.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 225:----\n",
      "Question: What is the physical appearance of venlafaxine hydrochloride?\n",
      "\n",
      "Correct Answer: A:\n",
      "White to off-white crystalline powder\n",
      "\n",
      "Detailed Prediction: Venlafaxine hydrochloride is a medication commonly used as an antidepressant and in the treatment of anxiety disorders. \n",
      "\n",
      "In its physical form, venlafaxine hydrochloride is typically presented in the form of tablets or capsules. The appearance of these pharmaceutical forms can vary based on the manufacturer and specific formulation:\n",
      "\n",
      "1. **Tablets**: The extended-release tablets may resemble conventional tablets and typically have a smooth surface with a specific coating for gradual release of the medication. The appearance can be described as circular and may contain specific identifiers such as numbers or letters stamped on them for identification.\n",
      "\n",
      "2. **Capsules**: For the capsule form, venlafaxine hydrochloride might be presented in a hard or soft gelatin shell, generally in colors such as light green or blue, and may be oval or elongated in shape. Each capsule usually contains the active ingredient as well as various inactive ingredients necessary for stability and absorption.\n",
      "\n",
      "3. **Color and Texture**: The color can range from off-white to tan when in solid form (e.g., as a powder before compression into tablets or encapsulation). When describing the physical properties, some studies report the color and texture may vary slightly among different preparations, but they remain within a specific pharmaceutical standard.\n",
      "\n",
      "For specific appearances, more details can be checked through pharmaceutical labels or product descriptions provided by the manufacturers and regulatory bodies (e.g., FDA labels).\n",
      "\n",
      "Overall, the precise physical appearance of venlafaxine hydrochloride can depend on the dosage form and manufacturer but generally conforms to these descriptions. For a more detailed visual reference, you may consult the manufacturer's product label.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 233:----\n",
      "Question: Which of the following is NOT a contraindication for Ciprofloxacin use?\n",
      "\n",
      "Correct Answer: D:\n",
      "A history of hypersensitivity to cephalosporins\n",
      "\n",
      "Detailed Prediction: Ciprofloxacin is an antibiotic that is part of the fluoroquinolone class, and it has several contraindications for its use. The common contraindications include:\n",
      "\n",
      "1. **History of tendon disorders**: Ciprofloxacin has been associated with an increased risk of tendon rupture, especially in patients with a history of tendon disorders, particularly the Achilles tendon.\n",
      "2. **Myasthenia gravis**: The use of ciprofloxacin may exacerbate muscle weakness in patients with myasthenia gravis.\n",
      "3. **Pregnancy**: Ciprofloxacin is generally contraindicated in pregnancy due to the potential risk to the developing fetus.\n",
      "\n",
      "However, there are certain conditions where ciprofloxacin use may not be contraindicated, which might include:\n",
      "\n",
      "- **Mild to moderate renal impairment**, if the dosage is adjusted accordingly.\n",
      "- **Certain types of infections**, where ciprofloxacin is found to be effective despite other risk factors.\n",
      "\n",
      "Thus, it is essential for healthcare providers to carefully assess the risks and benefits before prescribing ciprofloxacin in patients with varying health conditions. Therefore, the answer to the question regarding which is NOT a contraindication for ciprofloxacin would involve identifying a condition that does not fall under the typical contraindications mentioned above.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 250:----\n",
      "Question: What is the recommendation for dosing Lantus Solostar in geriatric patients?\n",
      "\n",
      "Correct Answer: C:\n",
      "Start with conservative dosing to avoid hypoglycemia.\n",
      "\n",
      "Detailed Prediction: In geriatric patients, dosing recommendations for Lantus (insulin glargine) should be approached with caution due to the physiological changes associated with aging, potential comorbidities, and the possibility of polypharmacy effects. \n",
      "\n",
      "1. **Starting Dose**: It is generally recommended to start at a lower dose than in younger patients. A typical initiation dose might range from 0.2 to 0.4 units/kg/day, depending on the individual patient's requirements and current blood glucose levels.\n",
      "\n",
      "2. **Adjustment Based on Glycemic Control**: The dose should then be titrated based on self-monitored blood glucose readings, with adjustments typically made in increments of 2 to 4 units as necessary. \n",
      "\n",
      "3. **Risk of Hypoglycemia**: Geriatric patients are at a higher risk for hypoglycemia due to factors like decreased renal function, altered pharmacokinetics of insulin, and cognitive impairment. Therefore, it is crucial to monitor for signs of hypoglycemia and adjust the dosage accordingly.\n",
      "\n",
      "4. **Consideration for Comorbidities**: Many elderly patients may have comorbid conditions such as renal impairment or cardiovascular diseases that could influence insulin metabolism and action. \n",
      "\n",
      "5. **Regular Monitoring**: Frequent monitoring of glucose levels is recommended to prevent both hyperglycemia and hypoglycemia, especially during dose adjustments.\n",
      "\n",
      "In summary, while using Lantus in geriatric patients, careful consideration of the starting dose, monitoring for hypoglycemia, and adjustment based on individual patient needs are essential for effective and safe management of diabetes in this population.\n",
      "\n",
      "For more detailed clinical guidelines and specific studies, please refer to recent literature from resources such as PubMed.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 256:----\n",
      "Question: What is the recommendation for dose adjustment of Signifor LAR in patients with renal impairment?\n",
      "\n",
      "Correct Answer: A:\n",
      "No dose adjustment is required.\n",
      "\n",
      "Detailed Prediction: The dosing recommendations for Signifor LAR (pasireotide) in patients with renal impairment specifically are not well detailed in available literature. However, it is generally accepted that drugs primarily excreted by the kidneys may require dose adjustments in patients with renal impairment.\n",
      "\n",
      "Based on the information gathered:\n",
      "- **General Dosing**: The standard initial dose of Signifor LAR for the treatment of conditions like acromegaly is typically 40 mg administered by intramuscular injection once every 4 weeks. Adjustments may be considered if the patient experiences side effects or inadequate response.\n",
      "- **Lack of Specific Guidance**: There is limited data directly addressing dosage adjustments for Signifor LAR in patients with renal impairment, which suggests that more individualized assessment may be necessary. \n",
      "\n",
      "For deeper insights, referring to the package insert and consulting a healthcare provider or pharmacist is recommended. Additionally, continuous monitoring is important in any patient with renal impairment receiving this medication. \n",
      "\n",
      "For more detailed information, you can refer to sources such as the [Drugs.com package insert](https://www.drugs.com/pro/signifor-lar-injection.html).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 296:----\n",
      "Question: In which scenario should Lamotrigine not be prescribed?\n",
      "\n",
      "Correct Answer: A:\n",
      "A patient with hypersensitivity to Lamotrigine\n",
      "\n",
      "Detailed Prediction: Lamotrigine is a medication primarily used to treat epilepsy and bipolar disorder. However, there are specific scenarios where its use is contraindicated or should be approached with caution:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Individuals who have a known hypersensitivity to lamotrigine or any of its components should not be prescribed this medication. Rash or other allergic reactions can occur, and in some cases, they may lead to severe conditions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).\n",
      "\n",
      "2. **History of Serious Skin Reactions**: Patients who have experienced severe skin reactions from lamotrigine in the past should avoid its use. This includes cases of SJS, TEN, or other serious cutaneous adverse drug reactions.\n",
      "\n",
      "3. **Concurrent Use with Valproate**: Lamotrigine metabolism can be significantly affected by the concomitant use of valproate (valproic acid), leading to increased levels of lamotrigine and a higher risk of serious side effects, particularly skin rashes. Caution is needed when these medications are used together, and dosage adjustments may be necessary.\n",
      "\n",
      "4. **Pregnancy and Lactation**: While lamotrigine can be used in pregnancy under careful monitoring, potential risks to the fetus exist, particularly regarding neural tube defects if used at high doses. Pregnant individuals or those planning to become pregnant should consult healthcare providers to evaluate risks versus benefits.\n",
      "\n",
      "5. **Renal or Hepatic Impairment**: Patients with significant renal or hepatic impairment may require dosage adjustments, and potential risks associated with lamotrigine should be considered carefully.\n",
      "\n",
      "6. **Non-dystrophic Myotonia**: While there have been studies showing efficacy, patients with specific neuromuscular disorders where muscle relaxation is significantly impaired should be evaluated carefully due to potential unusual responses (as per the findings observed in real-world cases).\n",
      "\n",
      "In summary, lamotrigine should not be prescribed in cases of hypersensitivity to the drug or its components, in patients with a history of severe skin reactions caused by lamotrigine, when used in conjunction with valproate without careful monitoring, during pregnancy (without a thorough risk assessment), in significant renal or hepatic impairment, and with caution in patients with certain neuromuscular disorders. Always consulting with a healthcare provider for individualized assessment is essential.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 321:----\n",
      "Question: What action should patients take if they develop signs of heart failure while on REMICADE?\n",
      "\n",
      "Correct Answer: B:\n",
      "Seek medical attention and consult their prescriber.\n",
      "\n",
      "Detailed Prediction: If a patient develops signs of heart failure while on REMICADE (infliximab), they should take the following actions:\n",
      "\n",
      "1. **Immediate Consultation**: Patients are advised to seek immediate medical attention. Heart failure can manifest as symptoms like shortness of breath, swelling in the legs or abdomen, fatigue, and rapid or irregular heartbeat. Recognizing these signs and acting promptly is vital.\n",
      "\n",
      "2. **Discontinuation of REMICADE**: Upon presentation with symptoms suggestive of heart failure, healthcare providers may recommend discontinuing REMICADE, as it has been associated with cardiovascular issues in some patients.\n",
      "\n",
      "3. **Comprehensive Evaluation**: The healthcare provider will likely conduct a thorough evaluation, including physical exams and diagnostic tests such as echocardiograms and EKGs, to assess cardiovascular function and rule out other possible causes of heart failure.\n",
      "\n",
      "4. **Management of Heart Failure**: If diagnosed, treatment may include medication to help manage heart failure symptoms such as diuretics to reduce fluid overload, ACE inhibitors, or beta-blockers to improve heart function.\n",
      "\n",
      "5. **Monitoring and Follow-Up**: Close monitoring by a cardiologist or primary care provider is crucial to manage heart health effectively. Follow-up visits and adjustments to medication and treatment plans may be necessary based on the patient's response.\n",
      "\n",
      "It is essential for patients to communicate openly with their healthcare team regarding any symptoms experienced while on immunotherapy treatments like REMICADE, as timely intervention can significantly improve outcomes.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 338:----\n",
      "Question: If a user requires higher sunburn protection than Arizona Sun Sunscreen SPF15, what should they consider?\n",
      "\n",
      "Correct Answer: A:\n",
      "Using a sunscreen with a higher SPF\n",
      "\n",
      "Detailed Prediction: When considering higher sunburn protection than Arizona Sun Sunscreen SPF 15, users should keep the following factors in mind:\n",
      "\n",
      "1. **Higher SPF Values**: Choose sunscreens with higher SPF ratings. The SPF (Sun Protection Factor) indicates the level of protection from UVB rays. For instance, products with SPF 30 to SPF 50 provide significantly better protection. It's important to note that SPF values above 50 offer diminishing returns in terms of protection.\n",
      "\n",
      "2. **Broad-Spectrum Protection**: Ensure that the sunscreen provides broad-spectrum protection against both UVA and UVB rays. UVB rays cause sunburn and contribute to skin cancer, while UVA rays penetrate the skin more deeply and can cause aging and also contribute to skin cancer.\n",
      "\n",
      "3. **Water Resistance**: Consider water-resistant formulations if engaging in activities that involve swimming or sweating. Look for products labeled as \"water-resistant\" for 40 or 80 minutes, as these can retain their SPF for that duration even when exposed to water.\n",
      "\n",
      "4. **Active Ingredients**: The effectiveness of sunscreens can vary based on their active ingredients. Common ingredients include:\n",
      "   - **Chemical Filters**: Such as avobenzone, octisalate, and octocrylene, which absorb UV radiation.\n",
      "   - **Physical (Mineral) Filters**: Such as zinc oxide or titanium dioxide, which reflect UV rays and are often recommended for sensitive skin.\n",
      "\n",
      "5. **Formulation and Application**: Choose a formulation that suits the user's skin type and preference (gel, cream, lotion, spray, etc.). It's essential to apply sunscreen generously and evenly to all exposed skin, using about an ounce (a shot glass full) for full body coverage.\n",
      "\n",
      "6. **Reapplication**: Reapply sunscreen every two hours, or more frequently if swimming or sweating. This is critical for maintaining effective protection.\n",
      "\n",
      "7. **Additional Protective Measures**: Along with using high SPF sunscreen, users should consider other protective measures such as wearing protective clothing, sunglasses, and seeking shade during peak sun hours (10 a.m. to 4 p.m.).\n",
      "\n",
      "8. **New Innovations**: Recent developments in sunscreen technology, like the use of bilayer hydrogels with exceptional UV absorption and enhanced skin adhesion, offer promising advancements for sun protection. These formulations can significantly exceed traditional SPF levels, providing better protection and therapeutic benefits to the skin (as noted in recent studies).\n",
      "\n",
      "In summary, when seeking higher sunburn protection, users should opt for a higher SPF, ensure broad-spectrum coverage, choose suitable formulations, and incorporate additional protective practices to effectively safeguard their skin from UV damage.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 340:----\n",
      "Question: What should be done if a patient taking Tri Femynor experiences a significant increase in blood pressure?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue Tri Femynor immediately.\n",
      "\n",
      "Detailed Prediction: If a patient taking Tri Femynor (a combination oral contraceptive containing ethinyl estradiol and norgestimate) experiences a significant increase in blood pressure, the following steps should be taken:\n",
      "\n",
      "1. **Monitor Blood Pressure**: The first step is to consistently monitor the patient's blood pressure to confirm the significant increase. Blood pressure measurements should be taken at different times to ensure accuracy.\n",
      "\n",
      "2. **Assess Symptoms**: Evaluate the patient for any additional symptoms that may accompany the increased blood pressure, such as headaches, visual changes, or shortness of breath, which may indicate a more serious condition.\n",
      "\n",
      "3. **Review Medical History**: Consider the patient's medical history, including any pre-existing hypertension, risk factors (such as smoking, obesity, or a family history of hypertension), and other medications that the patient may be taking that could contribute to increased blood pressure.\n",
      "\n",
      "4. **Consult Healthcare Provider**: The patient should consult their healthcare provider to discuss the increase in blood pressure in the context of their overall health and any potential risk factors. The provider may consider switching the patient to a different contraceptive method that has a lower risk of affecting blood pressure.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage the patient to adopt lifestyle changes that can help manage blood pressure, such as dietary adjustments (reducing sodium intake), regular physical activity, weight management, and stress reduction techniques.\n",
      "\n",
      "6. **Consider Discontinuation or Alternatives**: If high blood pressure persists and is concerning, it may be necessary to discontinue Tri Femynor and explore alternative contraceptive options that do not affect blood pressure as significantly.\n",
      "\n",
      "7. **Follow-up**: Ensure that the patient has regular follow-up appointments to monitor their blood pressure and assess the effectiveness of any changes made to their treatment plan.\n",
      "\n",
      "In summary, addressing a significant increase in blood pressure while taking Tri Femynor involves monitoring, assessing, and potentially adjusting the treatment plan in consultation with a healthcare provider.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 348:----\n",
      "Question: What is the approximate incidence rate of serious rashes, including Stevens-Johnson syndrome, in pediatric patients aged 2 to 17 years taking lamotrigine?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.3% to 0.8%\n",
      "\n",
      "Detailed Prediction: The incidence rate of serious rashes, including Stevens-Johnson syndrome (SJS), in pediatric patients aged 2 to 17 years taking lamotrigine is relatively low. A retrospective cohort study involving adolescents aged 13 to 20 years treated with lamotrigine reported that out of 102 patients, 23 developed a skin rash, leading to an incidence of approximately 22.5%. However, only one patient developed a serious rash classified as Stevens-Johnson syndrome. This indicates that while skin rashes are not uncommon, serious adverse reactions such as SJS are rare, highlighting an incidence rate of about 1% for severe rashes in this specific demographic.\n",
      "\n",
      "Additional studies support that the overall risk of developing serious skin reactions with lamotrigine, particularly when introduced at higher doses or more rapidly, has potential to increase, but careful dosing and monitoring can mitigate risks. Therefore, healthcare providers often recommend gradually titrating the dosage of lamotrigine to lower the likelihood of rash development. \n",
      "\n",
      "In summary, while rashes are a common side effect of lamotrigine treatment in pediatric patients, serious complications such as Stevens-Johnson syndrome occur infrequently, emphasizing the importance of careful clinical monitoring.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 353:----\n",
      "Question: What monitoring is recommended for patients on chronic warfarin therapy who are administered FOSAPREPITANT?\n",
      "\n",
      "Correct Answer: B:\n",
      "Monitor INR in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant.\n",
      "\n",
      "Detailed Prediction: The interaction between warfarin and fosaprepitant necessitates careful monitoring due to the potential for altered anticoagulation effects. Here are some considerations and recommendations for monitoring patients on chronic warfarin therapy who are administered fosaprepitant:\n",
      "\n",
      "1. **INR Monitoring**: Regular INR (International Normalized Ratio) tests are crucial. Patients should have their INR checked more frequently (at least once a week) after initiating fosaprepitant, as it may affect warfarin metabolism due to its influence on CYP3A4.\n",
      "\n",
      "2. **Clinical Assessment**: Monitor for signs of bleeding or thrombosis closely. Increased vigilance is warranted during the initial days of therapy with fosaprepitant as it may interact with the pharmacokinetics of warfarin.\n",
      "\n",
      "3. **Dosage Adjustment**: Be prepared to adjust the dose of warfarin based on INR results. If significant changes in INR occur, modifications to the warfarin regimen should be done cautiously.\n",
      "\n",
      "4. **Patient Education**: Educate patients about the signs of bleeding, such as unusual bruising, blood in urine or stool, and prolonged bleeding from cuts. They should also be informed about the importance of adherence to follow-up INR checks.\n",
      "\n",
      "5. **Duration of Monitoring**: The adjustments and increased monitoring should continue until the INR stabilizes at the desired therapeutic range post-initiation of fosaprepitant therapy.\n",
      "\n",
      "6. **Professional Collaboration**: Consider involving a pharmacist or anticoagulation management service for optimal management strategies during this concurrent therapy.\n",
      "\n",
      "Due to the lack of specific clinical trials currently linking these therapies directly, healthcare providers should base their decisions on pharmacological principles and existing guidelines on warfarin management and the effects of CYP3A4 inhibitors. Always assess the individual patient's risk factors and clinical scenario when determining monitoring strategies.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 361:----\n",
      "Question: What should a user do if irritation or sensitivity develops while using BP Wash?\n",
      "\n",
      "Correct Answer: B:\n",
      "Stop using BP Wash and consult a doctor.\n",
      "\n",
      "Detailed Prediction: If irritation or sensitivity develops while using BP (benzoyl peroxide) Wash, here are some recommended steps to manage the situation:\n",
      "\n",
      "1. **Discontinue Use**: Immediately stop using the BP Wash to prevent further irritation. Continuing to use the product can worsen the sensitivity and delay healing.\n",
      "\n",
      "2. **Rinse Thoroughly**: Gently rinse your skin with lukewarm water to remove any residual product. This helps to soothe the skin and reduce the irritation.\n",
      "\n",
      "3. **Use a Gentle Cleanser**: Switch to a mild, non-irritating cleanser for your regular skin care routine. Look for products that are fragrance-free and formulated for sensitive skin.\n",
      "\n",
      "4. **Apply Soothing Agents**: Consider applying soothing agents such as aloe vera gel or hydrocortisone cream (if approved by a healthcare professional) to alleviate irritation. These products can help calm the skin and reduce redness.\n",
      "\n",
      "5. **Moisturize**: Use a gentle, non-comedogenic moisturizer to help restore the skin barrier. Keeping your skin hydrated can reduce dryness and irritation.\n",
      "\n",
      "6. **Avoid Active Ingredients**: While your skin is healing, avoid using other active ingredients that may irritate the skin, such as salicylic acid, retinoids, or other exfoliants.\n",
      "\n",
      "7. **Gradual Reintroduction**: Once the irritation has resolved, if you wish to continue using benzoyl peroxide, consider reintroducing it slowly. You can start with a lower concentration and use it less frequently (e.g., every other day) to see how your skin reacts.\n",
      "\n",
      "8. **Consult a Healthcare Professional**: If irritation persists or worsens, consult a dermatologist or healthcare provider for tailored advice and possible alternative treatments.\n",
      "\n",
      "For more detailed information on managing skin irritation while using benzoyl peroxide, you can refer to [this article](https://viraltrench.com/reduce-irritation-using-benzoyl-peroxide-wash/).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 366:----\n",
      "Question: What is the incidence of infusion-site erythema in patients receiving FOSAPREPITANT for HEC compared to oral aprepitant?\n",
      "\n",
      "Correct Answer: B:\n",
      "0.5% in FOSAPREPITANT group and 0.1% in oral aprepitant group\n",
      "\n",
      "Detailed Prediction: The incidence of infusion-site erythema in patients receiving FOSAPREPITANT has been reported to be significant. In a study that evaluated symptoms from 61 injections of Fosaprepitant, erythema was observed in 10 patients, representing approximately 16% of the injections. Pain at the injection site was noted in 23% of cases, further indicating that injection-site reactions can be prevalent. \n",
      "\n",
      "Currently, specific comparative data for the incidence of infusion-site erythema between FOSAPREPITANT and oral aprepitant is limited, but the infusion-related reactions to FOSAPREPITANT appear to be notable. Oral aprepitant typically does not involve injection-site reactions as it is administered orally; thus, it offers a different route of administration that may mitigate such local reactions, but direct comparative incidence rates remain to be elucidated in research. \n",
      "\n",
      "For further details, you can refer to the relevant study discussing these findings [here](https://www.jcancer.org/v05p0390.htm).\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 381:----\n",
      "Question: Based on animal studies, what is the role of leucovorin in the context of Pemetrexed for injection overdose?\n",
      "\n",
      "Correct Answer: B:\n",
      "It mitigates the toxicities of Pemetrexed\n",
      "\n",
      "Detailed Prediction: Leucovorin, also known as folinic acid, is a medication primarily used to mitigate the toxic effects of certain drugs, particularly methotrexate, and can play a supportive role in chemotherapy regimens. In the context of pemetrexed (a chemotherapy agent used to treat certain types of cancer), animal studies suggest that leucovorin may indeed help to reduce the toxicities associated with pemetrexed overdose.\n",
      "\n",
      "The mechanism thought to underlie the protective role of leucovorin involves its function as a reduced form of folate, which can help to replenish folate levels in the body. Pemetrexed exerts its effects by inhibiting several enzymes involved in folate metabolism, leading to a potential depletion of folates and resultant toxicity. By administering leucovorin, the goal is to provide the body with a source of folate that can help counteract this depletion and mitigate side effects.\n",
      "\n",
      "According to resources, the specific finding is that in animal studies, administration of leucovorin can alleviate the toxic effects seen during pemetrexed overdose, although the precise dosing and efficacy may vary based on animal models and individual responses. It is important to note, however, that while the animal models provide useful insights, clinical protocols for overdose management in humans must always integrate comprehensive clinical judgment and adhere to established medical guidelines. \n",
      "\n",
      "In conclusion, leucovorin appears to play a beneficial role in scenarios of Pemtrexed overdose based on animal studies, primarily by counteracting the drug's toxicity through folate replenishment. Further research and clinical studies are, however, essential to fully understand this interaction and guidelines for application in human cases.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 386:----\n",
      "Question: Which of the following statements is true regarding the storage conditions of the drug 'sterile'?\n",
      "\n",
      "Correct Answer: B:\n",
      "It should be stored at room temperature between 15 - 30¬∞C.\n",
      "\n",
      "Detailed Prediction: The storage conditions for sterile drugs are critical to maintaining their efficacy and preventing contamination. Based on the reviewed literature, here are key points about sterile drug storage:\n",
      "\n",
      "1. **Temperature Regulation**: Most sterile drugs need to be stored in controlled environments, with specific temperatures being crucial. For example, certain formulations may require refrigeration at 4¬∞C to maintain stability, while others may be affected negatively by freezing temperatures (-20¬∞C to -80¬∞C) (PubMed PMID: 41414880, 41266122).\n",
      "\n",
      "2. **Microbial Contamination Prevention**: Sterile medications must be stored in a manner that prevents microbial contamination. This often involves using aseptic techniques during preparation and storage in sterile, airtight containers (PubMed PMID: 41176402).\n",
      "\n",
      "3. **Stability Considerations**: The stability of sterile drugs can differ based on the medium they are compounded in. For instance, preservative-free formulations may exhibit different stability profiles compared to those that contain preservatives (PubMed PMID: 41266122).\n",
      "\n",
      "4. **Humidity Control**: In addition to temperature, humidity control may also impact the stability of certain sterile medications. High humidity can encourage contamination or degradation.\n",
      "\n",
      "5. **Shelf Life Monitoring**: It is essential to actively monitor the shelf life of sterile products. Proper labeling with expiration dates and adherence to storage guidelines helps ensure efficacy throughout their intended use.\n",
      "\n",
      "In summary, the proper storage conditions for sterile drugs typically include maintaining specific temperature controls (most commonly refrigeration but avoiding freezing for many), using sterile containers, ensuring microbiological safety during storage, and monitoring for stability.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 390:----\n",
      "Question: What action should be taken if a patient develops a serious infection while on REMICADE therapy?\n",
      "\n",
      "Correct Answer: B:\n",
      "Discontinue REMICADE immediately\n",
      "\n",
      "Detailed Prediction: If a patient develops a serious infection while undergoing therapy with REMICADE (infliximab), immediate and appropriate actions should be taken. REMICADE is a tumor necrosis factor (TNF) inhibitor used primarily to treat autoimmune diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, and others. However, patients on such therapies are at an increased risk for infections due to their immunosuppressive effects.\n",
      "\n",
      "### Steps to Take When a Serious Infection Develops:\n",
      "\n",
      "1. **Discontinue REMICADE**: The first step is to discontinue REMICADE immediately. Continuing treatment can worsen the infection or complicate the patient's condition.\n",
      "\n",
      "2. **Clinical Assessment**: A thorough clinical evaluation should be conducted to assess the severity and type of infection. This often includes:\n",
      "   - Physical examination\n",
      "   - Laboratory tests (e.g., blood cultures, complete blood count, inflammatory markers)\n",
      "   - Imaging studies, if necessary (e.g., X-rays, CT scans) to localize the infection.\n",
      "\n",
      "3. **Initiate Appropriate Antibiotic Therapy**: Based on the clinical assessment and laboratory results, appropriate empirical antibacterial therapy should start as soon as possible. The choice of antibiotics may depend on the suspected source and type of infection.\n",
      "\n",
      "4. **Monitor the Patient**: Close monitoring of vital signs and the patient's clinical status is essential to ensure that the infection does not worsen and that there are no signs of sepsis or other complications.\n",
      "\n",
      "5. **Consult Specialists**: If necessary, consultations with infectious disease specialists may be warranted, especially if the infection is atypical or resistant to initial treatment.\n",
      "\n",
      "6. **Adjunctive Care**: Supportive care, including hydration and management of symptoms, should be provided as needed. This may involve pain management and any specific interventions required based on the site and severity of the infection.\n",
      "\n",
      "7. **Evaluate for Re-initiating Therapy**: Once the infection is resolved and the patient has stabilized, healthcare providers should consider the risks versus benefits of re-initiating REMICADE therapy. This evaluation may include assessing the reasons for therapy (the condition being treated) versus the potential for recurrent infections.\n",
      "\n",
      "8. **Patient Education**: Educating the patient about recognizing signs of infection in the future is vital. Patients should be informed to report any concerning symptoms promptly, especially fever, chills, or other systemic signs.\n",
      "\n",
      "9. **Screening and Prevention**: Prior to restarting any immunosuppressive therapy, patients should be screened for latent infections like tuberculosis, and vaccination status should be reviewed to prevent future complications.\n",
      "\n",
      "In summary, the management of a serious infection in a patient on REMICADE requires immediate action, careful evaluation, and a coordinated approach to treatment to ensure patient safety and adequate management of their pre-existing conditions.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 392:----\n",
      "Question: What is the recommended action if a patient taking Iclusig develops hypertension that is not medically controlled?\n",
      "\n",
      "Correct Answer: B:\n",
      "Interrupt, dose reduce, or stop Iclusig.\n",
      "\n",
      "Detailed Prediction: In managing a patient taking Iclusig (ponatinib) who develops uncontrolled hypertension, the following recommended actions should be considered:\n",
      "\n",
      "1. **Consultation with a Specialist**: It is advisable to involve a cardiologist or a healthcare provider specializing in hypertension management to assess the severity of the hypertension and ensure a comprehensive evaluation.\n",
      "\n",
      "2. **Review and Adjust Antihypertensive Medications**: Evaluate the current antihypertensive regimen. Many patients on Iclusig may require an adjustment or addition of antihypertensive medications, particularly those that can counteract the effects of ponatinib, as it has the potential to exacerbate hypertension. Common classes of antihypertensive medications include ACE inhibitors, ARBs, calcium channel blockers, and diuretics.\n",
      "\n",
      "3. **Discontinue or Reduce Iclusig Dosage**: If the hypertension is particularly severe or not responding to the typical treatment strategies, consider reducing the dose of Iclusig or discontinuing it under the guidance of the treating oncologist. The risk-to-benefit ratio should be carefully evaluated, as controlling hypertension is crucial to prevent cardiovascular complications associated with ponatinib.\n",
      "\n",
      "4. **Monitor Blood Pressure Regularly**: Ensure frequent monitoring of blood pressure to assess the efficacy of the treatment adjustments and confirm that the hypertension is being effectively managed. This may involve routine follow-ups and possibly home monitoring.\n",
      "\n",
      "5. **Lifestyle Modifications**: Encourage lifestyle changes that can positively impact blood pressure, such as dietary modifications (e.g., reducing sodium intake), increased physical activity, weight management, and smoking cessation if applicable.\n",
      "\n",
      "6. **Patient Education**: Educate the patient about the symptoms of uncontrolled hypertension and the importance of adhering to both the cancer treatment and hypertension management plans. Helping the patient understand potential side effects of Iclusig, including hypertension, can enhance collaboration in managing their health.\n",
      "\n",
      "7. **Consider Alternative Therapies**: If hypertension remains uncontrolled despite these measures, it may be necessary to explore alternative therapies rather than continuing Iclusig. This decision should involve a multidisciplinary team and thorough discussion with the patient about their treatment options.\n",
      "\n",
      "It‚Äôs important to note that careful management is paramount to mitigate the cardiovascular risks associated with tyrosine kinase inhibitors like Iclusig, especially given their potential to induce hypertension and other cardiovascular toxicities.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 405:----\n",
      "Question: What is one of the uses of sunmark ibuprofen related to fever?\n",
      "\n",
      "Correct Answer: B:\n",
      "It temporarily reduces fever.\n",
      "\n",
      "Detailed Prediction: Sunmark ibuprofen, a common over-the-counter medication, is primarily used as a pain reliever and fever reducer. One of its notable uses related to fever management is its effectiveness in lowering elevated body temperature.\n",
      "\n",
      "Ibuprofen works by inhibiting the production of prostaglandins, which are chemicals in the body responsible for causing inflammation, pain, and fever. When the body encounters an infection or inflammatory response, prostaglandin levels increase, leading to fever. By reducing these levels, ibuprofen effectively brings down the fever, providing symptomatic relief.\n",
      "\n",
      "In clinical settings, ibuprofen is often suggested for use in both adults and children for managing febrile illnesses, such as colds or flu, making it a suitable option for those experiencing fever due to various causes. It is important to follow dosage instructions to minimize the risk of side effects.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 407:----\n",
      "Question: Which statement accurately describes the pharmacological risk of Hydrocort overdosage?\n",
      "\n",
      "Correct Answer: B:\n",
      "Hydrocort overdosage can result in systemic effects due to absorption.\n",
      "\n",
      "Detailed Prediction: Hydrocortisone (also known as hydrocortisol) is a glucocorticoid medication commonly used for its anti-inflammatory and immunosuppressive properties. In cases of overdose, it poses several pharmacological risks that can lead to significant health complications.\n",
      "\n",
      "1. **Adrenal Suppression**: Chronic use of hydrocortisone can suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency, especially in cases of overdose. Patients may experience symptoms like fatigue, weakness, and hypotension due to insufficient cortisol production by the adrenal glands (PMID: 35550494).\n",
      "\n",
      "2. **Cushing's Syndrome**: Overdose of hydrocortisone can result in symptoms of Cushing's syndrome, which is characterized by excessive cortisol levels. Symptoms may include obesity (particularly central obesity), moon facies, skin changes (such as purple striae), and hypertension (PMID: 30627312).\n",
      "\n",
      "3. **Metabolic Effects**: High cortisol levels can disturb metabolic processes, potentially leading to hyperglycemia (high blood sugar), increased appetite, and weight gain (PMID: 31763206). This can also exacerbate pre-existing diabetes or lead to the onset of new cases of diabetes mellitus.\n",
      "\n",
      "4. **Psychiatric Effects**: Hydrocortisone overdosing can also exacerbate psychiatric symptoms, leading to anxiety, depression, or psychosis, particularly if the overdose is substantial or chronic (PMID: 37625179).\n",
      "\n",
      "Given these potential risks, monitoring is critical in patients receiving hydrocortisone, especially when treatment duration is extended or doses are elevated. Thus, appropriate therapeutic drug monitoring could help prevent overdosing and its consequences related to hypercortisolism by tracking glucocorticoid levels in the body (PMID: 35550494).\n",
      "\n",
      "In summary, the pharmacological risk of hydrocortisone overdosage includes a spectrum of adverse effects ranging from adrenal suppression to metabolic and psychiatric disorders, emphasizing the importance of careful dosing and monitoring in clinical practice.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 420:----\n",
      "Question: Which precaution should be taken when administering Albuterol to patients receiving non-potassium-sparing diuretics?\n",
      "\n",
      "Correct Answer: A:\n",
      "Monitor serum potassium levels closely.\n",
      "\n",
      "Detailed Prediction: When administering Albuterol to patients who are also receiving non-potassium-sparing diuretics (such as loop or thiazide diuretics), it is essential to take precautions primarily related to the risk of hypokalemia and associated cardiac effects.\n",
      "\n",
      "**Precautions:**\n",
      "\n",
      "1. **Monitor Potassium Levels:** Non-potassium-sparing diuretics can lead to potassium depletion (hypokalemia). Since Albuterol, as a beta-agonist, can also cause a decrease in serum potassium levels, the risk of developing significant hypokalemia is increased when these two medications are used together. Therefore, it is prudent to monitor serum potassium levels periodically in patients receiving this combination.\n",
      "\n",
      "2. **ECG Monitoring:** Due to the potential for ECG changes associated with hypokalemia, it may be necessary to monitor the ECG in patients on both Albuterol and non-potassium-sparing diuretics. This is particularly important if the patient exhibits symptoms of low potassium or arrhythmias.\n",
      "\n",
      "3. **Adjusting Albuterol Dosage:** Caution should be taken to avoid exceeding the recommended dose of Albuterol, as higher doses may exacerbate hypokalemia and its associated risks. \n",
      "\n",
      "4. **Patient Education:** Patients should be educated about the signs of hypokalemia, such as muscle weakness, cramping, or palpitations, and advised to seek medical attention if they experience these symptoms.\n",
      "\n",
      "Overall, the combination of Albuterol with non-potassium-sparing diuretics can potentiate the risk of hypokalemia and necessitates careful monitoring and management to ensure patient safety.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 443:----\n",
      "Question: What should a patient do if they experience mild COVID-19 symptoms and are prescribed Paxlovid?\n",
      "\n",
      "Correct Answer: B:\n",
      "Start Paxlovid treatment as soon as possible and within 5 days of symptom onset.\n",
      "\n",
      "Detailed Prediction: If a patient experiences mild COVID-19 symptoms and is prescribed Paxlovid (nirmatrelvir/ritonavir), here are the recommended steps they should take:\n",
      "\n",
      "1. **Understand the Prescription**: Paxlovid is an antiviral medication specifically designed for treating mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease. It is crucial for patients to comprehend the importance of adhering to this treatment to decrease the risk of severe illness.\n",
      "\n",
      "2. **Consult with Healthcare Providers**: Patients should discuss any other medications they are currently taking with their healthcare provider. Paxlovid can interact with various drugs, potentially leading to adverse effects or reduced effectiveness. If there are drugs that may interact, the healthcare provider might suggest alternatives or dosage adjustments.\n",
      "\n",
      "3. **Start Treatment Promptly**: Paxlovid should be taken as soon as possible after the onset of symptoms. The treatment is most effective when started within the first few days of symptom appearance. Patients should follow the prescribed regimen strictly, usually for five days.\n",
      "\n",
      "4. **Monitor Symptoms**: Patients should keep track of their symptoms and any changes in their condition. If symptoms worsen (e.g., breathing difficulties, chest pain), they should seek immediate medical attention.\n",
      "\n",
      "5. **Stay Hydrated and Rest**: Patients are encouraged to drink plenty of fluids and get adequate rest, as these are important aspects of recovery from any viral infection.\n",
      "\n",
      "6. **Report Side Effects**: If patients experience any side effects from Paxlovid, such as changes in taste, gastrointestinal upset, or allergic reactions, they should report these to their healthcare provider immediately.\n",
      "\n",
      "7. **Follow Up**: A follow-up appointment may be necessary to assess recovery and to determine if any additional care or treatment is required.\n",
      "\n",
      "8. **Take Preventive Measures**: While taking Paxlovid, it's also essential to continue practicing public health measures, such as wearing masks in crowded places and maintaining good hygiene, to prevent the spread of COVID-19 to others.\n",
      "\n",
      "Following these guidelines can help ensure optimal care during a mild COVID-19 infection when treated with Paxlovid.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 444:----\n",
      "Question: What is the recommended action if a patient on Tybost experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline?\n",
      "\n",
      "Correct Answer: B:\n",
      "Closely monitor the patient for renal safety.\n",
      "\n",
      "Detailed Prediction: If a patient on Tybost (cobicistat) experiences a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline, the recommended action includes the following steps:\n",
      "\n",
      "1. **Assessment**: Re-evaluate the patient's kidney function baseline and the context of the increase. It's important to determine if this increase is isolated or part of a trend.\n",
      "\n",
      "2. **Monitor Renal Function**: Close monitoring of the patient's renal function is critical. This may involve regular serum creatinine tests and possibly urine tests to assess for any additional changes.\n",
      "\n",
      "3. **Review Medications**: Since Tybost can cause drug-drug interactions, particularly with other medications that are metabolized through the CYP3A pathway, a review of all concurrent medications should be performed. Attention should be given to any other nephrotoxic drugs that the patient may be taking.\n",
      "\n",
      "4. **Dosing Considerations**: Based on the degree of increase in serum creatinine, consider adjusting the dosing of Tybost or any other affected medications, particularly if they have narrow therapeutic indices.\n",
      "\n",
      "5. **Hydration and Supportive Care**: Ensure the patient is adequately hydrated, as dehydration can exacerbate renal impairment. Supportive care may also involve adjusting dietary intake or managing any other symptoms.\n",
      "\n",
      "6. **Consultations**: If the renal impairment persists or worsens despite above management steps, consider consulting a nephrologist to further evaluate the cause and management strategies.\n",
      "\n",
      "7. **Discontinuation of Tybost**: In cases where the increase in serum creatinine is substantial and persistent, discontinuation of Tybost may be warranted, considering the benefits versus risks in the context of the patient's health condition.\n",
      "\n",
      "These steps help ensure that the patient's renal function is carefully monitored and managed while minimizing the risks associated with continued use of Tybost.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 449:----\n",
      "Question: How should a patient start Tri Femynor if switching from a progestin-only method such as an implant or injection?\n",
      "\n",
      "Correct Answer: A:\n",
      "Start Tri Femynor on the day of removal of the implant or the day of the next injection.\n",
      "\n",
      "Detailed Prediction: When switching to Tri Femynor from a progestin-only method such as an implant or injection, the transition should be managed carefully to ensure continued contraceptive effectiveness.\n",
      "\n",
      "1. **Start Timing**: Patients should begin taking Tri Femynor on the day of removal of the progestin-only implant. If they are using an injectable method, they should start Tri Femynor on the day when their next injection would have been due.\n",
      "\n",
      "2. **Continuing Contraception**: It's important for patients to understand that there may be a brief period during which they could be at risk for pregnancy if they do not follow the correct switch protocol. Therefore, using a backup contraceptive method, such as condoms, is advisable during the first seven days of taking Tri Femynor, especially if the transition timing is not strictly followed.\n",
      "\n",
      "3. **Consult Healthcare Provider**: Patients should always consult with their healthcare provider before making any changes to their contraceptive regimen. This allows for personalized advice based on individual health profiles and potential risks.\n",
      "\n",
      "4. **Monitoring for Side Effects**: After switching, patients should monitor for any side effects or changes in their menstrual cycle, as their body adjusts to the new hormone combination present in Tri Femynor.\n",
      "\n",
      "For detailed instructions and to address any specific concerns, referring to a healthcare provider or the medication guide is recommended.\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "----Row 451:----\n",
      "Question: What is the recommended time of day to take esomeprazole magnesium during the 14-day treatment course?\n",
      "\n",
      "Correct Answer: A:\n",
      "Before eating in the morning\n",
      "\n",
      "Detailed Prediction: Error\n",
      "\n",
      "Final Choice: NOTAVALUE\n",
      "\n",
      "\n",
      "‚ÑπÔ∏èValid Answers: 2\n",
      "‚ÑπÔ∏èInvalid Answers: 44\n",
      "üü¢ACC: 100.0%\n"
     ]
    }
   ],
   "execution_count": 51
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
